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IN VITRO AND IN VIVO INVESTIGATIONS INTO THE INTERACTIONS BETWEEN THE 
ACYL GLUCURONIDE METABOLITE OF DICLOFENAC AND SERUM ALBUMIN 
 
Thomas Hammond 
Department of Pharmacology and Therapeutics, MRC Centre for Drug Safety Science, 
University of Liverpool, UK 
 
Adverse drug reactions represent a major challenge to clinicians, healthcare systems, 
pharmaceutical companies and academia.  With carboxylic acid drugs accounting for 
the most common class of drugs withdrawn from the market, the carboxylate 
pharmacophore has received much attention as a potential toxicophore.  Direct 
glucuronidation of the carboxylate group, producing chemically unstable and protein 
reactive acyl glucuronide (AG) metabolites has received much attention as a 
bioactivation pathway responsible for generation of these off-target hypersensitivity 
and hepatotoxicity.  It is the chemical instability and protein reactivity of AG 
metabolites that has led to their hypothesised ability to covalently modify proteins in 
vivo and subsequently stimulate inappropriate immune responses in susceptible 
patients.  Despite this, whilst the reactivity of AGs has been shown in vitro, their 
reactivity has never been confirmed in any in vivo system, meaning their association 
with toxicity may be unjustified.  The focus of this thesis was to investigate whether 
acyl glucuronides could identify covalent adducts to protein in vivo.   
 
To address this aim, the thesis first investigates the chemistry of interaction between 
acyl glucuronides and protein during in vitro investigation.  2mM 1-β diclofenac-AG 
was found to degrade spontaneously via acyl migration following incubation with 0.1M 
phosphate buffer pH 7.4 at 37°C with a degradation half-life of 0.78 hours, confirming 
diclofenac as amongst the most reactive AGs.  Further incubations confirmed the 
action of human serum albumin (HSA) as a mild esterase, and the presence of plasma 
esterases acting to hydrolyse AGs.  The covalent binding of diclofenac-AG to HSA was 
confirmed using both an alkaline hydrolysis as well as direct mass-spectrometric 
analyses of modified proteins.  Covalent modification of lysine residues was specifically 
identified, and was found to be concentration and time dependent.  Further in vitro 
incubation experiments revealed for the first time that the 1-β isomer of AGs is 
responsible for the formation of transacylation adducts, and confirmed previous 
suggestion that acyl migration is required for the extensive glycation of HSA.   
 
Following characterisation of the interaction of diclofenac-AG with HSA, investigations 
were undertaken in the rat to identify interactions of AGs with circulating rat serum 
albumin in vivo.  In vitro incubations of diclofenac-AG revealed RSA contained fewer 
binding sites when compared to HSA.  Further to this no covalent modification of RSA 
could be detected in vivo following intravenous administration of 60mg/kg diclofenac-
AG.  The rapid plasma clearance of diclofenac-AG (67.81 ± 12.83 ml min-1 kg-1) in the 
rat was shown to be 600 fold faster than that of diclofenac (12.00 ± 2.98 ml min-1 kg-1) 
following bolus intravenous administration.  Use of a continuous intravenous infusion 
drug delivery system revealed an adaptive change in rats upon continuous infusion of 
diclofenac, resulting in enhanced plasma elimination of the drug, and induction of the 
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ROS scavenging enzymes catalase and superoxide dismutase-2, without detection of 
hepatotoxicity.  
 
The final experiments in the thesis revealed for the first time the detection of glycation 
adducts to HSA extracted from volunteer patients receiving chronic diclofenac therapy. 
These were shown through the detection of glycation adducts in three out of six 
patients tested.  Between 1 and 4 lysine residues were identified in patients, with 
modifications towards one or all of lysine residues 195, 199, 432 and 525.  
Transacylation adducts were detected towards lysine residues in all six patient samples 
analysed.  Whilst identification of transacylation adducts reveals bioactivation of the 
carboxylic acid functional group, it is the identification of glycation adducts to albumin 
isolated from three of the six patients which reveals, for the first time, definitive 
evidence for AG reactivity in vivo.  This reinforces concerns over the potential of AGs to 
act as haptens, and re-affirms the carboxylic acid structure as a site of bioactivation 
forming reactive metabolites. 
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1.1 ADVERSE DRUG REACTIONS 
1.1.1 Introduction to adverse drug reactions 
Adverse drug reactions (ADR) have been defined by Edwards and Aronson as: ‘an 
appreciably harmful or unpleasant reaction, resulting from an intervention related to 
the use of a medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of the dosage regimen, or 
withdrawal of the product’ (Edwards and Aronson, 2000).   
Approximately 6.5% of hospital admissions in the U.K. have been attributed to ADRs, 
incurring an estimated cost of approximately £500 million for the NHS (Pirmohamed et 
al., 2004).  In addition, drug withdrawals or restrictions on drug usage impose a major 
financial burden on pharmaceutical companies.  Therefore ADRs represent a major 
challenge for clinicians, regulatory authorities and the pharmaceutical industry.   
A huge financial investment is required to assess the value of a candidate drug in 
clinical trials.  Currently the second most frequent cause of attrition of novel 
compounds following their administration to man is concerns with respect to drug 
safety (Kola and Landis, 2004).  Consequently, early identification of properties of 
novel compounds that correlate with a high risk of toxicity is required.  If this can be 
achieved, it may be possible to select lead compounds for development that  have low 
toxicity risk for development, so that large investments can be targeted towards 
molecules that have the greatest chance of success.   
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1.1.2 On-target adverse drug reactions 
On-target ADRs (also known as Type A) usually present as an exacerbation of the 
known primary or secondary pharmacological response of the drug target.  As a 
consequence of this, they usually show a clear dose-response relationship (Rawlins and 
Thompson, 1977), meaning that they are often simply managed clinically through a 
reduction of dose or through administration of combinational pharmacological 
intervention.   
A classic example of an on-target ADR is bleeding associated with warfarin therapy.  
Warfarin inhibits the vitamin K cycle, reducing the carboxylation, and consequently the 
biological activity, of pro-coagulation factors including factors VII, IX and X.  This 
reduces the risk of embolism, and has been shown to reduce risk of stroke in atrial 
fibrillation patients by 70% (Hart et al., 2003).  However, a major limitation to warfarin 
therapy is the risk of serious haemorrhage, occurring with an incidence of between 1.3 
to 4.2 per 100 patient years of drug exposure (1994; 1996; Aithal et al., 1999).  Serious 
haemorrhage is encountered as a consequence of the exacerbation of the drug’s 
pharmacological action, resulting from above desired inhibition of the vitamin K cycle.  
Warfarin is known to have a notably small therapeutic window, where the doses 
required for pharmacological effect and generation of haemorrhage are not markedly 
different.  Extensive inter-individual variation in response to warfarin, partly due to 
differences in vitamin K dietary intake, makes haemorrhage not uncommon (Aithal et 
al., 1999). 
Whilst undesirable, on-target adverse drug reactions are usually simply managed, 
often without the necessity of drug withdrawal.  Frequently, dose reduction with close 
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monitoring of the patient is sufficient for reduction of toxicological risk, whilst 
maintaining drug therapy. 
1.1.3 Off target ADRs 
Unlike on-target ADRs, off target ADRs (also known as Type B) do not show a clear 
dose-response relationship, cannot be predicted from the known primary or secondary 
pharmacology of the compound, cannot be predicted using known animal models and 
are only apparent in a small subset of the population (Rawlins and Thompson, 1977; 
Kalgutkar and Soglia, 2005).  Essentially they are unexpected reactions with signs and 
symptoms inconsistent with the known toxicity of the drug.  Consequently, accurate 
associations between drugs and off-target ADRs cannot be made until sufficiently large 
populations are exposed (Park et al., 2000), often during late-stage clinical trials or 
following drug release to the market.  Once a drug has reached these stages in its 
development massive financial investments in the compound have already been made. 
Clinically, off-target ADRs range from mild to severe, and may occasionally be life-
threatening.  However, it is their unpredictable nature that makes management of off-
target ADRs difficult (Park et al., 2000).  Often, upon detection of the reaction, 
withdrawal of the otherwise effective drug from the patient is required, especially for 
off-target ADRs with suspected immunological pathogenesis.    
A good drug example of off-target ADRs is represented by hepatotoxicity associated 
with ximelagatran.  Ximelagatran was the first of the direct thrombin inhibitor 
anticoagulants, providing a wider therapeutic window than the coumarins, reducing 
the risk of bleeding and consequently eliminating the necessity for tight patient 
monitoring (Mattsson et al., 2005).  Its efficacy was proven in man and a good safety 
profile was observed in pre-clinical and short term clinical trials.  Longer clinical trials 
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(>35 days), however revealed the potential of the molecule to elicit hepatotoxicity in a 
low frequency of individuals (Petersen et al., 2003).  Plasma alanine transaminase (ALT) 
activities were raised to above 3x the upper limit of normal (ULN) in 11 patients at 3 
weeks following cessation of drug exposure, while one patient was hospitalised due to 
plasma ALT activities up to 27x ULN (Agnelli et al., 2009).  Subsequently, ximelagatran’s 
development was ceased and the drug was withdrawn from all markets (Keisu and 
Andersson, 2010). 
As with other off-target ADRs, no clear relationship between ximelagatran dose and 
incidence of toxicity could be elucidated following retrospective analysis of clinical 
trials (Keisu and Andersson, 2010).  Despite re-analysis of pre-clinical safety testing, 
and retrospective analysis, to date, hepatotoxicity has not been established in any 
animal model, meaning mechanisms for its pathogenesis in man have not been 
established.   
Until mechanisms of off-target ADRs are understood, which integrate the biochemistry 
of the compound with the intrinsic variation in biology or environment of the patient, 
early prediction of off-target ADRs administration to large numbers of humans will not 
be possible. 
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1.2 XENOBIOTIC METABOLISM 
Humans are continually exposed to a wide range of xenobiotics, either via the diet, 
non-dietary environmental exposure or pharmaceutical treatment.  Many xenobiotics 
have the potential to be harmful. Consequently, xenobiotic deactivation and 
subsequent clearance from both the cell and organism is important to avoid potential 
toxicological consequences (Park et al., 2005).  One of the key mechanisms in 
xenobiotic deactivation and clearance is metabolism.  The overall chemical 
modifications of a compound usually enhance its hydrophilicity and its affinity for 
export transporters, resulting in enhanced clearance (Meyer, 1996).  Xenobiotic 
metabolism has been usefully categorised into two biochemical phases.  Phase I 
metabolism frequently enhances the electrophilicity of a molecule through insertion of 
polar functional groups via one of several metabolic pathways.  Molecules with 
enhanced electrophilicity are often more susceptible to conjugative (Phase II) 
metabolic reactions than parent molecules.  In Phase II reactions, molecules are 
conjugated with polar residues, resulting in complexes that possess sufficient 
hydrophilicity to enable their rapid excretion (Gibson and Skett, 2001).  
1.2.1 Phase I metabolism 
The apparent biochemical purpose of Phase I metabolism is to enhance a molecule’s 
electrophilicity, usually through the provision of functional groups susceptible to Phase 
II conjugation, and consequently the excretion of the molecule.  In some cases, 
however, Phase I metabolites may have sufficient polarity for direct elimination 
without the necessity for conjugation. 
 Phase I metabolism involves several different metabolic reactions, including oxidation, 
reduction, hydrolysis, hydration and isomerisation, with the reactions almost invariably 
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requiring enzymatic catalysis by enzymes including cytochrome P450s, monoamine 
oxidases and esterases.  Being collectively the most abundantly and widely expressed, 
and responsible for the metabolism of an enormous range of substrates, the isoforms 
of the cytochrome P450 superfamily are the most important Phase I metabolising 
enzymes (Gibson and Skett, 2001; Guengerich, 2001).   
1.2.2 Phase II metabolism 
Phase II metabolism involves the conjugation of endogenous moieties to both 
xenobiotics and other endogenous metabolism products (Caldwell, 1982).  This 
frequently results in the conjugate’s increased hydrophilicity and affinity for export 
transporters, enhancing renal and biliary elimination.  Several different conjugation 
reactions are considered in Phase II metabolism, including glucuronidation, sulfation, 
methylation, acetylation, as well as the conjugation of glutathione and amino acids 
(Gibson and Skett, 2001).  These conjugations are site specific, targeted to electrophilic 
sites of molecules.  Occasionally these sites may possess intrinsic chemical reactivity, 
which, if not deactivated may have harmful consequences, as is found in the quinone-
imine metabolite of paracetamol.  Consequently, conjugation at these sites has 
historically thought to abate a potential toxicological risk (Caldwell, 1982).  This 
traditional view of phase II metabolites as metabolic end products lacking 
pharmacological activity, however, has been challenged in recent years, with 
pharmacological activity reported for the glucuronide metabolites of morphine-6β-
glucuronide (Paul et al., 1989), codeine-6-glucuronide (Vree et al., 2000) and 
dabigatran-AG (Stangier et al., 2007). 
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1.2.3 Glucuronidation 
Phase II metabolism by glucuronidation is the conjugation of glucuronic acid to 
xenobiotics or endogenous molecules, catalysed by UDP-glucuronosyltransferase 
(UGT) enzymes of the endoplasmic reticulum, usually targeted to hydroxyl (alcohol and 
phenol), carboxyl, sulphhydryl and amine groups of xenobiotics (Caldwell, 1982; Tukey 
and Strassburg, 2000).  Expression of 19 human UGT isoforms belonging to two distinct 
families (UGT1 and UGT2) (Ritter, 2000; Tukey and Strassburg, 2000; Mackenzie et al., 
2005) is thought to allow the accommodation of this wide range of substrates.  Like 
P450s, mammalian UGTs display somewhat broad and often overlapping substrate 
specificities (Picard et al., 2005; Alonen et al., 2008), stereoselectivity (Mano et al., 
2007a) and genetic polymorphisms (Daly et al., 2007).  
Conjugation of substrates by glucuronidation is usually considered to be a low affinity, 
high capacity, reaction. Due to the abundance of glucuronic acid, this pathway plays a 
major role in drug metabolism, with glucuronidation a listed metabolic pathway of 8% 
of the top 200 prescribed drugs in the US in 2002 (Williams et al., 2004).  
Glucuronidation is also estimated to account for approximately 10% of the major drug 
elimination pathways (Gardiner and Begg, 2006).  Products of glucuronidation are 
conventionally categorised into four broad types dependent on the atom to which the 
glucuronic acid is linked, namely O-glucuronides, C-glucuronides, N-glucuronides and 
S-glucuronides (Figure 1. 1).  Of these conjugation reactions, O-glucuronidation is most 
frequently encountered. 
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Figure 1. 1:  Representative subtypes of glucuronides.  O-glucuronides include 
alcohol, phenol, carboxyl and N-carbamoyl conjugates.  Certain drug substrates can 
form more than one subtype of glucuronide in a mammalian species, e.g. an acyl 
glucuronide and either a phenolic glucuronide (Dickinson et al., 1993; Picard et al., 
2005) or an N-glucuronide (Alonen et al., 2008).  A glucuronide can itself be a substrate 
for glucuronidation, sulphonation or oxidation by 450s (Kumar et al., 2002).  
 
The principal site of glucuronidation is the liver.  However, expression of UGTs has also 
been reported in the kidney, GI tract and lung, as well as in the mammary gland and 
prostate, where glucuronidation of steroids is important (Ohno and Nakajin, 2009).  
UGTs are usually found expressed as membrane bound enzymes, located in the 
endoplasmic reticulum (Tukey and Strassburg, 2000).   
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1.3 ROLE OF DRUG BIOACTIVATION IN ADVERSE DRUG REACTIONS 
The usual consequence of drug metabolism – with the important exception of pro-drug 
activation - is the conversion of active substrates into pharmacologically inactive 
products, primed for rapid elimination from biological systems (Park et al., 2005).  
Occasionally, however, metabolism may lead to the formation of intermediates or end 
products with intrinsic chemical reactivity, instability, or activity at secondary 
pharmacological targets. 
1.3.1 Bioactivation of xenobiotics to chemically reactive metabolites 
(chemical activation) 
Bioactivation through metabolism may also result in the formation of compounds with 
intrinsic chemical reactivity.  Usually these chemically reactive metabolites (CRMs) are 
rapidly bio-inactivated, generally through phase II metabolism.  Occasionally, however, 
exposure or intrinsic reactivity of CRMs may overwhelm detoxification pathways.  In 
this situation CRMs may elicit a toxicological effect (Park et al., 2005).  This may be 
either through covalent binding to endogenous macromolecules, possibly resulting in 
cell death, immune sensitisation or carcinogenesis.  Alternatively, the chemical 
instability of CRMs may result in their redox cycling, resulting in cellular stress through 
oxidative stress. 
1.3.2 Potential of CRMs to elicit intrinsic cellular stress through covalent 
modification of endogenous macromolecules 
Strong associations have been drawn between the formation of CRMs, their covalent 
modification of endogenous macromolecules, and subsequent potential for toxicity 
and cell death (Brodie et al., 1971; Gillette et al., 1974; Park et al., 2005; Zhou et al., 
2005).  This relationship, however, is somewhat complex, with covalent modification of 
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macromolecules not universally resulting in toxicological output (Evans et al., 2004).  
An example of this is comparison of the model hepatotoxin acetaminophen (APAP) 
with its isomer N-acetyl-m-aminophenol (AMAP).  Both molecules are metabolised to 
reactive benzoquinone and benzoquinoneimine intermediates in vivo, and have been 
shown to form covalent adducts to hepatic proteins in mice to a similar extent (Rashed 
and Nelson, 1989; Rashed et al., 1990).   However, whilst APAP was found to elicit 
hepatotoxicity in mouse models, AMAP did not (Nelson, 1980).  Perturbation of 
function of macromolecules involved in molecular pathways critical for cellular survival 
through covalent adduct formation is thought to have a role in the mechanism and 
aetiology of some ADRs (Kalgutkar and Soglia, 2005; Park et al., 2005), as shown by 
Figure 1. 2.  Examples of this are highlighted by Table 1. 1, including APAP’s 
modification of mitochondrial proteins (Nazareth et al., 1991; Landin et al., 1996) and 
covalent modification of DNA by polycylclic aromatic hydrocarbons (PAH) resulting in 
carcinogenesis (Brookes and Lawley, 1964; Mastrangelo et al., 1996).  Alternatively, 
whilst not perturbing cellular function, modification of endogenous macromolecules is 
thought to have a key role in the generation of several drug allergies including 
halothane (Kenna et al., 1988a; Kenna et al., 1988b; Kenna et al., 1992) and penicillins 
(Brander et al., 1995; Padovan et al., 1997).  Consequently, identification of drugs 
capable of forming covalent adducts in vivo leads to anxiety as to their management, 
and future progression in development (Park et al., 1994; Evans et al., 2004; Kalgutkar 
and Soglia, 2005).  
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Figure 1. 2:  Physiological consequences of drug bioactivation.  Adapted from (Park et al., 2005) 
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Table 1. 1:  Drugs associated with eliciting toxicity through their metabolism into chemically reactive metabolites, and their associated 
protein targets 
Drug 
Bioactivating 
enzyme 
Chemically reactive metabolite Protein target if identified 
Toxicity 
associated 
References 
Paracetamol 
CYP1A2, 
CYP2E1, 
CYP3A4 
N-acetyl-p-benzoquinone imine 
Microsomal glutatmine synthetase, 
Nuclear lamin A, Selenium-binding 
protein, N-10-
formyltetrahydrofolate 
dehydrogenase, Mitochondrial 
glutamate dehydrogenase, 
Mitochondrial aldehyde 
dehydrogenase 
Hepatotoxicity 
(Nazareth et al., 1991; 
Bartolone et al., 1992; 
Pumford et al., 1992; Patten et 
al., 1993; Bulera et al., 1995; 
Landin et al., 1996; Pumford et 
al., 1997a; Pumford et al., 
1997b) 
Halothane CYP2E1 Trifluoroacetyl chloride 
Glutathione-S-transferase b, 
CYP2E1, CYP2B, Protein disulphide 
isomerase, UDP-glucose 
glycoprotein glucosyltransferase, 
Carboxylesterase, Erp72, 
BiP/GRP78, Erp99. 
Hepatitis 
(Kenna et al., 1988b; Satoh et 
al., 1989; Martin et al., 1993; 
Pumford et al., 1993a; Eliasson 
and Kenna, 1996; Amouzadeh 
et al., 1997; Pumford et al., 
1997a) 
Diclofenac 
UGT 2B7 
CYP2C8 
CYP3A4 
CYP2C9 
Acyl Glucuronide 
1’, 4’-Quinoneimine 
2’, 5’-Quinoneimine 
Coenzyme A thioester 
Dipeptidyl peptidase IV Hepatotoxicity 
(Stierlin and Faigle, 1979; 
Hargus et al., 1995; Shen et al., 
1999; Poon et al., 2001; Kenny 
et al., 2004) 
Tienilic Acid CYP2C9 Thiophene-S-oxide CYP2C9 Hepatotoxicity 
(Zimmerman et al., 1984; 
Koenigs et al., 1999) 
Troglitazone CYP3A4 
p-benzoquinoneimine 
quinone-epoxide 
Microsomal proteins 
BSEP 
Hepatotoxicity 
(Kawai et al., 1997; Watkins 
and Whitcomb, 1998; Funk et 
al., 2001; Kassahun et al., 
2001; Yamamoto et al., 2002; 
He et al., 2004) 
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1.4 CARBOXYLIC ACID FUNCTIONAL GROUPS IN PHARMACEUTICAL DRUGS 
Carboxylic acid groups are important molecular tools for medicinal chemists, 
incorporated into pharmaceutical agents for improved metabolism and disposition 
profiles for lead compounds.  Most carboxylic acid drugs are monocarboxylates but 
there are examples of dicarboxylates (MacFadyen et al., 1993; Wen et al., 2007).  In 
addition to being unmasked by facile hydrolysis of ester moieties (MacFadyen et al., 
1993), carboxyl groups can be formed on carboxylate (Sumner et al., 1975; Balani et 
al., 1997; Hermening et al., 2000) and non-carboxylate (Dalgaard and Larsen, 1999; 
Paulson et al., 2000a; Paulson et al., 2000b; Paulson et al., 2000c; Mutlib et al., 2002) 
drugs by oxidative metabolism, lactone hydrolysis (Prueksaritanont et al., 2002; 
Ramadan et al., 2006) or a combination of oxidative and hydrolytic reactions (Pekol et 
al., 2005).  In certain cases the pathways of formation are complex and unexpected 
(Umehara et al., 2004), exacerbating the difficulties of assessing the overall biological 
impacts of pharmaceutical carboxylates.  For a number of classes of drugs, including 
classes currently in development, the carboxylic acid group may be the 
pharmacophore, or a component of the pharmacophore, having a direct role in the 
mechanism of action of the compound (Istvan and Deisenhofer, 2001; Rowlinson et al., 
2003).  Consequently, over 450 pharmaceuticals marketed worldwide contain a 
carboxylic acid functional group (Smith, 2010). 
For some compounds, the carboxylic acid group may have a direct role in the 
mechanism of action of the compound.  In the simplest cases, carboxylic acid drugs 
and/or their metabolites match the functional group chemistry of natural substrates or 
ligands.  A prime example of this is in the carboxylic non-steroidal anti-inflammatory 
drugs (NSAIDs), where the carboxylic acid structure is important for the mimicking of 
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the arachidonic acid metabolite (Rowlinson et al., 2003); resulting in the competitive 
antagonism of arachidonic acid binding to cyclooxygenase (COX-2 and/or COX-1) 
isozymes (Rowlinson et al., 2003; Khairullina et al., 2007), inhibition of prostaglandin 
synthesis, and consequently, anti-inflammatory effects (Waterbury et al., 2006).  The 
propensity of carboxylic acids to form hydrogen bonds with polypeptide side chains 
and the ability of carboxylate anions to engage in electrostatic interactions (ion 
pairing) are also important in forming non-covalent interactions with target receptors 
and active sites of enzymes (Istvan and Deisenhofer, 2001). 
Carboxylate groups are also commonly incorporated into medicinal compounds as a 
method to provide improved aqueous solubility. Good aqueous solubility is often a 
desired property for a pharmaceutical compound, as this enhances a molecules passive 
absorption from the GI tract to the bloodstream, without requiring affinity for 
transporters. However, if the carboxylic acid is matched with a complementary basic 
centre in the molecule, and the resulting isoelectric point is close to pH 7.4, the 
compound’s zwitterion species will have increased membrane penetration at 
physiological pH and potentially increased bioavailability (Cavet et al., 1997).  Due to 
their polar nature, represented by their ionisation in aqueous conditions and ability to 
form hydrogen bonds with water through the (=O) acting as a hydrogen bond acceptor 
and the (-OH) acting as a hydrogen bond donor, carboxylic acid structures are often 
desired to enhance hydrophilicity of lead compounds.  Alternatively, due to the their 
polarity and electronegativity, carboxylic acid groups may be inserted into aromatic 
ring side-chains to protect against P450 metabolism, pulling electrons away from sites 
of susceptible oxidation (Smith, 2010). 
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However, the increased polarity and resulting hydrophilicity introduced to compounds 
through carboxylic acids can also result in their notoriously poor ability to passively 
diffuse across plasma membranes, particularly when it is in negatively charged states 
(Austin et al., 1995).  Consequently, without the action of uptake transporters, 
distribution of carboxylate compounds to intracellular targets is poor.  This poor 
diffusion across plasma membranes represents a particular challenge for drugs 
targeted towards the central nervous system (CNS) where passive absorption across 
the blood brain barrier is required for efficacy (Pajouhesh and Lenz, 2005).  This 
resulting low volume of distribution (VDss) of carboxylic acid drugs (Smith and Obach, 
2005; Smith, 2010) is further reduced through their extensive non-covalent binding to 
plasma proteins (often >99% fraction bound) (Kratochwil et al., 2002).   In order to 
overcome these problems with distribution, carboxylic acid drugs are frequently 
administered at high daily doses in order to allow drug disposition to its mechanistic 
site of action at concentrations sufficient to elicit pharmacological effect, meaning that 
circulating doses of the drug generally are high.  With carboxylate drugs associated 
with liability towards generating off-target liabilities as a consequence of bioactivation 
at this site (see sections 1.4.1, 1.4.3, 1.6 and 1.8.1) this is a situation which is desirably 
avoided (Sakatis et al., 2012).   
1.4.1 Association of carboxylic acid drugs with ADRs 
Clinically, patients are exposed to a wide range of carboxylic acids, for varying 
therapeutic indications, including NSAIDs, fibrates, loop diuretics, iron chelators, 
antiasthmatics, antibiotics, anticonvulsants, antiretrovirals, angiotensin II receptor 
antagonist, thromboxane synthase inhibitors, direct thrombin inhibitors and PPARα/β 
agonists.  The most important of which are NSAIDs, of which 6% of the adult 
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population in the US reported using a prescription NSAID in a month, and 24% using 
non-prescription ibuprofen (Paulose-Ram et al., 2003).  This large range of important 
therapeutic drug classes means large numbers of the population are exposed to 
carboxylic acid pharmaceuticals.  The majority of patients receive effective therapy, 
with few safety concerns. 
Despite the majority of carboxylic acids acting as safe therapeutics to the majority of 
patients who are exposed to them, on rare occasions, carboxylic acids individually, or 
as a sub-class, such as the carboxylic NSAIDs, have been associated with eliciting 
immune mediated hepatotoxic and hypersensitivity adverse drug reactions.   This 
association led to 17 out of 121 (14%) drugs withdrawn between 1960-1999 containing 
a carboxylic acid functional group (Fung et al., 2001).  Further to this, some older 
carboxylic acid drugs remaining on the market, such as diclofenac, do so with black box 
warnings or reported cases of eliciting these ADRs (Skonberg et al., 2008). 
1.4.2 Immediate hypersensitivity reactions 
NSAIDs have been associated with a wide range of differing hypersensitivity adverse 
drug reactions.  These ADRs may be immediate, with disease pathogenesis occurring 
within 1-7 hours of first administration of the compound.  Immediate hypersensitivity 
reactions are generally less serious than delayed hypersensitivity reactions, although 
occasionally these immediate ADRs may progress into more serious generalised 
anaphylactic reactions (Stevenson et al., 2001; Berkes, 2003).  Therefore it is 
generation of delayed hypersensitivity adverse drug reactions that is the most 
common cause for carboxylic acid drug withdrawal. 
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1.4.3 Delayed hypersensitivity reactions 
Delayed hypersensitivity ADRs are generally classified as developing over 24 hours 
following drug exposure, but usually develop between 1-8 weeks following initiation of 
drug therapy (Gunawan and Kaplowitz, 2004; Kaplowitz, 2001).  The most common 
delayed ADRs associated with carboxylic acid drugs are cutaneous (including severe 
bullous cutaneous reactions, fixed drug eruptions and maculopapular drug eruptions).  
These ADRs led to the withdrawal of zomepirac (Levy and Vasilomanolakis, 1984).  
Further to this, several carboxylic acid drugs were also associated with the generation 
of tissue specific hypersensitivity reactions including hepatotoxicity, leading to the 
withdrawal of drugs including benoxaprofen, bromfenac and fenclozic acid, although 
these reactions were less common (Bakke et al., 1995; Fung et al., 2001; Sanchez-
Borges et al., 2005). 
Drug induced delayed hypersensitivity ADRs are off-target, and consequently only 
affect a small fraction of the population (Strom et al., 1987; Banks et al., 1995), with 
confident prediction of ‘at-risk’ individuals not currently possible.  Adaptive immune 
responses are thought to play a key role in the pathogenesis of these ADRs (Posadas 
and Pichler, 2007).  Evidence for this is strengthened with observations that following 
withdrawal of the compound to alleviate ADRs, re-exposure may lead to rapid re-
stimulation of the ADR (Helfgott et al., 1990).  The short timeframe between re-
exposure and redevelopment provides further suggestion of adaptive immune 
involvement, with reactions suspected to be cytotoxic T-cell mediated (Posadas and 
Pichler, 2007).  
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1.5 ROLE OF ANTIGEN PRESENTATION IN DELAYED HYPERSENSITIVITY 
REACTIONS 
1.5.1 Pro-hapten and hapten hypotheses 
Most pharmaceutical compounds on the market are small molecules.  Consequently, 
they are assumed to be of insufficient size to be recognised as foreign and presented 
to the immune system.  It has been hypothesised that parent compounds or their 
CRMs must be presented to the immune system in an altered state with higher 
molecular weight for recognition as foreign entities (Padovan et al., 1997). 
The hapten concept describes how low molecular weight organic compounds (<1000 
Da), undetectable by the immune system due to their size, may be presented through 
the formation of covalent adducts with endogenous macromolecules (Park et al., 1987; 
Padovan et al., 1997; Park et al., 2001; Posadas and Pichler, 2007).  This suggests that 
parent molecules must have protein reactivity.  Most pharmaceuticals, however, are 
devoid of chemical reactivity but their bioactivation into CRMs capable of forming 
covalent adducts with endogenous macromolecules may lead to their presentation 
(Kenna et al., 1988b; Park et al., 2001; Naisbitt et al., 2002; Aithal et al., 2004; Posadas 
and Pichler, 2007).  Molecules able to directly modify endogenous macromolecules 
without processing are known as haptens, whereas molecules requiring bioactivation 
into CRMs are known as pro-haptens.   
Haptenation may occur on autologous proteins, or alternatively, may occur directly 
onto the major histocompatibility complex (MHC) of T-cells.  Those antigens formed on 
endogenous macromolecules, either intracellularly or to extracellular cell surfaces, 
may require processing by antigen presenting cells before presentation to T-cells for 
stimulation of sensitization and immune responses (Posadas and Pichler, 2007). 
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1.5.2 Antigen presentation as a response to the cellular site of endogenous 
modification 
Following adduct formation with endogenous protein, the resulting drug-protein 
complex may either activate MHC molecules directly or require processing for this.   
Antigen presenting cells cleave the hapten-protein adduct into peptide fragments, 
onto some of which the hapten may be bound.  The haptenated peptide is able to bind 
weakly to the MHC in the cell (Naisbitt et al., 2007).  Where the haptenated peptide 
locates in the cell has an effect on which class of MHC molecule it is presented by.  
Haptens which bind to extracellular proteins usually require capture in the endosome, 
followed by subsequent lysozyme degradation, and are usually presented by MHC class 
II molecules, leading to CD4+ T-cell responses.  Intracellular haptens, on the other 
hand, appear to be presented specifically by MHC class I molecules.  Following 
processing of the protein adducts, the antigen presenting cell locates to the lymphatic 
organs, where antigens are then presented to the T-cells through the MHC molecules, 
resulting in CD8+ T-cell responses (Pichler, 2003).  
1.5.3 Pharmacological interaction (PI) hypothesis 
Whilst immune stimulation through the covalent binding of drug species to 
endogenous macromolecules is assumed to play a large role in a wide range of ADRs, 
Pichler (Pichler, 2002) has proposed that in some cases of drug hypersensitivity 
covalent binding may not be critical.  Instead, compounds form weak, reversible, non-
covalent interactions with MHCs and T-cell receptors.  Interaction with the MHC may 
result in antigen presentation to T-cells expressing appropriate T-cell receptors, 
subsequently resulting in the initiation of immune stimulation. 
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1.5.4 Danger hypothesis 
To elicit an efficient immune response, the innate immune system needs to be 
activated.  The innate immune response provides defence against a wide range of 
pathogens but its defence is non-specific.  However, the innate immune system 
includes the antigen presenting cells, which, as described above, present hapten-
peptide adducts to T-cells, initiating the more specific adaptive immune response 
(Medzhitov and Janeway, 2000).  The activation of the antigen presenting cells has also 
been postulated to cause the expression of co-stimulatory molecules, which aid in 
activating resting T-cells (Kamradt and Mitchison, 2001).  It is also likely that an 
underlying infection may result in the activation of the innate immune system as 
described above, resulting in cytokine and co-stimulatory molecule release.  This 
effect, when occurring concomitantly with the administration of an immunogenic drug, 
may also result in increased T-cell activation, producing an immune response to the 
drug which otherwise might not have been initiated (Heller, 2000).  This may help to 
explain why individuals suffering with an underlying infection often show an increased 
risk of developing immune mediated adverse drug reactions (Pichler, 2003). 
Another factor which is thought to be involved in drug hypersensitivity reactions is 
Matzinger’s danger hypothesis.  The danger hypothesis proposes that an inflammatory 
response is not initiated through just the recognition of a non-self antigen, but that 
other signals are required to indicate that the foreign antigen is dangerous (Matzinger, 
1994a).  Curtsinger (Curtsinger et al., 1999a) has subsequently hypothesised that three 
signals are required for the eliciting of an immune response.  The first signal is the 
presentation of the antigen to the T-cell through the MHC complex of an antigen 
presenting cell.  The second signal is from co-stimulatory molecules and pro-
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inflammatory cytokines, which cause antigen-presenting cells to release other 
stimulatory molecules.  The third signal is from polarising cytokines, which act on T-
cells and lead to immune responses.  Whilst signal 1 is the recognition of the foreign 
antigen, receipt of only this signal results in tolerance to the antigen (Matzinger, 
1994b), further receipt of signal 2 results in T-cell activation and signal 3 acts as an 
adjuvant, resulting in the propagation in the immune response (Cai et al., 1996; 
Curtsinger et al., 1999b; Pirmohamed et al., 2002) (Figure 1. 3). 
 
Figure 1. 3:  Potential mechanism for carboxylic acid drugs to elicit inappropriate 
immune responses according to the hapten and danger hypotheses.  
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1.6 DRUG METABOLISM TO ACYL GLUCURONIDE METABOLITES  
Direct glucuronidation, resulting in the formation of AG metabolites is quantitatively 
the most important route of biotransformation for carboxylic acid drugs (Skonberg et 
al., 2008).  Acyl glucuronidation of both mono- and di- carboxylic acids have been 
reported (Wen et al., 2007), with di- carboxylic acids capable of forming either two 
distinct mono-AG (Devissaguet et al., 1990; Wen et al., 2006), as well as di-AG 
conjugates (Wen et al., 2006).   
In addition to acyl glucuronidation, many carboxylic acid drugs also undergo oxidative 
(Stierlin and Faigle, 1979; Balani et al., 1997; Hermening et al., 2000; Wang et al., 2006; 
Albrecht et al., 2008), and other conjugative metabolism (Dickinson et al., 1993; Sun et 
al., 1996; Dahms et al., 1997; Picard et al., 2005; Alonen et al., 2008).  Further to this, 
oxidative metabolites of carboxylate pharmaceuticals may also undergo acyl 
glucuronidation (Hermening et al., 2000; Zhou et al., 2001; Kenny et al., 2004; Wang et 
al., 2006; Albrecht et al., 2008).  Oxidative metabolism of non-carboxylate drugs may 
also reveal carboxylic acid functional groups, which may subsequently be 
glucuronidated into AG metabolites as is shown for celecoxib (Paulson et al., 2000a; 
Paulson et al., 2000b; Paulson et al., 2000c). 
Direct glucuronidation of carboxylic acids, forming AG metabolites can represent a 
large fraction of their metabolic clearance (Zhou et al., 2001; Wang et al., 2006), with 
the dicarboxylic acid fibrate gemcabene cleared almost exclusively by acyl 
glucuronidation followed by renal elimination (Yuan et al., 2009).  In rare instances, 
acyl glucuronidation may represent the sole pathway of biotransformation of a 
carboxylic acid, as appears to be the case for telmisartan (Stangier et al., 2000) and 
ifetroban (Dockens et al., 2000), although glucuronidation is not a universal metabolic 
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pathway of carboxylate drugs, as shown by the lack of a glucuronide metabolite for 
captopril, and identification of the acyl glucuronidation of two of four structurally 
similar di-acid ACE inhibitors (Devissaguet et al., 1990; Drummer et al., 1990; Tan et al., 
2009). 
Glucuronidation of numerous pharmaceuticals is catalysed by the UGT isoform 
UGT2B7, including carboxylic acids such as diclofenac (King et al., 2001), gemfibrozil 
(Mano et al., 2007b) and mycophenolic acid (Picard et al., 2005), for all of which it is 
the predominant catalyst.  However, other human UGT isoforms contribute to the 
clearance of carboxylic acid drugs and carboxylate metabolites, with UGT2B7 not 
always the major catalyst (Wen et al., 2007; Alonen et al., 2008), as exemplified by the 
glucuronidation of bilirubin in man catalysed by the UGT1A1 isoform (Kadakol et al., 
2000).  Turnover of various carboxylic acids to their acyl glucuronides is exemplified by 
Table 1. 2. 
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Table 1. 2:  Carboxylic acid drugs that undergo glucuronidation in human liver 
microsomes or following clinical administration of the parent drug (Regan et al., 
2010) 
Drug Drug class 
Fraction 
glucuronidated 
Zomepirac NSAID 90 
Isoxepac NSAID 90 
Ketoprofen NSAID 74 
Carprofen NSAID 75 
Diclofenac NSAID 75 
Keterloac NSAID 73 
Suprofen NSAID 62 
Clofibric Acid Fibrate 61 
S-Naproxen NSAID 57 
Aclofenac NSAID 56 
Nalidixic Acid Antibacterial 54 
Tiaprofenic 
Acid 
NSAID 51 
Fenoprofen NSAID 49 
Benoxaprofen NSAID 47 
Pirprofen NSAID 45 
Probenacid 
Uricosuric 
agent 
44 
Diflusinal NSAID 40 
Fenofibric 
Acid 
Fibrate 39 
Oxaprozin NSAID 39 
Valproic Acid Anticonvulsant 33 
Tocainide Antiarrhythmic 31 
Etodolac NSAID 25 
Salicylic Acid 
Keratolytic 
agent 
10 
Lumiracoxib NSAID 2.5 
 
Generally AGs and other glucuronides are eliminated in urine and bile.  For example 
the acyl and phenolic glucuronides of the NSAID diflunisal are both excreted in urine 
and bile in both humans (Verbeeck et al., 1988) and rats (Brunelle and Verbeeck, 
1997).  Biliary excretion of AGs in humans has only been investigated on few occasions 
but it is clearly a highly variable process, representing a minor route of elimination for 
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certain AGs (Verbeeck et al., 1988; Balani et al., 1997) and a major route for others 
(Hofmann et al., 2005; Wang et al., 2006).  
1.6.1 Toxicological concerns regarding acyl glucuronide formation 
Phase II conjugative metabolism is usually seen as a detoxification process.  This is 
through the pharmacological deactivation of the drug, and increased rate of clearance 
via enhanced hydrophilicity of the molecule and increased affinity for export 
transporters (Caldwell, 1982; Miners and Mackenzie, 1991; Mulder, 1992; Spahn-
Langguth and Benet, 1992).  AG metabolites, however, have been shown to be 
chemically unstable and protein reactive in vitro  (Munafo et al., 1990; Volland et al., 
1991; Spahn-Langguth and Benet, 1992; Ding et al., 1993; Ding et al., 1995; Qiu et al., 
1998; Ebner et al., 1999; Iwaki et al., 1999; Mortensen et al., 2001; Walker et al., 
2007), resulting in much interest in these metabolites as a potential toxicological 
concern (Faed, 1984; Spahn-Langguth and Benet, 1992; Shipkova et al., 2003).  The 
protein reactivity of AG metabolites has led to suggestion of their ability to act as 
CRMs capable of forming haptens in vivo, and consequently having a mechanistic role 
in the pathogenesis of idiosyncratic delayed hypersensitivity reactions associated with 
their parent drugs (Spahn-Langguth and Benet, 1992).  These general assumptions 
have been incorporated in the Food and Drug Administration’s Metabolites In Safety 
Testing (MIST) guidance, which states: 
 “Phase II conjugation reactions generally render a compound more water soluble and 
pharmacologically inactive, thereby eliminating the need for further elimination.  
However, if the compound forms a toxic conjugate such as an acyl glucuronide, 
additional safety assessment may be required (Faed, 1984)” (FDA, 2008).   
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This assertive labelling of AG metabolites as toxic, however, is controversial.  Whilst 
their reactivity in vitro is well defined, when compared with other CRMs, reactivity of 
AG metabolites is low.  This low reactivity of AGs does allow them to be widely 
distributed through the blood stream (Volland et al., 1990; Benet et al., 1993; Mayer et 
al., 1993; Zia-Amirhosseini et al., 1994; Stangier et al., 2000; Zhou et al., 2001; Wang et 
al., 2006), and transported into tissues (Shackleford et al., 2006), but despite this wide 
distribution, no definitive identification of AG metabolites reactivity towards 
endogenous macromolecules has ever been shown using in vivo models or in man.  
The only reported chemical reaction of drug AG administered intravenously to 
experimental animals is rapid and extensive hydrolysis (Watt et al., 1991; Iwaki et al., 
1995).  Consequently, evidence associating AG metabolites with toxicity may not be 
justified.  Nonetheless, the speculative association of AG formation and clinical toxicity 
has resulted in persistent concern in the pharmaceutical industry regarding 
management of compounds forming reactive AG metabolites, even when the 
glucuronide is a minor product (Lundahl et al., 2009).   
1.6.2 Acyl glucuronide chemical instability and protein reactivity  
Chemical instability of AGs following in vitro incubation under aqueous conditions is 
almost a universal chemical characteristic of these phase II metabolites.  The actual 
chemical instability of AG metabolites is greatly variable, with the degradation half-life 
for the disappearance of the 1-beta isomer ranging from 0.26 hours for tolmetin-AG to 
79 hours for valproic acid-AG (Ebner et al., 1999).  This marked variation of the intrinsic 
reactivity of differing acyl glucuronides has been attributed to the electronic and steric 
properties of the aglycones (Benet et al., 1993).  Currently, research is being 
undertaken into assessing structure activity relationships of aglycone structure to 
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allow understanding of the attributes of chemical structure attributing to this variation 
in acyl glucuronide reactivity.  The general rate of acyl glucuronide reactivity is 
understood to be acetic acid > proponoic acid > benzoic acid derivatives (Benet et al., 
1993; Wang et al., 2004).  This order is thought to be attributable to the level of 
substitution of the carbon alpha to the carboxylic acid in the aglycone structure.  With 
good correlations (r2 = 0.995) being drawn between the intrinsic chemical instability of 
AG metabolites and their reactivity towards protein following in vitro incubation 
(Benet et al., 1993), compounds extensively metabolised to reactive AGs have been 
suggested to provide greater risk for generation of ADRs.  Comparisons of AG 
instability with the risk of ADR generation and fate of both previously and currently 
marketed carboxylic acid drugs, however, are not always clear.    
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1.7 ACYL GLUCURONIDE REACTIVITY WITH PROTEINS IN VIVO 
1.7.1 Evidence from studies in humans 
Circumstantial evidence for the ability of AG metabolites to act as haptens in vivo has 
been provided through the identification of modification of plasma proteins in patients 
administered either zomepirac, ibuprofen or tolmetin, as measured using an alkaline 
hydrolysis technique, correlating with plasma exposure (AUC) of the AG metabolite 
(Smith et al., 1986; Hyneck et al., 1988; Castillo et al., 1995).  Further identification that 
AG metabolites are responsible for these covalent adducts was obtained through the 
co-administration of probenecid and zomepirac to volunteers.  Probenecid increased 
plasma zomepirac-AG exposure by competing for renal clearance, consequently 
increasing zomepirac’s modification of plasma protein (Smith et al., 1986). 
1.7.2 Animal models 
Further indications that the protein reactivity of AG metabolites is operative in vivo 
have been achieved through investigations using rats and guinea pigs as model 
species. 
As with studies in humans, covalent modifications of plasma proteins following 
administration of several carboxylic acid drugs were detected, with binding correlating 
with AG exposure (Sallustio and Foster, 1995; Liu et al., 1996; Dong et al., 2005).  
Further suggestion for the role of AG metabolites to covalently bind with endogenous 
macromolecules was achieved through the detection of increased covalent binding 
through disruption of chemical and surgical disruption of elimination pathways, with 
chemical induction of renal failure in rats through the administration of uranyl nitrate 
enhancing plasma AG exposure following administration of salicylic acid, along with 
subsequent enhanced irreversible modification of plasma proteins (Liu et al., 1996).  
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Interruption of biliary excretion through surgical ligation of the bile duct in rats was 
also shown to increase the plasma exposure of zomepirac-AG, causing enhanced 
modification of plasma proteins (Wang and Dickinson, 2000).  Chemical inhibition of 
plasma esterases (using phenylmethylsulfonylfluoride PMSF) has also been used to 
increase plasma AG exposure, through reduction of AG hydrolysis in vivo.  In guinea 
pigs, bile duct ligation was required in order to produce detectable levels of 
zomepirac-AG in the plasma.  Concomitant administration of PMSF to guinea pigs 
administered an intravenous dose of zomepirac resulted in enhanced plasma AG 
exposure.  This further increase in AG plasma exposure was again found to again show 
good correlation with irreversible binding, and to date is the most convincing in vivo 
evidence of the ability of AG metabolites to covalently modify plasma proteins (Smith 
et al., 1990).   
(Bailey and Dickinson, 1996), using four test carboxylate drugs (zomepirac, diflunisal, 
clofibric acid and valproic acid) in rats, observed a generally rationalizable relationship 
between the intrinsic chemical reactivity of the drug’s acyl glucuronides in vitro and 
the extent of protein adduction in liver and plasma.  However, there was an important 
exception: the protein adduction by valproic acid in the liver was disproportionately 
high.  This enhanced covalent binding was attributed to the localised reactions of acyl 
CoA (thioester) conjugates, in addition to that from AGs.  Western blot analysis with 
anti-drug antibodies was used for partial identification of hepatic protein adducts, but 
this only allowed estimation of the molecular weights of proteins that were modified. 
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1.7.3 Detection of hepatic adducts in experimental animal models 
Whilst some carboxylic acid drugs are associated with generalised delayed 
hypersensitivity reactions, others, including benoxaprofen, diclofenac and ibufenac are 
more frequently associated with delayed off-target hepatotoxicity reactions (Driver et 
al., 1982; Rake and Jacobs, 1983; Banks et al., 1995; Fung et al., 2001; Boelsterli, 
2002a; Goldkind and Laine, 2006).  Strong suggestions of immune involvement in the 
pathogenesis of these ADRs have also led to the investigation of hepatic protein 
adducts in animal models. 
Administration of diclofenac, zomepirac, ibuprofen and diclofenac to the rat or mouse 
has revealed selective modification of hepatic proteins.  Hepatic proteins modified 
were found to have molecular weights including 110, 140 and 200 kDa (Bailey and 
Dickinson, 1996; Wade et al., 1997).  Work by (Hargus et al., 1995) went on to identify 
the 110 kDa protein using sequence analysis and immunoblotting as the enzyme 
dipeptidylpeptidase IV (DPPIV and also known as CD26) following diclofenac 
administration.  Work with zomepirac also identified DPPIV as a protein target (Wang 
et al., 2001; Wang et al., 2002).  Further adducts of 50 and 70 kDa were identified by 
(Pumford et al., 1993b; Wade et al., 1997). 
Immunohistochemical analysis has allowed sub-cellular location of hepatic protein 
modification by carboxylic acid drugs in rats.  Covalent adducts in the rat were found 
localised to the canalicular membrane (Hargus et al., 1994; Seitz et al., 1998; Aithal et 
al., 2004).  TR- rats, which do not express functioning MRP2 export proteins on the 
canalicular membrane, show minimal biliary excretion of diclofenac-AG and do not 
show canalicular protein adducts following treatment with diclofenac (Seitz et al., 
1998).  Due to the extensive biliary export of acyl glucuronides, in part due to the 
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abundance of export transporters (Sallustio et al., 1996; Sallustio et al., 2000), 
exposures of proteins along the canalicular membrane to AGs are likely to be high.  
This association has also resulted in further implication of acyl glucuronide metabolites 
in eliciting these canalicular localised adducts. 
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1.8 OTHER FACTORS INFLUENCING TOXICOLOGICAL RISK POSED BY ACYL 
GLUCURONIDES IN HUMANS 
The implication of acyl glucuronidation as a potential toxicological process is centred 
on the potential of AGs to act as haptens, forming covalent protein adducts.  This has 
been well defined and characterised following in vitro incubation (Benet et al., 1993; 
Ding et al., 1993; Ding et al., 1995; Qiu et al., 1998), and is the basis of much of the 
concern within the pharmaceutical industry as to the management of novel 
compounds extensively metabolised to reactive acyl glucuronides.  Despite this 
persistent concern, no evidence as yet has definitively shown AG metabolites of drugs 
are directly responsible for covalent adduct formation in vivo.  Potentially this may 
mean the anxiety over AGs, at least in the respect of direct protein adduction, may be 
unjustified.  Further to this, many AG-forming drugs remain on the market providing 
safe and effective therapy for patients, as well as considerable profit for the 
pharmaceutical industry (Paulose-Ram et al., 2003; Barton et al., 2006).   
1.8.1 Metabolism of carboxylic acid drugs to CRMs other than acyl 
glucuronides 
Commonly, xenobiotic carboxylic acids, including drugs, may also undergo conjugation 
reactions catalysed by acyl-Coenzyme A synthetases forming acyl-Coenzyme A 
thioesters (Olsen et al., 2002; Grillo et al., 2003; Olsen et al., 2005; Olsen et al., 2007).  
Formation of coenzyme A thioesters is thought to represent a low abundance 
metabolic pathway, however, the resulting metabolites are considered as highly 
reactive.  This is in comparison to AG metabolites, which are considered to represent 
high exposure but lower reactivity (Boelsterli, 2002b).  The synthetic coenzyme A 
thioester of 2-phenylpropionic acid has been shown to undergo a transacylation 
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reaction with glutathione, and to react with serum albumin in vitro (Li et al., 2002).  
Naproxen coenzyme A thioester acylates several amino acid side chains of HSA in vitro 
(Olsen et al., 2003b).  Whilst coenzyme A thioesters are becoming an area of interest 
as a potential toxicological concern, this interest has only begun relatively recently 
(Boelsterli, 2002b).  However, whereas drug AGs are frequently found in plasma, 
coenzyme A conjugates are thought to be confined to their cellular site of formation.  
Thus the existence of coenzyme A conjugates of xenobiotics in vivo is known only from 
the presence of stable metabolic derivatives (Olsen et al., 2003a; Grillo and Hua, 2008; 
Grillo et al., 2008). 
Further to reactive biosynthetic esters, individual carboxylate compounds may have 
sites of reactivity generated through oxidative metabolism.  An example of this 
mechanism is the formation of a quinone-imine structure following oxidative 
metabolism of diclofenac to the 5-hydroxy metabolite (Poon et al., 2001).  These 
reactive metabolites also have the ability to form covalent adducts with proteins (Shen 
et al., 1999), as is the case with NAPQI.  Therefore a drug might be metabolised to 
several chemically reactive and potentially toxic intermediates, with an AG being just 
one of them. 
1.8.2 Limitations of alkaline hydrolysis as a method to investigate acyl 
glucuronide reactivity in vivo 
Alkaline hydrolysis with subsequent HPLC analysis (Hyneck et al., 1988; Smith et al., 
1990; Benet et al., 1993; Munafo et al., 1993; Bischer et al., 1995) and antibody 
techniques (Hargus et al., 1994; Bailey and Dickinson, 1996; Aithal et al., 2004) have 
been the usual techniques for the identification of carboxylic acid compound 
modification of proteins in vivo.  A major limitation of this approach, however, is that 
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these techniques are unable to identify or differentiate between the reactive 
metabolites responsible for the modifications detected.  Consequently, with carboxylic 
acids potentially metabolised to several different products with the potential for 
covalent modification of macromolecules in vivo (Li et al., 2002; Olsen et al., 2002; 
Kenny et al., 2004; Sidenius et al., 2004), adducts detected may not necessarily be AG-
metabolite mediated.   
Whilst covalent modifications to plasma proteins in rodent and human studies 
correlate to plasma AG exposure (Hyneck et al., 1988; Benet et al., 1993; Castillo et al., 
1995; Liu et al., 1996), it is also possible that metabolism into other metabolites not 
tested may also show equal or improved correlation.  Consequently, until the 
identification of glycation adducts of proteins in samples taken in vivo is achieved using 
MS/MS techniques, questions will remain as to the true potential of AG metabolites to 
act as haptens. 
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1.9 DICLOFENAC AS A TEST CARBOXYLATE DRUG 
Diclofenac, a phenylacetic acid NSAID, is currently used principally in the treatment of 
rheumatoid arthritis (Boelsterli, 2003).  The mechanism of action in vivo is expected to 
be through non-selective inhibition of the cyclooxygenase (COX-1 and COX-2) 
isoenzymes, inhibiting the metabolism of arachidonic acid to prostaglandins 
(Waterbury et al., 2006).  Approximately 15% of patients taking repeated doses of 
diclofenac develop raised liver enzyme activity, with a threefold rise in transaminase 
levels reported in 5% (Banks et al., 1995).  Usually these minor rises are not a clinical 
cause for concern, and treatment may be continued with monitoring of the patient.  
Diclofenac has also been associated with more serious off-target hepatotoxic 
reactions, with 6.3 out of 100,000 diclofenac users requiring hospitalisation (de Abajo 
et al., 2004).  These off-target ADRs usually manifest with either a hepatocellular or 
cholestatic pattern (Banks et al., 1995; Aithal and Day, 2007; Aithal, 2011).  Further to 
this, diclofenac has also been associated with case reports of generalised 
hypersensitivity ADRs (Alkhawajah et al., 1993; Romano et al., 1998).  
In humans, diclofenac is metabolised to several metabolites (Stierlin and Faigle, 1979).  
Diclofenac is oxidised by CYP2C9 to the 4’-OH metabolite, and by CYP2C8, 3A4 or 2C19 
to the 5’-OH metabolite (Tang et al., 1999a; Tang et al., 1999b).  Spontaneous 
oxidation of the 5’-OH metabolite yields a chemically reactive quinone-imine (Shen et 
al., 1999; Sparidans et al., 2008).  Both 4’OH-diclofenac and 5’OH-diclofenac yield 
electrophilic quinone-imine derivatives that react with GSH in vivo (Poon et al., 2001; 
Kenny et al., 2004).  Additionally, diclofenac may be conjugated with coenzyme A, 
resulting in the formation of a reactive CoA thioester conjugate (Grillo et al., 2003), as 
well as directly glucuronidated to an acyl glucuronide metabolite (Stierlin and Faigle, 
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1979).  The S-acyl glutathione adduct of diclofenac produced in human hepatocytes 
might be formed via transacylation of GSH by a CoA thioester intermediate and/or the 
known AG conjugate (Grillo et al., 2003). 
Figure 1. 4:  Metabolism of diclofenac to its acyl glucuronide metabolite in human 
liver.  Diclofenac is glucuronidated principally by UGT2B7, to a lesser extent by 
UGT1A9, and to minor extents UGT1A6 and UGT2B15 (King et al., 2001). 
 
Hepatic microsomal metabolism experiments estimated acyl glucuronidation of 
diclofenac to be approximately 75% of the drug’s clearance in man (Kumar et al., 
2002).  In phosphate buffer, pH7.4, the acyl glucuronide of diclofenac is chemically 
unstable, with a half-life of 0.51 hours (Ebner et al., 1999).  Nevertheless, it has been 
detected in the plasma of mice administered diclofenac (Sparidans et al., 2008).  
Diclofenac-AG has been shown to form covalent adducts with HSA in vitro (Kenny et 
al., 2004) and with protein in rat liver microsomes (Kretz-Rommel and Boelsterli, 
1994).  Identification of antibodies to diclofenac metabolite-modified liver protein 
adducts in the sera of 7/7 patients diagnosed with diclofenac-induced hepatotoxicity, 
and 12 out of 20 without hepatotoxicity and none of four healthy controls (Aithal et 
al., 2004) provides evidence that reactive diclofenac metabolites form covalent 
adducts in man.  However, as with all other AG-forming compounds, no definitive 
evidence of AG metabolites being responsible for these adducts has ever been shown.  
Due to these properties, diclofenac represents a suitable model compound for 
investigating idiosyncratic reactions to carboxylic acid drugs, and more specifically the 
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potential of AG reactive metabolites to form covalent adducts with proteins in vivo 
(Boelsterli, 2003; Aithal, 2004). 
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1.10 AIMS OF THE THESIS 
AG drug metabolites remain a major challenge for the pharmaceutical industry as to 
their management.  Extensive metabolism of a novel chemical entity into a carboxylic 
acid drug results in much anxiety as to its management and future progression.  The 
reason for this is the assumed potential of these reactive metabolites to form haptens 
capable of eliciting inappropriate autoimmune responses historically associated with 
carboxylic acid drugs.  Whilst the protein reactivity of AG metabolites has been shown 
following in vitro incubation, and associations have been drawn from in vivo studies, 
direct and definitive associations for carboxylic acid drugs to form covalent adducts in 
vivo or in patients have never been reported.  Consequently the anxiety of AG 
metabolites to act as haptens, and have a causal role in eliciting the inappropriate 
immune responses which are characteristic in the pathogenesis of carboxylic acid 
mediated hypersensitivity and hepatotoxicity may be unjustified.  Until the 
mechanisms of carboxylic acid drug induced delayed hypersensitivity reactions are 
fully elucidated, and metabolites responsible are identified, prediction of the risk of 
novel chemical entities will remain challenging, and potentially inaccurate.  The work 
undertaken in this thesis is designed to provide a further insight into the potential of 
AG metabolites to act as haptens through the attempt to define their ability to form 
covalent adducts in man, using the AG metabolite of diclofenac as a test compound.  
This will be undertaken through the following experimental aims. 
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a. To define the chemical instability and protein reactivity of diclofenac-AG as 
well as the chemistry of interaction between the AG metabolite and protein 
through analysis of their protein binding and stabilities in phosphate buffer, 
HSA solution and plasma solutions.  Acyl glucuronides have been shown to be 
chemically unstable and protein reactive molecules, subsequently leading to 
their association with idiosyncratic ADRs.  Chemical instability of AGs in 
aqueous conditions has been associated with their rate of covalent adduct 
formation, subsequently leading to the current working hypothesis within drug 
development that generation of a chemically unstable acyl glucuronide 
metabolite is a toxicological concern.  Through this chapter, the in vitro 
chemical instability and protein reactivity of the acyl glucuronide of the model 
drug diclofenac will be explored.  Diclofenac-AG will be incubated in phosphate 
buffer to assess its chemical instability.  Incubations with HSA solution will 
investigate its protein reactivity.  Degradation studies will be used to provide 
increased information on the chemical interactions between AG metabolites 
and protein. 
b. Investigate the plasma clearance of diclofenac-AG from the rat following 
intravenous administration.  The physiological role of glucuronidation of 
carboxylic acids is to i) deactivate the pharmacophore ii) increase rate of 
clearance, through enhancing polarity (and therefore hydrophilicity) and 
affinity for export transporters.  Despite AGs being protein reactive in vitro, 
their potential rapid clearance in vivo may prevent any accumulation of 
metabolite concentrations sufficient to form detectable adducts.  To 
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investigate this, the rate of clearance of diclofenac-AG following intravenous 
administration to the rat was measured and compared to that of the aglycone 
c. Investigate the use of continuous infusion to enhance plasma diclofenac-AG 
exposure to detectable levels, and as a method to investigate potential 
mechanisms for diclofenac-induced production of danger signals.  Clinically, 
diclofenac may be administered chronically for many years.  Subsequently 
acute exposure in vivo experiments may not be adequate in replicating the 
clinical situation.  Further to this, rats are known to exhibit higher rates of 
xenobiotic clearance than man.  Continuous infusion technologies, resulting in 
higher drug exposure may better represent the clinical situation.  Plasma 
pharmacokinetics of diclofenac were measured.  Investigation into potential 
hepatotoxicity of the drug was also undertaken, to investigate whether 
continuous drug exposure may elicit cell death, potentially revealing a 
mechanism for production of danger signals. 
d. Investigate if diclofenac is metabolised into its AG metabolite in patients 
receiving therapeutic doses, and if detectable serum albumin proteins can be 
detected in these patients using tandem mass spectrometry.  AG metabolites 
have been associated with forming covalent adducts to endogenous protein 
resulting in initiation of inappropriate immune responses in susceptible 
individuals.  Despite this hypothesis, no definitive identification of AG 
metabolite adduct formation has ever been definitively shown in vivo.  Through 
these experiments, using plasma samples isolated from patients receiving 
therapeutic doses of the drug will be assessed for covalent adducts using the 
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most sensitive mass spectrometry equipment available, in an attempt to reveal 
whether AG metabolites actually can form covalent adducts in vivo. 
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2.1 INTRODUCTION 
Chemical instability and protein reactivity of AGs are well-established characteristics of 
these metabolites from in vitro incubation experiments (Stachulski et al., 2006; Regan 
et al., 2010).  The perceived potential of AGs to manifest the same chemistry in vivo, 
and consequently form potentially immunogenic covalent adducts with endogenous 
proteins is central to the anxiety that AG metabolites of carboxylate drugs will elicit 
ADRs (Williams et al., 1992; Worrall and Dickinson, 1995; Bailey and Dickinson, 2003).   
Spontaneous chemical instability of AGs in aqueous solution at pHs > 7 is almost a 
universal characteristic of these Phase II metabolites.  As summarised by Table 2. 1, AG 
metabolites of drugs exhibit extensive variation in their chemical stabilities, with t½ of 
degradation at pH 7.4 and 37°C ranging from 0.26 hours for tolmetin-AG to 79 hours 
for the AG of valproate.  Strong correlations have been drawn between the chemical 
instability of AGs and their protein reactivity (r2 = 0.995 for nine AGs of carboxylate 
NSAIDs) (Benet et al., 1993).  These observations and associations between the 
chemical instability of AGs in phosphate buffer and toxicological risk of the parent 
carboxylate drug (Sawamura et al., 2010) have resulted in much interest in structural 
factors affecting the chemical stability of AGs (Nicholls et al., 1996; Johnson et al., 
2007; Johnson et al., 2010), and incorporation of AG stability studies into pre-clinical 
development of carboxylate drugs (Ebner et al., 1999; Wang et al., 2004; Walker et al., 
2007; Potter et al., 2011). 
The intrinsic chemical reactivity of an AG derives fundamentally from the 
electrophilicity of the ester carbonyl carbon (Baba and Yoshioka, 2009).  Consequently, 
these compounds degrade spontaneously under aqueous conditions and more rapidly 
when in the presence of simple nucleophiles, such as the hydroxide ion and short-
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chain alcohols (Dickinson and King, 1991; Silvestro et al., 2011), by two distinct 
chemical pathways, namely hydrolysis or acyl migration (Stachulski et al., 2006).  The 
relative rates of these pathways can vary considerably between AGs, as determined by 
the structure, including the stereochemistry of the aglycone (Johnson et al., 2007) and 
nature of the matrix (Johnson et al., 2010).  
The ester carbonyl carbon of the AG can undergo nucleophilic attack by -OH ions in 
biological media (Hyneck et al., 1988a), or be targeted by intracellular and extracellular 
enzymatic (hydrolase) attack (Smith et al., 1990b; Dubois-Presle et al., 1995; Bailey and 
Dickinson, 2003; Kenny et al., 2005; Iwamura et al., 2012).  This results in displacement 
of glucuronic acid and regeneration of the parent aglycone, and in vivo is responsible 
for conjugation-deconjugation cycles of AG metabolites (Brunelle and Verbeeck, 1997).   
Degradation of 1-β AG metabolites by intramolecular acyl migration is a consequence 
of nucleophilic attack on the carbonyl group by the adjacent hydroxyl group.  This 
causes electron displacement, resulting in the formation of an ortho-acid ester 
intermediate, before stabilisation with the aglycone moiety moved along the sugar ring 
as outlined by Figure 2.1.  Subsequently, this pathway allows the aglycone to move 
around the sugar ring from the C-1 position to the C2, 3 and 4 positions.  Following 
initial migration from the C-1 position, migration between the C2, 3 and 4 positions is 
reversible, however direct back migration to the C-1 position is not thought to be 
possible.  When the acyl residue is at C2, 3 and 4 positions, the hydroxyl group on C-1 
may reversibly move from the β to α orientation after a transient open ring 
intermediate is formed.  When the 1-β AG has rearranged to the 2α isomer, back acyl 
migration to the C-1 position is possible, forming the highly unstable 1α AG isomer 
(Corcoran et al., 2001; Baba and Yoshioka, 2009).  The α-1-O-acyl isomer in turn 
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undergoes acyl migration to a mixture of α/β-2-O-acyl isomers. Consequently, through 
acyl migration and epimerisation, the 1β AG metabolite can degrade into eight isomers 
in vitro, and through hydrolysis, may revert to the parent aglycone as outlined by 
Figure 2.1, Figure 2.2 and (Bailey and Dickinson, 2003; Stachulski et al., 2006). 
 
Figure 2. 1:  Positional isomers of acyl glucuronides and the electronic mechanism of 
acyl migration via ortho-ester transition states (Berry et al., 2009; Regan et al., 2010) 
 
Covalent modification of protein during in vitro incubation is essentially a generic 
reaction of AGs (Benet et al., 1993).  The rate and extent that AGs modify protein is 
likely to be distinct to each AG.  Factors influencing AG modification of protein include 
the chemistry of the aglycone, pH of the incubation mixture, concentration of protein 
and AG and the time course of incubation (Spahn-Langguth and Benet, 1992) 
The chemistry of the covalent interactions between AG metabolites and protein has 
been ascertained in part through the use of chemical modifications of the protein (site 
blocking) and its adducts (imine stabilisation) (Wells et al., 1987; Smith et al., 1990a) 
and radiochemical analysis of modified proteins following in vitro incubation with AGs 
(Ruelius et al., 1986).  This work has underpinned the identification of two pathways of 
AG adduct formation, namely acylation (intermolecular transacylation) and glycation 
(Ruelius et al., 1986; Wells et al., 1987; Smith et al., 1990a; Williams et al., 1992; Kretz-
Chapter 2 – Chemical Assessment of the Interactions between Acyl Glucuronide Drug 
Metabolites and Protein using HSA as a Model Protein 
Page 73 
 
Rommel and Boelsterli, 1994; Williams and Dickinson, 1994; Iwaki et al., 1999).  
However, it was not until the use of tandem mass spectrometric analysis that the 
covalent binding of AG to HSA was fully characterised (Ding et al., 1993; Ding et al., 
1995; Qiu et al., 1998).  Chemical pathways of adduct formation map closely to 
degradation pathways of the AG molecule, apparently forming covalent adducts only 
by these two pathways.  
As with the degradation of AGs by hydrolysis, AGs are also susceptible to nucleophilic 
attack by amino, guanidine, and hydroxyl groups found on proteins, resulting in the 
displacement of glucuronic acid.  This results in the acyl residue of the aglycone being 
covalently bound to the protein via amide and ester linkages (Ding et al., 1995; Qiu et 
al., 1998).  Formation of glycation adducts, however, from first principles of 
hemiacetal/aldehyde (pyranose/aldose) chemistry (Zhu et al., 2001; Brown et al., 
2011) requires prior migration of the acyl group to the 2, 3 and 4 ring positions (Smith 
et al., 1990a).  Following this rearrangement, a transient opening of the sugar 
(pyranose) ring can occur at C-1, during which the positional isomers can move 
between the β and α conformations.  The aldehyde function of the opened sugar ring 
(acyclic aldose structure) is susceptible to nucleophilic attack by amino groups found 
on proteins.  This aldehyde condenses with these groups, resulting in the reversible 
formation of imine adducts (Schiff bases) (Smith et al., 1990a).  The covalent reactions 
of aldohexoses and other sugars with proteins, at least in vitro, are governed generally 
by the proportion of the molecule present in its acyclic form (Syrovy, 1994).  However, 
this molecular parameter is apparently less influential in the reactions of AG with 
protein than the reversible non-covalent interactions preceding adduction (Smith and 
Wang, 1992).  The C-3 and C-4 Schiff bases may subsequently be stabilised through an 
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Amadori rearrangement, yielding 1-amino-keto adducts (Acharya and Sussman, 1984; 
Neglia et al., 1985; Smith et al., 1990a).  Based upon the rearrangements of simple 
sugar adducts of lysine residues, the rate of the hydroxyimine-ketoamine 
tautomerization can vary considerably between molecular sites; probably depending 
upon the proximity of nucleophilic amino acid side-chains that facilitate the 
isomerization (Acharya et al., 1991; Nacharaju and Acharya, 1992).  The formation of 
certain ketoamine (Amadori) adducts, such as those of glucose on N-terminal amino 
acids (Neglia et al., 1985), is nearly irreversible.  Adducts on -amino groups of lysines 
appear to be somewhat labile (Acharya and Sussman, 1984).  Buffer conditions 
considerably influence this reversibility in vitro: it is significantly higher in a TRIS buffer, 
pH 7.5, than in a phosphate buffer of the same pH (TRIS can act as a nitrogen 
nucleophile via its amino group and as an oxygen nucleophile via its hydroxyl groups). 
It has been suggested that under physiological conditions ketoamine adducts on  
-amino side-chains are in equilibrium with the imine tautomer, the equilibrium being 
biased toward the ketoamine (Acharya and Sussman, 1984).  Importantly, the 
phosphate buffer used for the present incubations of diclofenac-AG and HSA will have 
favoured retention of the Amadori rearrangement products.  The distinguishing 
feature of these glycation adducts is that the glucuronic acid moiety is retained in the 
covalent adduct (Figure 2. 2).  
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Figure 2. 2: Chemical pathways of formation of protein adducts from an acyl 
glucuronide, adapted from (Bailey and Dickinson, 2003).  In principle, all the open-
chain forms of C-2, C-3 and C-4 positional isomers of an AG can undergo glycation 
reactions with proteins. All the ring-open structures undergo mutarotation, giving α-
anomers at C1 on the sugar ring which themselves might undergo reactions with 
proteins. Within the constraints of steric hindrance, C2C3 and C3C4 acyl 
migrations, and even back migrations, might occur after formation of the Schiff base 
(imine) adducts. Therefore, potentially, the haptens formed by glycation are both 
highly heterogeneous and dynamic. However, only Schiff bases of the O-3 and O-4 
esters can undergo the Amadori rearrangement 
 
AGs have been shown to modify HSA in a time-dependent manner through the use of 
alkaline hydrolysis to liberate bound drug from the protein adducts, and subsequent 
LC-UV quantification of the drug.  Generally, modification occurs to a point where 
Cmax is reached.  Once this point is reached, covalent binding subsequently plateaus 
or slowly decreases. The latter observation suggests that AG adduction of protein may 
not be fully irreversible, and subsequently, AG and aglycone residues may be 
spontaneously hydrolysed away from albumin.  This pattern has been shown for the 
AGs of oxaprozin (Wells et al., 1987), zomepirac (Smith et al., 1986), tolmetin (Munafo 
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et al., 1990), diflunisal (Watt and Dickinson, 1990), ketoprofen (Presle et al., 1996) and 
ibuprofen (Castillo et al., 1995).   
Alkaline and mild-acid hydrolysis of AGs and HSA (Smith et al., 1990a) combined with 
selective inhibitors of reversible protein binding allowed some early suggestions as to 
the sites on the HSA molecule covalently modified by AGs (Williams and Dickinson, 
1994).  Whilst not yet allowing quantitative assessment of the covalent protein 
binding, MS/MS allows identification of the chemical route of modification and 
identification of the amino acids modified.  Consequently, whilst AGs had previously 
been suggested to form glycation adducts (Smith et al., 1990a), it was not until tandem 
mass spectrometric identification that these adducts were confirmed (Ding et al., 
1993).  Subsequently tandem mass spectrometric analyses of HSA adducts of the AGs 
of benoxaprofen and tolmetin (Ding et al., 1993; Ding et al., 1995; Qiu et al., 1998) and 
synthetic activated esters of tolmetin and zomepirac (Zia-Amirhosseini et al., 1995) 
have been reported.   
HSA is a protein containing three homologous helical domains (named I, II and III), each 
divided into subdomains (A and B) (Ghuman et al., 2005).  Within these binding 
domains, as a consequence of the protein’s folding in its tertiary structure, sites of the 
protein have been identified as binding pocket, largely located in hydrophobic pockets 
the first of which (the first named Sudlow Site I or warfarin binding site and the second 
as Sudlow Site II, benzodiazepine or diazepine binding site) (Sudlow et al., 1975; 
Sudlow et al., 1976). 
Covalent adducts formed by AGs were formed preferentially in these binding pockets 
of the HSA molecule, at the Sudlow I and II sites (located on HSA subdomains IIA and 
IIIA, respectively) (Sudlow et al., 1975; Sudlow et al., 1976; Ghuman et al., 2005).  
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Modifications were found to several amino acids, including Lys-199, Lys-195 and Lys-
525 through the glycation pathway, as well as Lys-199, Ser-312 and Arg-521 through 
the transacylation pathway (Ding et al., 1995; Zia-Amirhosseini et al., 1995; Qiu et al., 
1998). 
The principle aim of this in vitro work was to validate diclofenac-AG as a suitable tool 
to test the ability of AGs to form covalent adducts with HSA in vivo.  Due to the 
extensive literature of the interaction of AGs with HSA (Smith et al., 1986; Munafo et 
al., 1990; Watt and Dickinson, 1990; Ding et al., 1993; Mayer et al., 1993; Dubois et al., 
1994; Castillo et al., 1995; Ding et al., 1995; McGurk et al., 1996; Sallustio et al., 1997; 
Qiu et al., 1998) allowing comparison to our data, and its high concentration in human 
plasma (Anderson and Anderson, 2002) from which it can be readily extracted 
(Greenough et al., 2004; Jenkins et al., 2009) resulting in its applicability to in vivo 
assessment of covalent modification to be undertaken in later chapters, HSA was seen 
as a good model to investigate the interactions of diclofenac-AG with protein. 
For diclofenac-AG to represent a suitable tool for the investigation of the AG to form 
covalent adducts in vivo, it should be chemically unstable in solution at physiological 
pH, ideally, like the AGs of R-benoxaprofen and tolmetin with a degradation t½ of ≤ 
2hrs (Table 2. 1), and it should also form persistent covalent adducts with the protein.  
If a novel chemical entity was extensively metabolised to an unstable and protein-
reactive AG, anxiety would arise over its progression.  Further aims of this work were 
to obtain additional insights into the chemistry of the interactions between AGs and 
protein, and specifically to obtain reference data that would indicate how the AG 
might react in vivo.  
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Table 2. 1:  Clinical doses of selected carboxylic acid drugs and the degradation half-
lives of their AG metabolites in phosphate buffer, pH 7.4, at 37°C.  Table adapted 
from (Regan et al., 2010).  aTaken from (Ebner et al., 1999).  Note, only the protein 
(HSA) adducts of benoxaprofen AG (Qiu et al., 1998) and tolmetin AG (Ding et al., 1993; 
Ding et al., 1995) had been fully characterised (in vitro) before the present 
investigations.   
Drug Clinical dose 
AG Degradation Rate t1/2 
(h) 
Tolmetin 1.2g-1.8g daily 0.26 
Probenecid Up to 4g daily 0.3 
Zomepirac (ZP) 100mg 0.45 
Diclofenac (DCF) 75–150mg daily 
0.51a or 
0.79 (see Table 2. 4) 
Naproxen 0.5-1.25g daily 
R-Naproxen 0.92 
S-Naproxen 1.8 
Ibufenac  1.1 
Indomethacin 
50–200 mg daily in divided 
doses 
1.4 
Benoxaprofen 600mg/dose 
R-Benoxaprofen 2.0 
S-Benoxaprofen 4.1 
Ibuprofen 900mg – 2.4g daily 3.3 
Bilirubin n/a 4.4 
Furosemide 20-120mg daily 5.3 
Clofibrate 2g daily 7.3 
Mefenamic  acid 1.5g daily 16.5 
Telmisartin 20-80mg daily 26 
Gemfibrozil 0.9-1.2g daily 44 
Valproic Acid 1.5g-2.250g daily 79 
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2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Acetonitrile (LC-MS grade), ammonium acetate (LC-MS grade), concentrated 
phosphoric acid (99%), diethyl ether (HPLC grade), ethanol (LC-MS grade), ethyl 
acetate (HPLC grade), isopropanol (LC-MS grade), methanol (LC-MS grade) and 
trifluoroacetic acid (LC-MS grade) were purchased from Fisher Scientific, 
Leicestershire.  Bio Rad Bradford reagent was purchased from Bio Rad, Hertfordshire, 
UK.  Modified trypsin was purchased from Promega, Hampshire, UK.  Acetic acid  
(LC-MS grade), ammonium hydrogen carbonate, diclofenac sodium salt, dithiothreitol, 
formic acid (LC-MS grade), , HSA (approx. 99% pure, essentially globin free and fatty 
acid free) iodoacetamide, potassium hydroxide pellets and zomepirac sodium salt were 
purchased from Sigma-Aldrich, Dorset, UK.   
0.1M phosphate buffer pH 7.4 was made using 0.3117% monosodium phosphate 
monohydrate, 2.0747% disodium phosphate, heptahydrate w/v in distilled water.  
All other reagents were purchased from Sigma-Aldrich (Dorset, UK) unless otherwise 
stated.  
2.2.2 Chemical synthesis of 1-β diclofenac acyl glucuronide 
Synthetic 1-β diclofenac-AG was synthesised in a three stage process and characterised 
as described by (Bowkett et al., 2007).  This synthesis was kindly performed by Xiaoli 
Meng at the University of Liverpool and Stuart Bennet at AstraZeneca, Alderley Park, 
UK and is described in Supplementary section 1.1.  Purity of synthetic 1-β diclofenac-
AG was assessed using a combination of LC-UV and tandem mass-spectrometric 
assessment.  For acceptable use in experiments, purity was above 98%.  LC-UV 
conditions as described in section 2.2.4 were used to assess diclofenac purity.    
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2.2.3 Degradation of synthetic 1β-diclofenac acyl glucuronide in phosphate 
buffer, human serum albumin solution and isolated human plasma 
Chemically synthesised 1-β diclofenac-AG at a concentration of either 400µM or 2mM 
was incubated in triplicate for 16 hours in either 0.1M phosphate buffer, pH7.4, HSA 
solution (40µM in phosphate buffer) or isolated plasma pooled from three healthy 
male volunteers of ages between 21 and 25 years at 37°C.  The phosphate buffer, HSA 
solutions and plasma were incubated at 37°C for 20 minutes prior to addition of 
diclofenac-AG. 
For phosphate buffer incubations, at desired time points, 99µl of the incubation 
mixture were removed and immediately acidified through the addition of 1µl of 
concentrated phosphoric acid.  Acidified solutions were then immediately analysed by 
HPLC-UV (Kenny et al., 2004).   
For incubations with HSA and human plasma, 100µl of the incubation mixture were 
removed.  Degradation of the AG was stopped and protein was precipitated through 
the immediate sequential addition of two volumes of ice-cold acetonitrile containing 
2% acetic acid (v/v) and one volume of ice-cold ethanol.  Samples were vortex mixed, 
and protein immediately separated by centrifugation at 14,000rpm at 4°C.  The 
supernatant was removed, evaporated to dryness under a constant stream of nitrogen 
at 37°C, reconstituted in 100µl of 0.1M phosphate buffer containing 1% phosphoric 
acid (v/v), and immediately analysed by HPLC-UV.  
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2.2.4 HPLC-UV analysis of diclofenac acyl glucuronide degradation 
1-β diclofenac-AG, its α-anomer, its 2-, 3- and 4- positional isomers and the parent 
aglycone (Figure 2. 3) were chromatographically resolved using a Zorbax Eclipse XDB-
C8 column (150 x 4.6mm, 5µm; Agilent Technologies, Santa Clara, California, USA) 
fitted with a SecurityGuard guard column (Phenomenex, Macclesfield, Cheshire, UK).  
The Dionex Summit HPLC system comprised of an ASI-100 automated sample injector, 
a P580 pump and a UVD170S UV detector (Dionex Ltd., Macclesfield, Cheshire, UK) 
operated using Chromeleon software (Dionex Ltd). 
Analytes in aliquots of the incubation solutions after processing (20µl for phosphate 
buffer incubations, and 40µl for incubations in HSA solution and human plasma) were 
eluted at room temperature with a linear gradient of methanol containing 10% 
acetonitrile (v/v) in 10mM ammonium acetate, pH 4.5: 15-67.5% over 75minutes.  
Following this, the column was purged with methanol-acetonitrile (9:1, v/v) for 5 
minutes, and then re-equilibrated for a further 10 minutes.  The eluent flow rate was 
maintained at 0.9ml/minute.  Absorbance of eluted compounds was monitored at 254 
nm.  Analyte peak areas were calculated using Chromeleon, and represented as a 
percentage with respect to the combined peak areas of the AG isomers and aglycone.  
No peaks were detected on the UV chromatogram of blank HSA or human plasma 
samples which would have interfered with AG or aglycone analyte peaks.  Peaks with a 
signal-to-noise ratio of less than three were considered below the limit of detection 
and discounted from analysis. 
Samples containing AG and aglycone were assayed at 254nM, the standard wavelength 
for detection of aromatic systems, as glucuronic acid is not reported to have any 
absorbance at this wavelength (Shirao et al., 1994).  Although O-glucuronidation can 
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alter the absorbance of some phenolic compounds (Singh et al., 2010), the isomolar 
absorbency of the aglycone and AGs of the NSAIDs diflusinal (Dickinson and King, 
1991) and ketoprofen (Terrier et al., 1999) has been reported previously.  To confirm 
this observation applies to diclofenac, 100 µl aliquots of the 2 mM solution of the 1-β 
AG isomer and a 90 minute degraded sample, both spiked with 10µl of 10 mM 
zomepirac, were assayed at 254nm using the same HPLC-UV conditions outlined 
above.  Less than 5% variance in the peak area ratio of analyte and internal standard 
were detected between the 1-β diclofenac-AG and its degradation products, 
confirming isomolar absorbance of the AG isomers and diclofenac at 254nM. 
The identities of the chromatographic peaks of the 1-β diclofenac-AG isomer and the 
parent aglycone were confirmed using synthetic standards run on the assay.  Retention 
times of 1-β diclofenac-AG and diclofenac were confirmed using LC-MS.  The four 
resolved AG isomers showed qualitatively identical positive-ion electrospray mass 
spectra which were all indistinguishable from the 1-β AG’s spectrum.  AG spectra were 
all dominated by neutral loss of dehydroglucuronic acid.   
Following identification of the 1-β diclofenac-AG and diclofenac peaks, the remaining 
positional isomers were assigned from their chronological appearance during 
incubation in phosphate buffer, pH 7.4, at 37°C (Figure 2. 6A).  This method has been 
employed in previous studies of AG rearrangement (Watt and Dickinson, 1990).  The 
observed order of isomer elution (4-, 1-α, 1-β, 3-, 2-O-AG) is the most frequently 
reported order for AG isomer elution from reversed phase columns when the isomers 
have been defined by NMR spectroscopy (Corcoran et al., 2001; Akira et al., 2002; 
Stachulski et al., 2006). Whilst complete or near-complete separation of the 2-, 3-, and 
4- isomers was achieved, separation of anomers was only achieved for the 1-α and 1-β 
Chapter 2 – Chemical Assessment of the Interactions between Acyl Glucuronide Drug 
Metabolites and Protein using HSA as a Model Protein 
Page 83 
 
anomers.  The minor chromatographic peak directly in front of the 1-β anomer was 
designated the 1-α anomer in conformity with the standard verified order of elution of 
these epimers (Corcoran et al., 2001; Akira et al., 2002).  Chromatographic separation 
of the 1-β and 1-α anomers is not invariably achieved (Ebner et al., 1999).  No attempt 
was made to achieve chromatographic separation between the anomers of the 2-, 3- 
or 4- isomers.  Anomeric separation of these isomers is usually incomplete, and is 
associated with distorted peak shapes due to rapid inter-conversion of the anomers 
(Stachulski et al., 2006). 
 
Figure 2. 3:  Representative LC-UV trace showing chromatographic separation of 1-β 
diclofenac-AG, its α anomer, the 2-, 3- and 4- positional isomers and its parent 
aglycone at 254nm.  The mixture was produced by incubating 1-β diclofenac-AG in 
40µM HSA solution, pH 7.4, at 37°C for 90 min. The AG positional isomers were 
identified from their chronological appearance during the incubation. The α-anomer 
was identified from its chromatographic position, by comparison with isomer/anomer 
sets of other AG that have been characterised ab initio by NMR spectroscopy 
(Corcoran et al., 2001; Akira et al., 2002). 
 
Chapter 2 – Chemical Assessment of the Interactions between Acyl Glucuronide Drug 
Metabolites and Protein using HSA as a Model Protein 
Page 84 
 
2.2.5 Covalent binding of 1-β diclofenac acyl glucuronide to human serum 
albumin determined using an alkaline hydrolysis technique 
750 µM and 150 µM concentrations of diclofenac-AG were incubated with a 15 µM 
HSA solution in phosphate buffer, pH 7.4, in triplicate at 37°C.  Covalent binding was 
assessed using an alkaline hydrolysis technique based upon published methods (Zia-
Amirhosseini et al., 1994; Zia-Amirhosseini et al., 1995).  Aliquots (500µl) were 
removed at intervals between 5min and 16 hours.  The protein was precipitated 
through the sequential addition of 1.5ml of ice-cold acetonitrile followed by 500µl ice-
cold isopropanol.  The protein solution was separated by centrifugation at 2500 rpm.  
Following protein precipitation, non-covalently bound drug was washed from the 
protein pellet through vortex-mixing with seven 5 ml aliquots of methanol-diethyl 
ether (3:1, v/v).  The 6th and 7th organic extracts were retained, evaporated to dryness 
under a constant stream of nitrogen at 37°C and reconstituted in 250µl of 75% 500mM 
ammonium acetate pH 4.5, 25% acetonitrile (v/v) for LC-MS/MS analysis.  No drug was 
detected in these wash extracts by LC-MS/MS analysis.  The fully extracted protein 
pellet was dried under a constant stream of nitrogen at 37°C.  1 ml of 0.25M potassium 
hydroxide was added to the protein pellet, and subsequently incubated at 80°C in a 
water bath for 90 minutes to liberate covalently bound diclofenac.  An aliquot of the 
solution (20µl) was then removed for protein assay (Bradford, 1976), giving a recovery 
of 63.29 ± 10.14%.  The remaining alkaline hydrolysate was neutralised through 
addition of 45µl of 43% phosphoric acid (v/v in aqueous solution).  55µl of 100 µM 
zomepirac (in 50% acetonitrile) was added to the neutralised hydrolysate as an 
internal standard before addition of 5ml ethyl acetate.  Following mixing and 
centrifugation at 2500 rpm for 5 minutes, the upper phase was removed and 
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evaporated to dryness under a constant stream of nitrogen at 37°C.  The hydrolysate 
was reconstituted in 250µl of 35% 8.5mM ammonium acetate containing 0.0075% 
formic acid (v/v), 65% methanol (v/v), for LC-MS/MS quantification of liberated 
diclofenac. 
2.2.6 LC-MS/MS assay of diclofenac liberated from HSA adducts of 
diclofenac acyl glucuronide using an alkaline hydrolysis technique 
25µl of reconstituted sample following hydrolysis was injected onto the HPLC column.  
Analyte separation was performed at room temperature using a Zorbax Eclipse XDB-C8 
column (150 x 4.6mm, 5µm; Agilent Technologies, Santa Clara, Calafornia) fitted with a 
SecurityGuard guard column (Phenomenex, Macclesfield, Cheshire, UK), connected to 
a PerkinElmer series 200 HPLC system (PerkinElmer, Norwalk, Connecticut, USA) and 
an API 2000 triple quadrupole mass spectrometer (AB Sciex, Warrington, UK).  Analytes 
were eluted at room temperature with a linear gradient of methanol in 8.5mM 
ammonium acetate containing 0.0075% formic acid (v/v), 65-85% over 7 minutes.  
Following this, the column was purged with methanol for 1 minute before re-
equilibration for 3 minutes.  The eluent flow rate was maintained at 1ml/minute, 
achieving separation of diclofenac and zomepirac as represented by Figure 2.4.  MS 
operating parameters for the multiple reaction monitoring (MRM) assay of diclofenac 
with zomepirac as internal standard are shown in Table 2. 2.  The lower limit of 
detection of diclofenac spiked into buffered HSA solution before alkaline hydrolysis, as 
defined by a signal-to-noise ratio >3, was 100µM.  The corresponding lower limit of 
quantification, as defined by accuracy of between 80-120%, and precision (coefficient 
of variation) < 20%, was 100µM (accuracy 90.7% and precision of 17.3%).  
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Figure 2. 4:  Total ion current chromatogram representing chromatographic 
separation of diclofenac and zomepirac (internal standard) in the alkaline hydrolysis 
assay of covalent binding of diclofenac-AG to HSA in vitro.  The compounds were 
analysed by LC-MS/MS 
 
Table 2. 2: API 2000 operating parameters for the MRM assay of diclofenac with 
zomepirac as an internal standard. 
Parameters Diclofenac Zomepirac 
Fragmentation transition 296.066→214.9 292.038→139.000 
Declustering potential (V) 11.00 16.00 
Focussing Potential (V) 360.00 360.00 
Entrance Potential (V) 6.00 10.50 
Collision energy (eV) 25.000 27.00 
Collision cell entrance 
potential (V) 
12.000 12.000 
Collision cell exit potential 
(V) 
10.00 6.00 
Dwell time (ms) 150 150 
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2.2.7 Covalent modification of human serum albumin by diclofenac acyl 
glucuronide during in vitro incubation 
Concentration-dependent modification of HSA by diclofenac-AG was investigated in 
vitro.  Increasing concentrations of 1-β diclofenac-AG (400nM, 4µM, 40µM, 400µM 
and 2mM) were incubated with 40µM HSA in 0.1M phosphate buffer, pH 7.4, at 37°C 
for 16 hours.  To investigate time-dependent modifications of HSA, 2mM diclofenac-
AG was incubated with 40µM HSA for time points between 30 minutes to 16 hours.  To 
investigate the role of the 1-β isomer in the chemical pathways of AG covalent binding, 
a final concentration-effect experiment was performed.  Diclofenac-AG was pre-
degraded for 3 hours in 0.1M phosphate buffer, pH 7.4, at 37°C.  Separate experiments 
have shown that this incubation results in degradation of the 1-β isomer to 5.52 (± 
1.37)% presence in the incubation mixture, with acyl migration to the 2-, 3- and 4- 
isomers and minimal hydrolysis to parent diclofenac  (Figure 2. 6A).  Degraded 
diclofenac-AG was incubated with 40µM HSA at a final concentration of 2mM for 16 
hours.  A solution of 2mM undegraded 1-β diclofenac-AG was incubated with 40µM 
HSA alongside the degraded AG incubation for 16 hours for direct comparison. 
At desired time points 100 µl aliquots of the reaction mixture were removed.  The 
reaction was stopped and protein precipitated through immediate vortex mixing with 
900µl ice-cold methanol and subsequent centrifugation at 24,000g at 4°C for 15 
minutes.  The supernatant was removed, and the pellet washed three times with 60µl 
ice-cold methanol.  The precipitated protein was dissolved in 50µl of 0.1M phosphate 
buffer pH 7.4, reduced with dithiothreitol (10mM) for 15 minutes at room temperature 
and alkylated with iodoacetamide (55mM) for a further 15 minutes at room 
temperature to cap cysteine residues, preventing the formation of disulphide bridges 
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of peptides before mass spectrometric analysis.  The protein was then precipitated and 
washed with ice-cold methanol.  The protein pellet was re-dissolved in ammonium 
hydrogencarbonate solution (50µM, 30µl), assayed for protein content using the 
Bradford assay (Bradford, 1976), and 30µl aliquots of 3.2mg/ml protein solution were 
digested with 5µg trypsin overnight.  The digests were desalted using 0.6 µl bed C18 -
Zip-Tip pipette tips (Millipore, Cork, Republic of Ireland) as per the manufacturer’s 
instructions, eluted with 10µl 50% acetonitrile, 0.1% trifluoroacetic acid in deionised 
water and dried by centrifugation under vacuum (SpeedVac, Eppendorf UK Ltd, 
Cambridge) prior to LC-MS/MS analysis.  
2.2.8 Mass-spectrometric analysis of diclofenac acyl glucuronide modified 
tryptic peptides of human serum albumin 
Modified tryptic peptides were detected on a 5500 QTRAP hybrid triple-
quadrupole/linear ion trap instrument fitted with a Nanospray II source (AB Sciex, 
Foster City, California, USA).  MRM transitions specific for peptides modified by 
diclofenac-AG by either the transacylation or glycation pathway were selected as 
follows: the m/z values of all singly charged HSA peptides with a missed trypsin 
cleavage at the modified lysine residue and mass additions of either 277 amu (for the 
transacylated peptide) or 453 amu (for the glycated peptide) were calculated.  These 
m/z values were paired with the m/z values of the dominant fragment ions of 
diclofenac, namely m/z 215 and m/z 250 (Figure 2. 5) to complete the MRM 
transitions.  HSA peptides identified as modified following incubation with diclofenac-
AG (2mM diclofenac-AG, 40µM HSA) following exhaustive analysis using a QStar i 
hybrid mass spectrometer (Applied Biosystems, Warrington UK) (see chapter 3) were 
selected for MRM transitions, combined with other peptides identified as modified by 
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a range of drugs in our laboratory.  Transitions for which modified HSA peptides were 
detected following in vitro incubation are outlined in Supplementary Table 1 and 2.  
Relative MRM peak heights for each of the modified peptides were computed by 
MultiQuant software version 2.0 (AB Sciex) to produce an ‘epitope profile’ that is 
characteristic of each type of modifying species, i.e. transacylating and glycating.  
However, due to the unavailability of standards of the modified peptides allowing 
relative ionisation efficiencies of modified peptides to be ascertained, these ratios 
must be regarded as approximations.  
 
Figure 2. 5:  Mass-spectrometric fragmentations of diclofenac and diclofenac-AG 
residues when covalently bound to protein.  (A) represents transacylation adducts 
(B) represents glycation adducts. (The 2-ketoamine form of the 3-O-ester conjugate is 
shown; see Figure 2. 2). Mass values corresponding to the 12C35Cl2 isobars of adduct 
fragments are shown. See (Galmier et al., 2005) for the product-ion spectrum of 
diclofenac obtained by electrospray ionisation.  
 
The total ion count for each sample of tryptic peptides was normalised to that of the 
HSA conjugate produced by incubation of 2mM diclofenac-AG with 40µM HSA for 16 
hours.  This allows the magnitudes of MRM signal to be adjusted for differences 
between amounts of sample loaded on to the LC column. 
Aliquots of the modified tryptic peptides were injected onto a C18 PepMap column 
(75µm x 15 cm; Dionex) fitted with a 5 mm C18 nano-precolumn using an Ultimate 
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3000 HPLC system.  A gradient of 2% acetonitrile, 0.1% formic acid (v/v), to 50% 
acetonitrile, 0.1% formic acid (v/v), over 60 minutes at a flow rate of 300 nl/minute 
was used to separate the peptides, and they were delivered to the mass spectrometer 
through a 10 µm i.d. PicoTip ionspray emitter (New Objective, Woburn, MA).  The 
ionspray potential was set to 2200-3500 V, the nebuliser gas to 19 and the interface 
heater to 150°C.  MRM transitions were acquired at unit resolution in both Q1 and Q3 
to maximise specificity.  Collision energies were optimised for each MRM and dwell 
times were 20ms.  MRM survey scans were used to trigger up to three enhanced 
product-ion scans of modified peptides according to the multiple reaction monitoring-
initiated detection and sequencing (MIDAS) technique (Unwin et al., 2005; Unwin et 
al., 2009), with Q1 set to unit resolution and with dynamic fill of the trap.  The 
complete or partial amino acid sequence of the peptide and the location of the adduct 
were deduced from these product-ion spectra. 
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2.3 RESULTS 
2.3.1 Investigations into the chemical instability of synthetic 1β diclofenac 
acyl glucuronide in 0.1M phosphate buffer pH7.4, human serum 
albumin solution and isolated human plasma at 37°C 
Synthetic 1-β diclofenac-AG was found to degrade spontaneously in 0.1M phosphate 
buffer, pH7.4, and it also degraded in 40 µM HSA solution and human plasma at 37°C 
(Figure 2. 6).  Degradation of the 1-β isomer appeared to follow first-order kinetics.  
This allowed the rate of degradation to be analysed using non-linear regression 
analysis.  A curve was fitted to the lines following the equation C=C0exp
(-kdeg)(time), 
where C represents the peak area ratio of the 1-β isomer in the degradation mixture 
and kdeg represents the degradation rate constant (Figure 2. 7), allowing the half-life of 
degradation (t½) to be calculated.  All regression analyses were fitted to an r
2 value of 
above 0.99 (Table 2. 4). 
During incubation in 0.1M phosphate buffer, pH 7.4, a 2 mM solution of 1-β diclofenac-
AG was found to degrade with a half-life of 0.78 hours (Figure 2. 6A).  Degradation was 
primarily through the acyl migration pathway, resulting in sequential appearance of 
the 2-, 3- and 4- positional isomers.  The time taken for maximal appearance of these 
isomers was 100 (± 17.32), 260 (± 34.6) and 960 (± 0) minutes, respectively.  Together, 
over the 16 hour time course, these three positional isomers accounted for 87.75 (± 
2.1) % of combined AG and aglycone exposure.  Little back migration to the 1-α isomer 
or hydrolysis to the parent aglycone was detected throughout the experiment, 
accounting for only 2.21 (± 0.39) and 1.65 (± 0.28)% exposure in the incubation 
mixture over the 16 hour incubation respectively. 
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Little change in the kinetic profile of the degradation of 2 mM diclofenac-AG was seen 
when HSA was added to the incubation mixture at 40µM (Figure 2. 6B).  A slight 
increase (21.8%) in the degradation t½ of the 1-β isomer was observed, however, this 
is likely to be attributable to assay variation rather than a real difference.  Only a minor 
change in the % exposure of the degradation products was observed throughout the 
time course for any of the AG isomers or the parent aglycone, with less than 2% 
variation seen for the 1-α, 1-β, 3- isomers or diclofenac, and less than 5% variation for 
the 2- and 4- isomers.   
A five-fold reduction in the concentration of 1-β diclofenac-AG incubated with 40 µM 
HSA to 400µM, however, caused an increased level of hydrolysis (Figure 2. 6C).  This 
effect resulted in the % exposure of diclofenac over the 16 hour time course to 
increase from 2.33 (± 0.61)% for the 2 mM incubation to 24.23 (± 1.28)%.  
Accompanying the increased extent of hydrolysis, acyl migration was reduced, 
resulting in a combined reduction in exposure to the 2-, 3- and 4- isomers by 19.1%.  
Little change in the maximal presence of the 2-isomer in the incubation mixture was 
seen, but the shorter time to reach this concentration (by 60 minutes when compared 
to the 2 mM AG incubation in HSA solution) suggested the rate of acyl migration from 
C-1 to C-2 may also be enhanced.  However, evidence for an increased rate of further 
acyl migration to the 3- and 4- isomers is not clear.  The rate of appearance of 
diclofenac shows a similar profile to the loss of the 1-β isomer, where little further 
appearance of the aglycone was detected after 180-300 minutes, when exposure to 
the 1-β isomer is reduced to below 10% presence in the incubation mixture.  With 
exposure to the other positional isomers remaining considerable following this 
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timepoint, this observation may suggest that hydrolysis catalysed, or at least 
accelerated by HSA is selective to the 1-β isomer.   
Incubation of 2 mM 1-β diclofenac-AG with human plasma resulted in a faster rate of 
degradation of the conjugate, with its degradation t½ reduced to 7 minutes.  In human 
plasma, the principal mechanism of 1-β diclofenac-AG degradation was through 
hydrolysis, with exposure to diclofenac accounting for 54.56 (± 8.59) % of combined 
AG and aglycone exposure over the 16 hour time course of the assay.  A reduction in 
the time taken for maximal exposure of the 2- isomer to 15 minutes, 85, 105 and 45 
minutes shorter than incubation in phosphate buffer, or incubation in HSA solution at 
2mM or 400µM, respectively, combined with a 57% increase in the maximal 
concentration of this isomer, suggests an increased rate of acyl migration from C-1 to 
C-2.  The continuing rise of exposure to diclofenac following loss of the 1-β AG suggests 
in human plasma AG hydrolysis is not selective to that isomer. 
Reducing the concentration of the 1-β AG isomer in the incubation mixture with 
human plasma to 400µM resulted in a further shortening of the degradation t½ of the 
conjugate to 5.41 minutes.  Hydrolysis was further enhanced, with 82.24 (± 1.26) % of 
AG/aglycone exposure during the 16 hour time course attributable to diclofenac.  
Reduction of the concentration of diclofenac-AG also appeared to further increase the 
rate of acyl migration, as maximal concentrations of the 2- and 3- isomers remained 
similar to those in the other incubations, but the time taken to reach these 
concentrations was shortened to 10 and 30 minutes, respectively.  The % exposure of 
the combined 2-, 3- and 4- positional isomers was reduced to 16.68 (± 2.14) % 
exposure over the 16 hour incubation.  From the incubation at 400µM, it is clear that 
hydrolysis of diclofenac-AG is not isomer specific, as the concentration of diclofenac 
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increased consistently throughout the incubation until almost all the AG (98.21 ± 
0.28%) was hydrolysed by the end of the experiment. 
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Figure 2. 6:  Degradation of 1-β diclofenac-AG to its positional isomers, α anomer and 
parent aglycone during incubation in 0.1M phosphate buffer, pH 7.4, HSA solution or 
human plasma at 37°C.  Synthetic 1-β diclofenac-AG was incubated for 16 hours in 
0.1M phosphate buffer, at pH 7.4, 2mM (A), in buffered 40 µM HSA solution at 2 mM 
(B) or 400 µM (C), or pooled human plasma at 2 mM (D) or 400 µM (E).  Incubations 
were run in triplicate.  Data are presented as means (± standard deviation; n=3).  
Diclofenac-AG isomers are represented as follows, 1-α is represented by filled circles, 
1-β is represented by open circles, 2- is represented by filled triangles, 3- is 
represented by open triangles, 4- is represented by filled squares and diclofenac is 
represented by open squares. 
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Table 2. 3:  Representation of % exposure of AG isomers and aglycone following 
incubation of the 1-β isomer in 0.1M phosphate buffer (pH 7.4), buffered HSA 
solution or pooled human plasma at 37°C over the 16 hour time course, calculated 
from AUCs (Figure 2. 6).  Data presented as mean (± standard deviation; n=3). 
 1-alpha 1-beta 2 3 4 Diclofenac 
2mM DAG 
in 
phosphate 
buffer 
2.21  
(± 0.39) 
8.39  
(± 1.02) 
32.07 
(± 1.30) 
33.64 
(± 0.37) 
22.04 
(± 0.43) 
1.65 
(± 0.28) 
2mM DAG 
in 40µM 
HSA 
1.60 
(± 0.09) 
9.08 
(± 0.89) 
36.03 
(± 0.28) 
32.46 
(± 1.04) 
18.50 
(± 1.00) 
2.33 
(± 0.61) 
400µM 
DAG in 
40µM HSA 
1.38 
(± 0.11) 
5.74 
(± 0.59) 
27.47 
(± 0.38) 
25.13 
(± 0.51) 
16.05 
(± 0.69) 
24.23  
(± 1.28) 
2mM DAG 
in human 
plasma 
0.65 
(± 0.10) 
1.75  
(± 0.34) 
15.14 
(± 1.83) 
14.55 
(± 1.22) 
13.34 
(± 5.91) 
54.56  
(± 8.59) 
400µM 
DAG in 
human 
plasma 
0.23 
(± 0.01) 
0.86 
(± 0.19) 
6.38 
(± 0.45) 
7.16 
(± 1.26) 
3.14 
(± 0.43) 
82.24 
(± 1.26) 
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Figure 2. 7:  1st order regression curves fitted to the degradation of diclofenac-AG 
during in vitro incubations.  1st order regression curves fitted to mean 1-β diclofenac-
AG degradation during incubation at 37°C in 0.1M phosphate buffer, pH 7.4, at 2mM 
(A), in 40 µM buffered HSA solution at 2mM (B) or 400µM (C), or in isolated human 
plasma at a concentration of 2mM (D) or 400µM (E).  Regression curves are fitted to 
the equation C = C0exp
(-kdeg)(time).  Mean 1-β diclofenac-AG degradation data are 
represented by black circles.  Fitted regression curves are represented by the black 
line.  Degradation rate constants are recorded in Table 2. 4. 
  
Chapter 2 – Chemical Assessment of the Interactions between Acyl Glucuronide Drug 
Metabolites and Protein using HSA as a Model Protein 
Page 98 
 
Table 2. 4: Half-lives of degradation and parameters for the fitted degradation curves 
shown in Figure 2. 7.  Data fitted to the first-order degradation rate equation  
C=C0exp
(-kdeg)(time). 
 t ½ (hour) t ½ (min) Kdegradation R
2 
Phosphate 
buffer 
0.78 46.52 0.0149 0.9953 
2mM DAG 
in 40µM 
HSA 
0.95 56.82 0.0122 0.9987 
400µM 
DAG in 
40µM HSA 
0.53 31.94 0.0217 0.9994 
2mM DAG 
in human 
plasma 
0.12 7.02 0.0987 0.9933 
400µM 
DAG in 
human 
plasma 
0.09 5.41 0.1282 0.9953 
   
2.3.2 Assessment of the covalent modification of human serum albumin by 
diclofenac acyl glucuronide during in vitro incubation using an alkaline 
hydrolysis method 
Historically, alkaline hydrolysis has been the most commonly used technique in the 
analysis of acyl glucuronide modification of proteins (Smith et al., 1986; Hyneck et al., 
1988b; Munafo et al., 1990; Dubois et al., 1993b; Presle et al., 1996).  Consequently it 
was decided to apply this technique in the assessment of the covalent modification of 
HSA by diclofenac-AG. 
To assess diclofenac-AG modification of HSA, a 750 µM and a 150 µM solution of 
synthetic diclofenac-AG was incubated with a 15 µM solution of HSA at pH 7.4.  The 
molar ratios of AG : HSA were maintained consistent with the experiments 
investigating AG degradation in HSA solutions at 50 : 1 and 10 : 1. 
Both the 750 µM and 150 µM incubations showed similar profiles for covalent 
modification of HSA during in vitro incubation at 37°C (Figure 2. 8).  Over the first 6 
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hours of incubation, an increase in modification of HSA was detected.  Following this 6 
hour time point, due to the variation in the assay, it is unclear whether additional 
bound diclofenac-AG and/or the aglycone is liberated from the adduct, or if binding 
has simply ceased, and no change in AG covalent binding between the 6 and 16 hour 
time points is evident.  
To provide an assessment of the maximum % of diclofenac-AG in the incubation 
mixture covalently bound to HSA, the Cmax of binding for each concentration (data not 
shown) was taken, and normalised to the amount of protein in the incubation mixture 
for both the 750 µM and 150 µM incubations (Table 2. 5).  Total binding over the time 
course was represented by the area under the binding curve (AUC), and is recorded in 
Table 2. 5. 
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Figure 2. 8:  Time course of the covalent modification of HSA during incubation with 
1-β diclofenac-AG analysed by alkaline hydrolysis.  A 750 µM (A) or 150 µM (B) 
concentration of diclofenac-AG was incubated with 15 µM HSA at pH7.4 and 37°C for 
16 hours.  Covalent binding was analysed using an alkaline hydrolysis method.  Data 
presented as mean (± standard deviation; n=3). 
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Table 2. 5:  Area-under-the-curve data of diclofenac-AG modification of HSA and 
maximum % of diclofenac-AG covalently bound to HSA during incubation of a 750 
µM of 150 µM concentration of diclofenac-AG for 16 hours at 37°C.  Data presented 
as mean (± standard deviation; n=3) 
Concentration of 
diclofenac-AG 
incubated with 15µM 
HSA 
AUC (ng hr ml-1) 
Maximum % of 
diclofenac-AG 
covalently bound to 
HSA 
750 µM 238373.37 (± 17430.2) 0.62 (± 0.10) 
150µM 
124130.37  
(± 15621.62) 
1.78 (± 0.28) 
 
2.3.3 Concentration-dependent modification of HSA during incubation with 
diclofenac acyl glucuronide  
To investigate the covalent modification of HSA by diclofenac-AG, a concentration-
effect experiment was used; incubating diclofenac-AG with 40 µM HSA at 
concentrations ranging from 400nM to 2mM for 16 hours at pH 7.4 and 37°C.  
Normalised ion count data allowed some suggestions as to routes of adduct formation.  
Examples of mass spectra showing modification through the transacylation and 
glycation chemical pathway are shown in Figure 2. 9. 
Detection of glycation adducts and absence of transacylation adducts at lower 400nM 
and 4µM concentrations suggested that glycation was the preferential chemical 
pathway of adduct formation over 16 hour incubations (Table 2. 6).  
Modification of HSA by diclofenac-AG was found to be lysine specific (Table 2. 6).  This 
is as would be expected, as most of the MRM transitions used for analysis were 
directed towards modification of lysine residues.  Modification of only K190 by the 
glycation pathway was detected following incubation of diclofenac-AG at the lowest 
incubation concentration of 400nM.  Incubation of diclofenac-AG at concentrations 
above 400nM resulted in the detected modification of several other lysine residues, 
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and identification of transacylation adducts at concentrations above 40µM.  At all of 
these concentrations, greater normalised ion counts are detected for modification of 
K190 than other amino acid, excepting for the detection of glycation adducts following 
incubation of diclofenac-AG at 40µM.  At this concentration, normalised ion counts for 
modified K199 were greater.  Nevertheless, as described above, care does have to be 
taken in the interpretation of normalised ion count. 
A ribbon model of HSA was used to map the sites of covalent modification following 
incubation with 2mM diclofenac-AG (Figure 2. 10).  The greatest number of modified 
lysine residues following incubation with 2mM diclofenac-AG – five of the 8 residues – 
were found on subdomains IIA and IIIA, and the cleft linking the two subdomains Table 
2. 6.  These subdomains contain hydrophobic pockets, Sudlow sites I and II, where 
compounds, including NSAIDs and their AGs (Iwakawa et al., 1990; Williams and 
Dickinson, 1994; Mizuma et al., 1999), often have strong non-covalent interactions 
(Ghuman et al., 2005).  Only one site of AG modification was on subdomain IIIB, 
namely K525.  A single modification was found on subdomain IIB at K137. 
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Figure 2. 9:  Representative MS/MS spectra showing modification of the HSA tryptic 
peptide 198LKCASLQK205 at K199 by diclofenac-AG through transacylation (A) or 
glycation (B).  A tryptic digest of modified, reduced and alkylated HSA was analysed by 
LC-MS/MS using a QTRAP 5500. Ions derived from the fragmentation of the hapten 
itself are circled (see Figure 2. 5). C+iodo= cysteine residue alkylated with 
iodoacetamide. Note, the modified and unmodified peptides were not resolved 
completely by LC.  b ions are derived from the amino terminus of the peptide, and y 
ions are derived from the C-terminus. 
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Table 2. 6:  Identification of lysine residues modified by diclofenac-AG and the 
chemical pathways of modification following incubation of the AG with HSA for 16 
hours at 37°C.  40 µM HSA solution was incubated with 1-β diclofenac-AG at pH 7.4.  
The amino acids modified and the chemical pathways of modification were identified 
by tandem mass spectrometry (Figure 2. 5 and Figure 2. 9).  The adducted amino acid 
is marked with an asterisk.  Glycation adducts are represented as G, transacylation 
adducts are represented as T. 
Lysine 
Tryptic peptide 
sequence 
Concentration diclofenac-AG in 
incubation mixture 
400nM 4µM 40µM 400µM 2mM 
K137 K*YLEIAR    GT GT 
K190 LDELRDEGK*ASSAK G G GT GT GT 
K195 ASSAK*QR   GT GT GT 
K199 LK*CASLQK  G GT GT GT 
K351 LAK*TYETTLEK   G G G 
K432 NLGK*VGSK  G G GT GT 
K525 K*QTALVELVK   G GT GT 
K541 ATK*EQLK   GT GT GT 
 
 
Figure 2. 10:  A ribbon-model representation of the sites of modification of HSA 
during incubation with 2 mM diclofenac-AG.  The eight lysine residues of HSA 
modified by 1-β diclofenac-AG were identified by tandem mass-spectrometric analysis 
of tryptic peptides (see Table 2. 6).  The 51 unmodified lysine residues are represented 
by purple sticks, lysine residues modified by both transacylation and glycation 
pathways are represented by green spheres (see Figure 2. 2).  K351 was modified by 
only the glycation pathway and is represented by red spheres.  No lysine residues were 
modified by only the transacylation pathway.  Image was produced using PyMol 
Molecular Graphics System (www.pymol.org) 
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2.3.4 Time-course of modification of HSA during incubation with diclofenac 
acyl glucuronide.  
To allow further insight into the covalent interactions between diclofenac-AG and HSA 
a time-course experiment was run, incubating 2mM diclofenac-AG with 40µM HSA.  
Tryptic peptides were again analysed using mass spectrometry, allowing the earliest 
time point of detectable modification of each peptide to be estimated and the 
chemical route of formation to be ascertained.  Normalised ion counts allowed semi-
quantitative analysis of modification of the chemical pathways of adduct formation at 
individual lysine residues. 
Following incubation with 2mM diclofenac-AG, all amino acids identified as modified at 
16 hours were modified at the first 0.5 hour time point.  Again, modification was found 
to be lysine selective.  Normalised ion count data were used to provide a semi-
quantitative analysis of the chemical route of modification of individual lysine residues.  
Over the first two hours, normalised ion counts of transacylation adducts were higher 
than those of glycation adducts for six of the eight modified lysine residues (HSA 
contains 59 lysine residues).  Following this 2 hour time point, little further increase in 
transacylation adducts was detected, whereas ion counts for glycation adducts were 
greatly enhanced.  These trends are illustrated by Figure 2. 11, showing normalised ion 
counts for two representative modified amino acid residues, namely K190 and K525.  
Whilst the time courses of modification of K199 and K351 did not follow the same 
profile, they differed substantially only in the fact that counts for transacylation 
adducts were higher than those of glycation adducts of K525 during the first three 
hours.  Again, little increase in the detection of transacylation adducts was observed 
following two hours, whereas the intensity of glycation adducts increased. 
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Figure 2. 11:  Time courses of modification of K190 (A + B) and K525 (C + D) during 
incubation of HSA (40 µM) with diclofenac-AG (2 mM) at pH 7.4 and 37°C.  
Incubations over 16 hours (A + C) and the same incubations over the first 4 hours (B+D) 
are depicted.  The total ion count for each sample of tryptic peptides analysed by LC-
MS/MS was normalised to that of the HSA conjugate produced by incubation of 2 mM 
diclofenac-AG with 40µM HSA or 16 hours.  Hollow circles represent glycation adducts, 
filled circles represent transacylation adducts and filled triangles represent the sum of 
transacylation and glycation adducts. 
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2.3.5 Covalent modification of HSA during incubation with 1-β diclofenac 
acyl glucuronide or a mixture of diclofenac acyl glucuronide isomers 
produced through pre-degradation of 1-β diclofenac acyl glucuronide 
Following on from the observation that formation of covalent HSA adducts by the 
transacylation pathway did not increase after the first two hours of incubation with 1-β 
diclofenac-AG, with glycation apparently predominant thereafter, it was hypothesised 
that the transacylation adducts were formed preferentially by the 1-β diclofenac-AG 
isomer, whilst the esters generated by acyl migration were less productive.  The reason 
for this is that at the two hour time point, following incubation of the same 2 mM 
concentration of diclofenac-AG with HSA, the 1-β isomer had degraded to only 21.2 
(±2.53)% abundance, with abundance of the 2-, 3- and 4- isomers representing 50.59 
(± 0.63), 19.69 (± 1.20), 4.56 (± 0.58)%, respectively. 
To test this hypothesis, 1-β diclofenac-AG was pre-incubated at 37°C in phosphate 
buffer, pH 7.4, for three hours before incubation with 40µM HSA for 16 hours at 
increasing concentrations of diclofenac-AG to HSA.  Previous experiments showed pre-
incubation of diclofenac-AG in phosphate buffer for three hours would degrade the 1-β 
AG isomer to approximately 9.07 ± 1.39 % presence in the incubation mixture, with 
resulting formation of the 2-, 3- and 4- isomers to the extents of 48.6 (± 0.85),   
29.4 (± 1.28) and 9.57 (± 0.85)% respectively.  In this incubation only negligible 
degradation of the AG to the aglycone was detected, and the same observation was 
made when the 1-β AG was incubated at 2mM with HSA (Figure 2. 6).   Also, no back 
migration to the 1-β isomer, requiring improbable sequential βα anomerization, 
C2C1 migration and αβ anomerization (Corcoran et al., 2001), was detected.  
Chapter 2 – Chemical Assessment of the Interactions between Acyl Glucuronide Drug 
Metabolites and Protein using HSA as a Model Protein 
Page 108 
 
Analysis of modification at individual lysine residues using normalised ion counts 
revealed evidence of the loss of transacylation adducts following removal of the 1-β 
isomer from the reaction mixture (Figure 2. 12).  Complete loss of transacylation 
adducts was detected at K195 and 199 following incubation with 40µM pre-degraded 
AG.  Further to this, following incubation at 400µM, loss of the 1-β isomer resulted in 
complete absence of transacylation adducts at K199, a 27.9% reduction at K195 and a 
reduction of between 53.6 and 62.1 % at other modified lysines.  This trend continued 
at the 2mM AG concentration, with a complete loss in transacylation adducts at K199, 
a 30.2% loss at K195 and between a 63.1 and 81.5% loss of transacylation adducts at 
other modified peptides.  Whilst differential ionisation of peptides means that 
normalised ion counts should be analysed sceptically, this comparison of the loss of 
transacylation adducts at amino acid  residues negates the concern over differential 
ionisation, as it is a direct comparison of the same peptide, resulting in equal 
ionisation. 
Removal of the 1-β AG isomer, as would be expected from the first principles of AG 
chemistry (Figure 2. 2), and in the absence of substantial AG hydrolysis (Figure 2. 6), 
had little effect on the abundance of glycation adducts detected.  
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Figure 2. 12:  Effect of removing the 1-β diclofenac-AG by pre-incubation on the 
modification of individual HSA lysine residues.  Light bars represent incubation with 1-
β diclofenac-AG.  Dark bars represent incubation with diclofenac-AG pre-degraded in 
phosphate buffer, pH 7.4, at 37°C for three hours to remove the 1β isomer from the 
incubation mixture.   (A+B) 4µM, (C+D) 40 µM, (E+F) 400 µM, (G+H) 2mM.  (A+C+E+G) 
HSA modified by transacylation; (B+D+F+H) HSA modified by glycation.  All the 
incubations with HSA (40µM) were performed at pH 7.4 and 37 OC for 16 hours. The 
total ion count for each sample of tryptic peptides analysed by LC-MS/MS was 
normalised to that of the HSA conjugate produced by incubation of 2mM diclofenac-
AG with 40µM HSA for 16 hours.  
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2.4 DISCUSSION 
The broad aims of this work were to define the chemical stability and protein reactivity 
of diclofenac-AG, and specifically the chemistry of its instability in different 
biochemical and biological matrices and its covalent interaction with protein, using 
HSA as a representative, well characterised, soluble protein that has numerous 
nucleophilic side chains (Kristiansson et al., 2003).  Anticipating related studies in 
diclofenac patients (Chapter 5), HSA has the practical merits of being accessible and 
abundant (Johannesson et al., 2001; Jenkins et al., 2009; Meng et al., 2011; Whitaker 
et al., 2011) and is a physiologically relevant target for covalent modification because 
drug AGs frequently circulate in blood plasma (Volland et al., 1990; Benet et al., 1993; 
Mayer et al., 1993; Zia-Amirhosseini et al., 1994; Stangier et al., 2000; Zhou et al., 
2001; Wang et al., 2006). 
The degradation half-life of the 1-β AG isomer in phosphate buffer, pH 7.4, has been 
shown to be a good identifier for the protein reactivity of the molecule (Spahn-
Langguth and Benet, 1992; Benet et al., 1993), as well as a useful marker of potential 
clinical toxicity of the parent drug (Sawamura et al., 2010).   The degradation half-life 
of diclofenac-AG estimated in current investigations of 0.78 hours, shows the molecule 
to be amongst the most unstable AG metabolites studied (Table 2. 1), consequently 
suggesting that, if developed as a new chemical entity today, diclofenac might be 
considered to be at risk for generation of idiosyncratic reactions in man. 
This degradation half-life of 1-β diclofenac-AG in phosphate buffer is slightly longer 
than the previously reported value of 0.51 hours (Ebner et al., 1999), but similar to 
that reported by Sawamura et al of 0.7 hours (Sawamura et al., 2010).  Due to this 
expected rapid degradation of diclofenac-AG at pH 7.4, a greater number of sampling 
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time points (10 time points) were included over the first two hours of incubation, 
allowing more accurate tracking of the disappearance of the 1-β isomer from the 
degradation mixture (rather than the four sampling points used by (Ebner et al., 
1999)).  In addition to allowing better tracking of the loss of the 1-β isomer from the 
degradation mixture, may allow increased accuracy in fitting of regression curves to 
the data, resulting in improved precision in estimations of rate-constants of 
degradation and degradation half-lives. 
Acyl migration was revealed to be the predominant pathway of diclofenac-AG 
degradation during incubation in 0.1M phosphate buffer, pH 7.4.  Most AGs undergo 
preferential acyl migration, rather than hydrolysis, under these conditions (Watt and 
Dickinson, 1990; Iwaki et al., 1999; Corcoran et al., 2001; Akira et al., 2002; Berry et al., 
2009; Johnson et al., 2010; Karlsson et al., 2010).  Following the loss of the 1-β isomer 
from the incubation mixture, a sequential appearance of the positional isomers was 
detected chromatographically.  The concentrations of these positional isomers 
appeared to reach consistent values towards the later time points of the incubation.  
This step-wise pattern of acyl migration has been reported for several other AGs 
(Spahn-Langguth and Benet, 1992; Ebner et al., 1999; Iwaki et al., 1999).  It is generally 
accepted that the reason for this pattern of acyl migration is that the aglycone is only 
able to move around the ring one carbon at a time via ortho-ester transition states  
(Figure 2. 1) (Bradow et al., 1989; Berry et al., 2009).  All of these intramolecular 
migrations are considered to be reversible, though the C2C1 back migration is 
thought to require a preliminary βα anomerization (Corcoran et al., 2001). 
Little hydrolysis of the AG occurred during incubation in phosphate buffer.  This 
conflicts with the previous report of the kinetics of degradation of diclofenac-AG in 
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phosphate buffer, where, following 8 hours incubation, 20% of diclofenac-AG had 
hydrolysed to its parent aglycone (Ebner et al., 1999).  Reasons for this discrepancy 
between these data are unclear.  Whilst pH and temperature are well established to 
influence the rate of AG degradation (Spahn-Langguth and Benet, 1992; Stachulski et 
al., 2006), both experiments ensured these factors remained constant.  Whilst the 
concentration of diclofenac-AG was greater in the experiment presented here (2 mM), 
rather than the 300 µM incubations used by (Ebner et al., 1999), AG concentration is 
not known to influence the rate of degradation significantly (Watt and Dickinson, 1990; 
Berry et al., 2009); in conformity with the predominant degradation pathway being an 
intramolecular rearrangement.  Differences in the source of conjugate used here and 
by (Ebner et al., 1999) may provide an explanation as the diclofenac-AG used by Ebner 
was isolated from bile of rats administered diclofenac, where slight contamination by 
biliary proteins or lipids undetected through their LC-MS analysis might have reduced 
the AG’s stability. 
Addition of 40µM HSA solution to the incubation of 2mM diclofenac-AG in 0.1M 
phosphate buffer, pH 7.4 had little effect on the kinetics of the AG’s degradation.  A 
slight increase in the half-life of degradation was observed, however this was only by 
10 minutes, and variation in the precision of the assay cannot be discounted as a 
reason for this increased half-life.   It has been suggested that HSA can retard acyl 
migration in vitro, at least beyond the C-2 isomer in the case of naproxen-AG (Iwaki et 
al., 1999).  Serum albumin (human or rat) stabilises, additionally, the AG metabolites of 
diflunisal (Watt and Dickinson, 1990), tolmetin (Munafo et al., 1990), salicylic acid 
(Dickinson et al., 1994) and furosemide (Mizuma et al., 1999).  Reduction of conjugate 
degradation in these experiments was far more profound than any effect of HSA on 
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the rearrangement of 2mM diclofenac-AG.  Also, HSA seems to accelerate both the 
intramolecular rearrangement and hydrolysis of 1-β gemfibrozil-AG (Sallustio et al., 
1997).  With the concentration of AG in this experiment also far exceeding the 
maximum exposure of AG relative to HSA in any of the earlier experiments, it is 
possible that sites on HSA responsible for hydrolysing the AG may be saturated; 
resulting in diclofenac-AG degradation remaining principally a consequence of acyl 
migration.  Drug AGs are highly reversibly bound by HSA (Dubois et al., 1994; Williams 
and Dickinson, 1994; Sallustio et al., 1997; Mizuma et al., 1999), principally because of 
strong interactions between the aglycone residue and the protein (Dubois et al., 1994); 
generally, the glucuronic acid residue lowers the drug’s binding affinity (Iwakawa et al., 
1990). 
Hydrolysis remained a minor pathway of diclofenac-AG degradation when the 
conjugate was incubated at 2mM with HSA.  Only on incubation of a lower 
concentration of diclofenac-AG (400µM) was pronounced hydrolysis of the AG 
metabolite observed.  The esterase-like activity of HSA (Ma et al., 2005), accelerating 
hydrolysis of AG in vitro is well known, with greater hydrolysis of the AGs of 
furosemide (Mizuma et al., 1999), naproxen (Iwaki et al., 1999), probenecid (Akira et 
al., 2002), gemfibrozil (Sallustio et al., 1997), and diflunisal (Watt and Dickinson, 1990) 
in HSA solution than in phosphate buffer alone.  This hydrolytic activity of HSA, 
appropriately for an enzymic activity, can be highly dependent on the AG’s structure, 
with variations in the esterase-like activity of HSA between the R- and S- enantiomers 
of carprofen (Georges et al., 2000) and ketoprofen (Dubois et al., 1994).   
Few experiments have looked in depth at the effect of AG concentration on the 
esterase-like hydrolytic action of HSA.  Concentration-activity studies using 
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ketoprofen-AG reported the action of HSA follows Michaelis-Menton kinetics, and 
consequently in accordance with this, increased AG concentration should result in 
increased rate of hydrolysis (Dubois et al., 1994).  Conversely to this, little difference 
was observed between the hydrolysis of diflunisal-AG during incubation with HSA at 
117µM and 23µM (Watt and Dickinson, 1990).  Only on incubation at the lower 
concentration of 400µM was hydrolysis of diclofenac-AG evident, with only negligible 
hydrolysis detected at 2mM.  Potentially, incubation of 5-fold the molar concentration 
of diclofenac-AG compared to HSA is likely to result in saturation of active sites of the 
HSA molecule, and consequently most of the AG metabolite is free to degrade 
following kinetics similar to incubation in the absence of HSA.  Reducing the 
concentration of diclofenac-AG five-fold means a greater proportion is able to bind to 
hydrolytic sites of HSA, and less AG is free to degrade by acyl migration, resulting in a 
greater proportion of the AG hydrolysed at this concentration (Dubois-Presle et al., 
1995). Hydrolysis is increased if HSA is both globulin- and fatty acid-free rather than 
just fatty-acid free (Watt and Dickinson, 1990).  This is thought to be a consequence of 
globulin’s hindrance of AG access to sites of the HSA molecule capable of hydrolysing 
the metabolite.  It should be noted that even commercially produced HSA preparations 
contain very large numbers of minor/trace co-purified peptides and full-length 
proteins, and some of the proteins are associated with, or have an affinity for, HSA 
(Gay et al., 2010). 
The hydrolysis of diclofenac-AG during incubation with HSA follows similar kinetics to 
those described for several other AGs (Watt and Dickinson, 1990; Dickinson and King, 
1991; Dubois et al., 1994).  Following an initial rise in liberated aglycone, rate of 
hydrolysis slows and often eventually stops before the end of the incubation, resulting 
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in a plateau in the concentration of liberated aglycone.  Careful investigation of the 
diclofenac-AG degradation data reveals that little further AG hydrolysis occurs 
following the three hour time point.  At this time point, the concentration of the 1-β 
isomer in the incubation mixture is negligible.  The 2-, 3- and 4- diclofenac-AG 
positional isomers remaining at relatively high exposure for the remaining 13 hours of 
the experiment with little further hydrolysis suggests that esterase-like action of HSA 
towards diclofenac-AG may be selective to the 1-β isomer.  Selective hydrolysis of the 
1-β isomer of AGs is well documented for the specialist ester hydrolase β-
glucuronidase (Dickinson, 2011), and the incubation of isolated 1- and 2- isomers of 
naproxen-AG with HSA revealed a near doubling of the hydrolysis rate constant of the 
1- isomer when compared to the 2- isomer (Iwaki et al., 1999).  Other published 
studies showing a similar pattern of attenuated hydrolysis following loss of the 1-β 
isomer have not been found.  It must not be ruled out that covalent modification of 
HSA may result in inhibition of the protein’s esterase-like activity (Lockridge et al., 
2008). 
Further increased hydrolysis of diclofenac-AG was evident following incubation in 
pooled human plasma.  This resulted in complete hydrolysis over the 16 hour time 
course at both 400µM and 2mM diclofenac-AG.  Extensive hydrolysis of AG 
metabolites ex vivo by unidentified hydrolases/esterases has been reported for several 
conjugates (Ruelius et al., 1986; Volland et al., 1991; Williams et al., 1992; Akira et al., 
2002; Shipkova et al., 2003; Karlsson et al., 2010), and has been hypothesised as a 
potential de-toxification pathway of AG metabolites (Mizuma et al., 1999; Zhang et al., 
2011).  The relative contributions of tissue and plasma hydrolases/esterases to the 
clearance of drug AG from the plasma and recycling of parent compound are still 
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largely unknown but the plasma concentration of valproic acid is determined 
substantially by the glucuronidase activity of a hepatic hydrolase (Nakajima et al., 
2004; Suzuki et al., 2010).  Human plasma contains three esterases in high enough 
concentrations to significantly contribute to ester hydrolysis: butyrylcholinesterase, 
paraoxonase and albumin (Li et al., 2005).  However the relative contributions of these 
enzymes and of plasma β-glucuronidase (Soltaninejad et al., 2007) to the hydrolysis of 
drug AG are somewhat obscure.  Additionally, there are substantial species differences 
between esterase expression and hydrolase activity in mammalian plasma (Bahar et 
al., 2012).  This uncertainty over the influences of β-glucuronidase and esterases on 
the pharmacokinetics of AGs has led to the development of animal models where non-
specific esterase inhibitors have been used to perturb the disposition of AGs (Smith et 
al., 1990b).  Although treatment of guinea pigs with phenylmethylsulphonyl fluoride 
(PMSF) increased the plasma exposure of zomepirac-AG, this effect might have 
resulted principally from inhibition of tissue esterases and other intracellular 
hydrolases rather than the inhibition of plasma enzymes.  These esterases and 
hydrolases, and not β-glucuronidase, are known to play a dominant role in the 
intracellular hydrolysis of certain drug AG in humans (Suzuki et al., 2010; Iwamura et 
al., 2012).  The β-glucuronidase in a solid tissue can have an appreciable influence on 
aglycone exposure/elimination (Whiting et al., 1993; Tobin et al., 2006) but overall 
remarkably little is known about the enzymology, regulation and physiological effects 
of AG hydrolysis (Fukami and Yokoi, 2012). 
It was observed that on reduction of the concentration of diclofenac-AG incubated 
with human plasma from 2mM to 400µM an increased rate of hydrolysis was again 
obtained.  This may be through the same mechanism of enzyme saturation suggested 
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for HSA incubations.  The esterase activity of human plasma was clearly not specific to 
the 1-β isomer, as following loss of the 1-β isomer, hydrolysis of the positional isomers 
continued.  An apparent parallel decline of the 2-, 3- and 4- isomer exposure 
emphasises this susceptibility, as no isomer appears to be resistant to hydrolysis. 
Incubation of diclofenac-AG in human plasma also appeared to enhance the rate of 
acyl migration.  This was revealed by maximal exposure of the 2-, 3- and 4- isomers 
remaining either similar to or above those measured in either phosphate buffer or HSA 
solution, whereas the time taken to reach those concentrations was reduced.  This 
phenomenon has also been seen for incubation of oxaprozin-AG and fenprofen-AG 
(Ruelius et al., 1986; Volland et al., 1991).   
Following in vitro incubation of diclofenac-AG with HSA, an alkaline hydrolysis 
technique was used to assess covalent binding of the AG.  This technique allows 
quantitative assessment of AG-mediated protein modification through measurement 
of liberated aglycone, and thereby assays acetylation and glycation adducts collectively 
(Smith et al., 1990a).  It has been used in numerous in vitro and in vivo studies (Smith 
et al., 1986; Hyneck et al., 1988b; Munafo et al., 1990; Dubois et al., 1993b; Mayer et 
al., 1993; Castillo et al., 1995; McGurk et al., 1996; Presle et al., 1996; Sallustio et al., 
1997) but invariably yields only approximate values because the fractional recovery of 
covalently bound carboxylic acid is unknown.  Both the 150 and 750 µM incubations 
followed a similar kinetic pattern, whereby a rise in covalent modification of HSA was 
observed over early time points of the incubation.  However, between the 6 and 16 
hour time points, it is clear that this rise in modification had ceased.  It is, however, 
unclear whether following the six hour time point there is no change in modification, 
or if this is decreased.  This trend follows the kinetics of several other in vitro 
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incubations of differing AGs with HSA (Smith et al., 1986; Munafo et al., 1990; Watt 
and Dickinson, 1990; Mayer et al., 1993; Dubois et al., 1994; Castillo et al., 1995; 
McGurk et al., 1996; Sallustio et al., 1997).  Despite these incubations being run for 24-
70 hours, few of them appear to clearly show a definitive drop in the amount of 
covalent binding over the time course.  Only the incubation with the AG of mefenamic 
acid showed evidence of definitive reduction in covalent binding over its 24 hour 
course (McGurk et al., 1996), with a suggestion of a reduction from the incubation with 
ketoprofen-AG (Presle et al., 1996).  It is difficult to determine whether a decrease in 
binding is observed between the later time points because of the imprecision in the 
assay.  Changing the concentration of AG in the incubation mixture did not appear to 
elicit a change in the profile of adduct formation, as was previously seen with 
ketoprofen-AG (Dubois et al., 1994; Presle et al., 1996). 
It is clear, however, that the rate of covalent modification of HSA by diclofenac-AG 
does slow at later time points.  Slowing of modification is at a lower level of 
modification for the 150 µM than the 750 µM incubation.  This suggests a factor other 
than saturation of binding sites is responsible.   
The maximum % of AG covalently bound following incubation with HSA under standard 
conditions has been suggested as a quantity for ranking the protein reactivity of AG 
metabolites in vitro (Castillo et al., 1995).  The published values are 1.5% for ibuprofen 
(Castillo et al., 1995), 2.3% for zomepirac (Smith et al., 1990a), 3.2% for ketoprofen 
(Dubois et al., 1993b) and 3.3% for etodolac (Smith et al., 1992).  The calculated values 
for diclofenac of 1.78 (± 0.28)% in the 150 µM HSA incubation and 0.62 (± 0.10)% in 
the 750 µM incubation (Table 2. 5) place diclofenac-AG as the least reactive AG on this 
list.  Having a shorter half-life of degradation than ibuprofen-AG, it would be expected 
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that diclofenac-AG would be more protein reactive (Benet et al., 1993; Ebner et al., 
1999; Stachulski et al., 2006).  With different % binding found following incubation 
with the two concentrations of diclofenac-AG, as has also been seen with studies with 
ketoprofen-AG (Dubois et al., 1993a), this is evidently not a sound method for 
assessing protein reactivity, as the result depends heavily on the concentration of AG 
metabolite rather than just the intrinsic reactivity of the metabolite.  Confirmation of 
this method’s severe limitations is provided by the in vitro screening model of (Bolze et 
al., 2002), which yielded an excellent correlation between the extent of AG covalent 
binding to HSA and the aglycone appearance constant weighted by the percentage of 
isomerisation: diclofenac-AG was found to be much more protein reactive than 
ketoprofen-AG and ibuprofen-AG. 
Tandem mass-spectrometric analysis of the modification of purified serum albumin by 
AGs has only previously been reported for incubations of HSA with tolmetin-AG (Ding 
et al., 1993; Ding et al., 1995) and benoxaprofen-AG (Qiu et al., 1998).  However, the 
modification of HSA in vitro has been characterised in comparable molecular detail 
using other compounds (Kristiansson et al., 2003; Olsen et al., 2003; Alvarez-Sanchez 
et al., 2004; Aldini et al., 2006; Aleksic et al., 2007; Lockridge et al., 2008; Grigoryan et 
al., 2009; Jenkins et al., 2009; Frolov and Hoffmann, 2010; Meng et al., 2011; Whitaker 
et al., 2011; Deng et al., 2012).  By combining tryptic peptide HPLC, MRM survey 
scanning and product ion scanning, this technique enables identification of the site and 
structure of the modification and hence the chemical route of modification.  Because 
of its great abundance and long residence time in human blood (Tornqvist et al., 2002), 
HSA is seen as having an important place in the assessment of exposure to exogenous 
and endogenous electrophiles through the methodology of blood adductomics: the 
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characterisation and measurement of adducts formed by reactions between circulating 
electrophiles – such as drug AG – and blood nucleophiles (Rappaport et al., 2012). 
Diclofenac-AG was found to selectively modify lysine residues of HSA in vitro at pH 7.4: 
adducts were identified on only eight of the protein’s 59 lysines even when the AG was 
in 50-fold molar excess.  Whilst the selective modification of several HSA lysine 
residues by AG in vitro has been reported previously, modifications of small numbers 
of serine and arginine residues by AG have also been reported (Ding et al., 1995; Qiu et 
al., 1998).  The highest proportion of lysine modifications on HSA was shown to occur 
on the central part of the molecule, on subdomains IIA and IIIA.  These subdomains 
contain the hydrophobic pockets Sudlow sites I and II (located on IIA and IIIA, 
respectively).  Modifications on K195, K199 (site IIA) and K432 and 436 (site IIIA)were 
detected in these regions.  Additionally, two adducted lysines, namely K190 and K351, 
were located in a cleft between these two subdomains, and outside of the Sudlow sites 
(Sudlow et al., 1975).  A third subdomain on the HSA molecule, IIIB, contained the 
modified amino acids K525 and K541 (Ghuman et al., 2005).  The high proportion of 
adducts located in or around these pockets suggest that hydrophobic non-covalent 
interactions may be an important pre-requisite for covalent modification.   
The first indications of the importance of hydrophobic binding pockets for covalent 
modification of HSA by AGs came from the use of compounds known for their high-
affinity non-covalent binding at these sites.  For example, the covalent binding of 
diflunisal AG to HSA was decreased in the presence of diazepam (a Site II ligand) and 
diflunisal but increased in the presence of warfarin (a Site I ligand) (Williams and 
Dickinson, 1994); which suggests non-covalent binding of the conjugate at Site I is 
relatively unproductive of  covalent adducts.  Other experiments with site-selective 
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ligands also appeared to differentiate between low and high productivity non-covalent 
binding of NSAID AGs.  Thus warfarin reduced the non-covalent binding of (R)- and (S)-
carprofen AGs to a greater extent than did diazepam (Iwakawa et al., 1990); whereas 
diazepam displaced the unconjugated enantiomers to a greater extent than did 
warfarin (Iwakawa et al., 1990).  It seems reversible binding of an NSAID and covalent 
binding of its AG can occur selectively at Site II while reversible binding of the AG 
occurs selectively at Site I.  However, pre-incubation of HSA with diazepam, warfarin or 
tolmetin which did not significantly alter covalent binding of tolmetin-AG (Munafo et 
al., 1990).  Although diclofenac binds preferentially at Site II (Rahman et al., 1993) – in 
common with many carboxylate NSAIDs – its binding is displaced by ibuprofen, a Site II 
specific drug (Yamasaki et al., 2000). 
With the highest normalised ion counts for both transacylation and glycation adducts, 
K190 appears to be the most favourable lysine residue for modification by diclofenac-
AG (Figure 2. 12).  The location of K190 is in a cleft just outside Sudlow site I.  K190 was 
adducted detectably by benoxaprofen-AG (Qiu et al., 1998) but not by tolmetin-AG 
(Ding et al., 1993; Ding et al., 1995).  It is also adducted by a number of non-AG 
acetylating agents (Kristiansson et al., 2003; Jenkins et al., 2009; Meng et al., 2011; 
Whitaker et al., 2011), but not by several glycating (Aldini et al., 2006; Frolov and 
Hoffmann, 2010; Deng et al., 2012) or acylating (Olsen et al., 2003) agents.  Apparent 
preferential binding of benoxaprofen-AG to K159 (Qiu et al., 1998) and tolmetin-AG to 
K199 (Ding et al., 1995) suggests that the preferential modification of lysine residues 
may differ between AGs.  Whilst the UV absorbance and fluorescence of modified 
peptides was used for characterising the adduction selectivity tolmetin-AG and 
benoxaprofen-AG, respectively, differences between the ionisation and transmission 
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efficiencies of peptides mean that a greater mass spectral signal may not accurately 
reflect the abundance of a modified peptide. 
Normalised ion count data derived from time course incubation of 2mM diclofenac-AG 
with HSA in vitro suggested the transacylation adducts were formed preferentially 
during the first two hours, whereas after this time point little further increase in 
transacylation adducts was detected, but a sustained increase in the formation of 
glycation adducts was apparent (Figure 2. 11).  Comparing these data to the 
degradation of 2mM diclofenac-AG in HSA solution suggested that the 1-β isomer of 
diclofenac-AG may be responsible for early formation of transacylation adducts, with 
slower acyl migration and aldehyde-amine condensation inevitably retarding the 
formation of glycation adducts.  However, the contribution of the positional isomers of 
AGs to the formation of transacylation adducts on proteins remains unclear.  
Additionally, due to the quantitative limitations of normalised ion counts, it is by no 
means certain that glycation is the predominant mechanism of protein modification by 
the positional isomers. 
In an attempt to clarify this ambiguity over the direct protein reactivity of 1-β 
diclofenac-AG, synthetic 1-β diclofenac-AG was degraded in phosphate buffer to <10% 
exposure, with consequent formation of the acyl migration isomers.  This mixture was 
then incubated with HSA in increasing AG concentrations, and modification of the 
protein compared to a parallel incubation containing undegraded diclofenac-AG.  
Extensive removal of 1-β diclofenac-AG from the incubation mixture with HSA resulted 
in a reduction of transacylation adducts.  The consistent reduction of individual 
transacylated tryptic peptides (Figure 2. 12) provides definitive evidence for the 
contributory, and apparently disproportionate, role of the 1-β isomer in forming these 
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adducts because a direct comparison is made with the same modified peptides, which 
removes uncertainties relating to possible differential electrospray ionisation of 
different peptides.  This means that the experimental difference between ion counts of 
a transacylated peptide is equitable with molar quantities of the peptide.  In contrast, 
as expected, similar ion counts were seen for glycation adducts in the two incubations, 
probably due to similar exposure to the AG positional isomers in the pre-degraded and 
in-situ degraded solutions.  Although the qualitative features of protein adduction by 
AG are now well characterised, the quantitative aspects are still somewhat obscure.  In 
particular, the relative contributions of (i) acylation versus glycation, (ii) acylation 
versus glycation by the positional isomers and (iii) glycation by the individual positional 
isomers are essentially unknown.  (Dickinson and King, 1991) found that the rank order 
of covalent binding of diflunisal-AG and its isolated positional isomers to HSA is  
C-4>C-3>C-2>C-1.  The highest reactivity of the C-4 isomer is intuitively but 
hypothetically attributable to lowest steric hindrance by the acyl group of aldehyde-
amine condensation (Figure 2. 2).  However, the high reactivity of the C-4 isomer will 
be counterbalanced by the isomer’s low abundance in solution (Figure 2. 6).  In 
contrast, (Iwaki et al., 1999) found that HSA adduct formation from the 2-isomer of  
(S)-naproxen-AG proceeded more slowly than that from the 1-β-conjugate, which 
suggests particular structural features of AGs can be more influential than generic 
effects. 
Through these experiments, diclofenac-AG has been shown to be chemically unstable 
and protein reactive in vitro.  Whilst the % covalently binding of diclofenac-AG is lower 
than that of other NSAID AGs, the rapid rate of degradation, in the context of the 
relationships between degradation and HSA covalent binding derived by (Benet et al., 
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1993) and (Bolze et al., 2002), indicates that covalent binding is likely to be relatively 
extensive.  Consequently, these in vitro data suggest diclofenac-AG is a suitable drug 
AG to investigate potential hapten formation in experimental animals and patients.   
Incubations with pooled human plasma revealed extensive AG hydrolysis.  In vivo, this 
may represent a mechanism resulting in reduced exposure to AG metabolites (Mizuma 
et al., 1999; Zhang et al., 2011), consequently reducing the potential for protein adduct 
formation.  Good evidence was provided suggesting the role of the 1-β isomer, i.e. the 
biosynthetic product, in formation of acylation adducts.  Time course data provided 
clear evidence that the formation of covalent adducts of HSA by transacylation and 
glycation follows distinct time-lines in vitro.  The protein adducts generated with 
another electrophilic compound suggest adduction of lysine residues by AGs is likely to 
be a general phenomenon (Grigoryan et al., 2009). 
Finally, from early studies on the adduction of plasma proteins in humans 
administered carboxylic acid drugs (Smith et al., 1986; McKinnon and Dickinson, 1989; 
Volland et al., 1991; Benet et al., 1993; Mayer et al., 1993; Zia-Amirhosseini et al., 
1994; Sallustio et al., 1997), it is predicted that proteins modified by diclofenac-AG 
and/or other reactive metabolites of diclofenac will be present in the plasma of 
patients.  Recent advances in mass spectrometric technologies have brought within 
reach the structural characterisation of circulating protein haptens derived from drugs 
and their metabolites in patients on standard therapeutic doses (Jenkins et al., 2009; 
Meng et al., 2011).   
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3.1 INTRODUCTION   
In chapter 2, the protein reactivity and chemical instability of diclofenac-AG in vitro 
were described.  Diclofenac-AG was found to have a short half-life of degradation in 
phosphate buffer, pH 7.4, and was found to covalently bind to HSA in these 
incubations.  Consequently, with the reported 75% turnover of diclofenac into its AG 
metabolite in an incubation with human liver microsomes supplemented with UDPGA 
(Kumar et al., 2002), diclofenac would fit criteria outlined by the FDA in their MIST 
guidance (FDA, 2008) as necessitating ‘additional safety assessment’.   
The chemical instability and protein reactivity of diclofenac-AG defined in chapter 2 
could potentially result in cessation of development of the compound if it was a novel 
chemical entity, developed as a new NSAID for the market today, due to fears over the 
potential toxicity of its AG.  Despite this consideration, diclofenac has remained on the 
market as the most widely prescribed NSAID, accounting for over 35% of NSAID 
prescriptions in the Netherlands as long ago as 1990 (Leufkens et al., 1990), and 31.8% 
of NSAID prescriptions in general practice in the UK (Seager et al., 2000), resulting in an 
estimated 11 million people being exposed to the drug in the UK in the last 20 years 
(Jick et al., 2007).  Consequently, diclofenac clearly represents a pharmaceutical 
providing efficacious therapy with advantageous risk-benefit profile.  So much so that 
diclofenac is now available as an over-the-counter therapeutic in the UK (Hasford et 
al., 2004).  Despite its extensive therapeutic use, its chemically unstable and protein 
reactive AG still attracts frequent attention from toxicologists (Aithal et al., 2004; 
Sallustio et al., 2006; Lagas et al., 2010; Koga et al., 2011; Mueller et al., 2012; Pickup 
et al., 2012). 
Chapter 3 – The Use of a Rat Model to Study Acyl Glucuronide Reactivity 
Page 137 
 
Toxicological fears over acyl glucuronides are largely centred on their potential to act 
as haptens, modifying proteins in the host organism, resulting in inappropriate 
immune stimulation (Spahn-Langguth and Benet, 1992; Shipkova et al., 2003).  As 
described in chapter 2, protein reactivity and chemical instability of AG metabolites do 
appear to be ubiquitous characteristics of these phase II metabolites, and are very well 
characterised following in vitro incubation (Munafo et al., 1990; Volland et al., 1991; 
Spahn-Langguth and Benet, 1992; Ding et al., 1993; Ding et al., 1995; Qiu et al., 1998; 
Ebner et al., 1999; Iwaki et al., 1999; Mortensen et al., 2001; Walker et al., 2007).  
Evidence for the translation of this protein reactivity from in vitro incubation systems 
to in vivo, however, is much less abundant (Benet et al., 1993; Bailey and Dickinson, 
1996), despite considerable interest in this research over the last 30 years (Faed, 1984; 
Spahn-Langguth and Benet, 1992).   
Experimental investigations into AG reactivity in vivo have focussed on the 
administration of the parent carboxylate to test subjects, both animals and humans, 
and measuring chemically undefined covalent modifications of unfractionated plasma 
proteins or partly characterised hepatic proteins.  Correlation of the covalent binding 
of carboxylate compounds with plasma exposure of AGs provides the most compelling 
evidence of AG’s responsibility (Smith et al., 1986; Hyneck et al., 1988a; Castillo et al., 
1995; Bailey and Dickinson, 1996).  However, whilst plausible, this does not provide 
definitive evidence of AG’s responsibility, as the analytical techniques are unable to 
differentiate protein adducts derived from distinct CRMs.  Consequently, with most 
carboxylate compounds, including diclofenac, metabolised to other CRMs capable of 
forming covalent protein adducts, whether acyl glucuronidation is responsible for 
covalent binding of carboxylate drugs to proteins in vivo is not necessarily proven. 
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A challenging limitation to previous in vivo research into AGs was the inaccessibility of 
pure AG, in large quantities, with AGs for experimentation usually obtained through 
isolation from liver microsome incubations (Smith et al., 1990a; Dubois et al., 1993b), 
or isolated from rat (Dickinson et al., 1994) or human (Munafo et al., 1990; Watt et al., 
1991; Castillo et al., 1995; Ding et al., 1995) urine samples or alternatively rat bile 
(Williams et al., 1992; Ebner et al., 1999).  These sources do not yield large quantities 
of pure material, meaning biosynthesis of AGs for in vivo investigation using these 
techniques is highly time consuming and potentially expensive.  Only recently has 
chemical synthesis of AGs resulted in the preparation of these metabolites for research 
at relatively high yields (Kenny et al., 2004; Stachulski et al., 2006).  Consequently, 
access to chemically synthesised diclofenac-AG created amongst the first opportunity 
to properly characterise the AGs reactivity with protein in an in vivo model.   
Only a few experiments have ever administered AGs to experimental animals, 
investigating the plasma clearance of AGs (Watt et al., 1991; Iwaki et al., 1995; Dong et 
al., 2005).  All of these experiments found AG metabolites to be rapidly cleared from 
the plasma, with clearances exceeding those of their aglycone.  All of these 
experiments also showed extensive hydrolysis of AGs.  The extensive AG hydrolysis 
observed in bile duct-ligated animals implies that hydrolysis is a consequence of 
plasma and/or tissue hydrolysis, rather than enterohepatic recirculation (Watt et al., 
1991; Iwaki et al., 1995; Dong et al., 2005). Consequently, this observation suggests 
that not only is plasma AG clearance rapid, as would be expected for most Phase II 
metabolites, but also that plasma hydrolysis causes AG clearance to exceed what 
would be expected of a stable Phase II metabolite.  This suggestion implies that rapid 
AG clearance from plasma may preclude extensive protein conjugation in situ.  
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However, this idea remains speculative, as none of these experiments investigated the 
protein reactivity of AGs in vivo.  
To address this issue, experiments were undertaken as described in this chapter to 
investigate the applicability of the rat to study diclofenac-AG reactivity with serum 
albumin proteins in vivo, firstly through the characterisation of the covalent 
modification of RSA in vitro.  Following this study, chemically synthesised diclofenac-
AG was administered intravenously to a rat to investigate whether covalent protein 
adducts could be detected in plasma.  The final experiments in the rat investigated the 
plasma disposition of diclofenac-AG.  All of these factors combined may allow 
prediction of the risk of protein adduct formation from a drug AG in the rat.  
  
  
Chapter 3 – The Use of a Rat Model to Study Acyl Glucuronide Reactivity 
Page 140 
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Acetonitrile (LC-MS grade), hydrochloric acid (HCl), methanol (LC-MS grade) and 
trifluoroacetic acid (LC-MS grade) were purchased from Fisher Scientific, 
Leicestershire.  Bio Rad Bradford reagent was purchased from Bio Rad, Hertfordshire, 
UK.  Modified trypsin was purchased from Promega, Hampshire, UK.  Acetic acid  
(LC-MS grade), ammonium hydrogencarbonate, diclofenac sodium salt, dimethyl 
sulfoxide (DMSO), dithiothreitol, formic acid (LC-MS grade), HSA (approx. 99% pure, 
essentially globin free and fatty acid free), iodoacetamide, RSA (≥99% pure, lyophilized 
powder, essentially fatty acid free, essentially globulin free), sodium chloride, 
tris(hydroxymethyl)aminomethane (TRIS), urethane and zomepirac sodium salt were 
purchased from Sigma-Aldrich, Dorset, UK.  
0.1M phosphate buffer pH 7.4 was made using 0.3117% monosodium phosphate 
monohydrate, 2.0747% disodium phosphate, heptahydrate  w/v in distilled water.  
All other reagents were purchased from Sigma-Aldrich (Dorset, UK) unless otherwise 
stated. 
3.2.2 Animals 
Male rats of a Wistar substrain were purchased from Charles River UK Limited 
(Margate, Kent, UK) and were of body weight between 200-250 grams.  Animals were 
housed in groups and acclimatised to their surroundings for a minimum of five days 
prior to experiments.  All experiments were undertaken in accordance with criteria 
outlined in a license granted under the Animals (Scientific Procedures) act of 1986 and 
approved by the Animal Ethics Committee of the University of Liverpool. 
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3.2.3 Covalent modification of human and rat serum albumin by  
diclofenac acyl glucuronide during in vitro incubation 
Concentration-dependent modification of HSA and RSA by diclofenac-AG was 
investigated by in vitro incubation.  Increasing concentrations of 1-β diclofenac-AG 
(400nM, 4µM, 40µM, 400µM and 2mM) were incubated with 40µM HSA or RSA in 
0.1M phosphate buffer, pH 7.4, at 37°C for 16 hours.  The reaction was stopped and 
protein precipitated and separated through immediate vortex mixing with 900µl ice-
cold methanol and subsequent centrifugation at 24,000g at 4°C for 15 minutes.  The 
methanolic supernatant was removed, and the pellet washed three times with 60µl 
ice-cold methanol.  The precipitated protein was dissolved in 50µl of 0.1M phosphate 
buffer, pH 7.4, reduced with dithiothreitol (10mM) for 15 minutes at room 
temperature and alkylated with iodoacetamide (55mM) for a further 15 minutes at 
room temperature.  The protein mixture was then precipitated and washed with ice-
cold methanol as before.  The protein pellet was re-dissolved in ammonium 
hydrogencarbonate solution (50µM, 30µl), assayed for protein content using the 
Bradford assay (Bradford, 1976), and 30µl aliquots of 3.2mg/ml protein were digested 
with 5µg trypsin overnight.  The digests were desalted using 0.6 µl bed C18 Zip-Tip 
pipette tips (Millipore, Cork, Republic of Ireland) as per the manufacturer’s 
instructions, eluted with 10µl 50% acetonitrile, 0.1% trifluoroacetic acid in deionised 
water and dried by centrifugation under vacuum (SpeedVac, Eppendorf UK Ltd, 
Cambridge, UK) and stored at 4°C for a maximum of 2 weeks prior to LC-MS/MS 
analysis. For LC-MS/MS analysis, aliquots of 3 µL sample were delivered into a QSTAR 
Pulsar i hybrid mass spectrometer (AB Sciex) by automated in-line liquid 
chromatography (integrated LCPackings System, 5mm C18 nano-precolumn and  
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75μm x 15cm C18 PepMap column (Dionex, California, USA)) via a nano-electrospray 
source head and 10μm inner diameter PicoTip (New Objective, Massachusetts, USA). A 
gradient from 5% acetonitrile/0.05% TFA (v/v) to 48% acetonitrile/0.05% TFA (v/v) in 
60mins was applied at a flow rate of 300nL/min, and MS and MS/MS spectra were 
acquired automatically in positive ion mode using information-dependent acquisition 
(IDA) (Analyst, AB Sciex). Database searching was performed using ProteinPilot  
version 3 (AB Sciex) against the latest version of the SwissProt database, with 
biological modifications allowed and with the confidence level set to 10%. DAG was 
included as a high probability user-defined modification of Lys and carboxamidomethyl 
as a high probability user-defined modification of Cys. The data were also assessed 
manually for the presence of a dominant fragment ion of 278amu, indicative of 
cleavage of the transacylated hapten, and fragment ions of 215 and 250amu, indicative 
of cleavage of the glycated hapten.  
3.2.4 Investigations into the modification of serum albumin proteins of the 
rat following intravenous bolus administration 
A 264 gram rat was anaesthetised through intraperitoneal administration of 14% (w/v) 
urethane in 0.9% (w/v) saline, 1ml/kg.  Following induction of anaesthesia, the trachea 
was cannulated to maintain ease of respiration of the animal throughout the 
experiment.  The femoral vein was cannulated with a cannula flushed and filled with 
heparinised saline (250 U/ml).  A 60mg/kg (127 µmol/kg) dose of diclofenac-AG (made 
up as a 60mg/ml solution in 50% DMSO (v/v)) was administered as an intravenous 
bolus through the femoral cannula.  Two hours following drug administration, at a time 
point when the AG was expected to have been eliminated from literature (Watt et al., 
1991; Iwaki et al., 1995; Dong et al., 2005), the animal was exsanguinated through 
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cardiac puncture, and killed.  Plasma was isolated from blood following centrifugation 
at 2000g for 10 minutes at 4°C, and stored at -80°C until analysis.  RSA was isolated 
from 60 µl aliquots of plasma using affinity chromatography (Greenough et al., 2004; 
Jenkins et al., 2009b).  RSA was captured on a POROS anti-HSA affinity cartridge 
installed on a PerSeptive BioSystems Vision Workstation (Applied Biosystems, Foster 
City, CA, USA).  It was eluted with HCl (12 mM).  Eluted protein fractions were 
immediately neutralised with 0.1M Tris buffer, pH7.  Protein fractions were 
precipitated through vortex mixing with nine fold volumes of ice-cold methanol and 
separated by centrifugation at 14,000 rpm.  The methanolic supernatant was removed, 
and the pellet washed three times with 60µl ice-cold methanol.  The precipitated 
protein was dissolved in 50µl of 0.1M phosphate buffer, pH 7.4, reduced with 
dithiothreitol (10mM) for 15 minutes at room temperature and alkylated with 
iodoacetamide (55mM) for a further 15 minutes at room temperature.  The protein 
mixture was then precipitated and washed with ice-cold methanol as before.  The 
protein pellet was re-dissolved in ammonium hydrogencarbonate solution (50µM, 
30µl), assayed for protein content using the Bradford assay (Bradford, 1976), and 50µl 
aliquots of 3.2mg/ml protein were digested with 5µg trypsin overnight.  The digests 
were desalted using 0.6 µl bed C18 Zip-Tip pipette tips (Millipore, Cork, Republic of 
Ireland) as per the manufacturer’s instructions, eluted with 10µl 50% acetonitrile, 0.1% 
trifluoroacetic acid in deionised water, and dried by centrifugation under vacuum 
(SpeedVac, Eppendorf UK Ltd, Cambridge) and stored at 4°C prior to LC-MS/MS 
analysis within 2 weeks of sample preparation.  Mass spectrometric analysis was 
performed as outlined above for analysis of in vitro peptide samples. 
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3.2.5 Pharmacokinetic experiments 
Rats were anaesthetised through intraperitoneal administration of 14% (w/v) urethane 
in 0.9% (w/v) saline, 1ml/kg.  Following induction of anaesthesia, the trachea was 
cannulated to maintain ease of respiration of the animal throughout the experiment.  
The carotid artery and femoral vein were cannulated, with cannulae flushed and filled 
with heparinised saline (250 U/ml).  At desired time points, blood samples (100µl) 
were taken through the carotid artery cannula.  Diclofenac-AG (5mg/kg, 10.59µmol/kg) 
or diclofenac (3.36mg/kg, 11.35µmol/kg) dissolved in 0.1M phosphate buffer, pH 5 
was administered as an intravenous bolus through the femoral vein cannula (each 
dose group contained three animals).  The blood samples were taken 5 minutes before 
drug administration, and subsequently at 5, 10, 15, 20, 25, 30, 45, 60 and 120 minutes 
post-dose.  Blood samples were immediately centrifuged at 2100g for 10 minutes at 
room temperature, with AG in the separated plasma stabilised through the addition of 
2M acetic acid, 4% (v/v).  Plasma samples were stored at -80°C until analysis (Sparidans 
et al., 2008).   
3.2.6 Analysis of diclofenac and diclofenac-AG in plasma samples 
Stored plasma samples were thawed at room temperature and processed 
immediately.  Samples were diluted using acidified blank rat plasma, kindly provided 
by Julie Eakins, AstraZeneca, Alderley Park.  To 50 µl aliquots of acidified plasma 10µl 
of 3µM zomepirac internal standard was added in acetonitrile-water (1:1, v/v) 
containing 0.1% formic acid.  Protein was precipitated through addition of four times 
volume of ice-cold acetonitrile.  Precipitated protein was pelleted by centrifugation at 
14,000g for 5 minutes at 4°C.  Supernatant was removed, and filtered through 0.45-µm 
low-binding hydrophilic PTFE filter plates (Multiscreen Solvinert filter plates, Millipore, 
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Cork, Republic of Ireland) according to the manufacturer’s instructions to remove any 
remaining particulate material.  The filtrate was evaporated to dryness at 37°C under a 
constant stream of nitrogen, and reconstituted in 60µl of acetonitrile-water (1:1, v/v) 
containing 0.1% formic acid.  A 10 µl aliquot was injected onto the HPLC column.  
Analyte separation was performed at room temperature using a Zorbax Eclipse XDB-
C18 column (150 x 2.1 mm, 5µm; Agilent Technologies, Santa Clara, CA, USA) 
connected to a Dionex Ultimate 3000 HPLC system (Dionex Ltd., Macclesfield, 
Cheshire, UK) and a 4000 QTRAP hybrid quadrupole mass spectrometer (AB Sciex, 
Foster City, CA, USA).  Samples were maintained at 4°C in the autosampler.  Analytes 
were eluted using a gradient of acetonitrile containing 0.1% formic acid against 0.1% 
formic acid in water: 50-95% over 10 minutes.  The eluent flow rate was  
210µl/minute. Under these conditions diclofenac 1-β AG and its isomers eluted as a 
single peak at 2.7 minutes; zomepirac eluted at 5.2 minutes and diclofenac at 7.0 
minutes (Figure 3.1).  MS operating parameters for the multiple reaction monitoring 
(MRM) analyses of diclofenac and diclofenac-AG are shown in Table 3. 1.  No 
endogenous or artefactual materials interfering with analyte and internal standard 
signals in the selected MRM channels were detected in control plasma samples.  The 
lower limit of detection of diclofenac and the 1-β AG spiked into pooled rat plasma, as 
defined by signal to noise ratio > 3 was below 10nmol for both compounds.  The 
corresponding lower limits of quantification, as defined by accuracy of between 80-
120%, and precision (coefficient of variation) < 20% was 50nM for diclofenac (accuracy 
80.6%, precision 19.2%), and 30nM for diclofenac-AG (accuracy 99.0%, precision 
19.8%).  Three accuracy and precision replicates were run before sample analysis, and 
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one accuracy and precision run was also run for mass spectrometric assay for 
diclofenac and diclofenac-AG quantification. 
 
Figure 3. 1:  Total ion current chromatogram representing separation of diclofenac-
AG, zomepirac (internal standard) and diclofenac in rat plasma assays run on the API 
4000 QTrap mass spectrometer. 
 
Table 3. 1:  API 4000 QTrap mass spectrometric operating parameters for MRM 
assays of diclofenac-AG and diclofenac.  Parent ions are [M + H]+.  ** Internal 
standard. 
Parameters Diclofenac-AG Diclofenac Zomepirac** 
Fragmentation 
transition (m/z)* 
472.0296.1 296.1215.1 292.0139.0 
Declustering 
potential (V) 
37.00 31.00 40.00 
Entrance potential 
(V) 
10.00 10.00 10.00 
Collision energy 
(eV) 
14.00 41.00 27.00 
Collision exit 
potential (V) 
15.00 15.00 15.00 
Dwell time (ms) 200 200 200 
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3.2.7 Pharmacokinetic analysis 
Pharmacokinetic analysis of data was performed using Phoenix Winonlin (Version 5.2, 
Pharsight, St Louis, Missouri, USA).  Non-compartmental analysis was used to allow the 
AUC to be calculated for diclofenac and diclofenac-AG using the trapezoidal rule.  
Plasma clearance (CLp) was determined by the equation CLp= Dose/AUC0-∞.     
3.2.8 Statistical analysis 
To test if statistical significance was achieved between pharmacokinetic parameters 
for the plasma clearance of diclofenac or diclofenac-AG following intravenous bolus 
drug administration, data were assessed for normality using a Shapiro-Wilk test.  Data 
found to follow a normal distribution were assessed for significance using an unpaired 
t-test.  Data found to not to follow a normal distribution was assessed for significance 
using a Mann-Whitney Rank Sum test.  A statistically significant difference between 
groups was adjudged to be found if p<0.05.  Statistical analyses were performed using 
Sigmaplot for Windows Version 11.0.  
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3.3 RESULTS 
3.3.1 Comparison of the sensitivity of the API5500 QTrap mass spectrometer 
and the QStar I Pulsar hybrid mass spectrometer 
To allow assessment of the protein reactivity of diclofenac-AG towards RSA, in vitro 
incubations were undertaken.  At the time of this experimentation, no access to an API 
5500 QTrap (QTrap) mass spectrometer was available (chapter 2).  Consequently, mass 
spectrometric analysis of the covalent modification of RSA was undertaken using an 
ABI QStar Pulsar i hybrid (QStar) tandem mass spectrometer (AB Sciex, Foster City, CA, 
USA).  Diclofenac-AG was also incubated with HSA under the same conditions, with 
covalent modifications also analysed using the QStar mass spectrometer, to allow 
comparisons of modifications between RSA and HSA.  The QStar has been used 
successfully to characterise the adduction of HSA by β-lactams in vitro (Jenkins et al., 
2009a). 
On comparison of the data for the covalent modification of HSA by diclofenac-AG 
acquired by QStar and QTrap mass spectrometric analysis, it was apparent that the 
QTrap had greater sensitivity.  The lowest concentration of diclofenac-AG to produce a 
covalent adduct of HSA detectable by QStar analysis was 40µM, 100 fold higher than 
was achieved on the QTrap, which could detect a glycation adduct of K190 following 
incubation of 400nM diclofenac-AG with HSA.  The identification of greater numbers of 
modified lysine residues of HSA following incubation with diclofenac-AG at 4µM, 40µM 
and 400µM by QTrap than QStar analysis (3, 5 and 4 more lysine residues respectively) 
provided further evidence for the greater sensitivity of the QTrap.  Similar detection of 
HSA lysine modifications, however, was achieved following incubation with diclofenac-
AG at the highest concentration of 2mM. 
Chapter 3 – The Use of a Rat Model to Study Acyl Glucuronide Reactivity 
Page 149 
 
3.3.2 Investigation into the covalent modification of rat serum albumin 
following in vitro incubation 
To assess the covalent modification of RSA (Table 3. 2), and its comparison to HSA 
(Table 3.2), diclofenac-AG was incubated for 16 hours at pH 7.4 and 37°C with 40µM 
RSA or HSA at increasing concentrations, from 4µM to 2mM.  Due to the differences of 
amino acid sequence between RSA and HSA, and consequently the production of 
differing peptides by tryptic digestion, definitive assertions of the selectivity of 
modification cannot be made following mass-spectrometric analysis because of the 
differential ionisation of peptides as discussed in chapter 2.  It is noticeable, however, 
that the numbers of lysine residues detected as modified by diclofenac-AG were far 
lower for RSA in comparison with HSA (4 in comparison to 10 respectively).  It is also 
noticeable that the lowest concentration of diclofenac-AG producing detectable 
covalent adducts was higher in incubations with RSA than HSA (400µM compared to 
40µM respectively).  Consequently, this suggests that RSA may be less susceptible to 
modification by diclofenac-AG than HSA at physiological pH in vitro, and certainly 
identification of RSA modifications by tandem mass spectrometry was lower. 
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Table 3. 2:  Covalent modifications of 40µM rat serum albumin (A) or 40µM human 
serum albumin (B) during incubation with synthetic diclofenac-AG at increasing 
concentrations.  G represents a covalent adduct formed through the glycation 
pathway, T represents a covalent adduct formed through the transacylation pathway.  
The covalent modifications were identified by LC-MS/MS analysis of tryptic peptides.  
The adducted amino acid is represented by an asterisk.  See figure 2.2 for comparison. 
Lysine 
residue 
Peptide 
sequence 
Concentration of diclofenac-AG in the incubation 
mixture 
4µM 40µM 400µM 2mM 
K199 MK*CSSMQR   G G 
K212 AFK*AWAVAR    G 
K317 EVCK*NYAEK    T 
K525 K*QTALAELVK   T T 
 
Table 3. 2B 
Lysine 
residue 
Peptide sequence 
Concentration of diclofenac-AG in the 
incubation mixture 
4µM 40µM 400µM 2mM 
K137 K*YLYEIAR    G 
K162 YK*AAFTECCQAADK    G 
K190 LDELRDEGK*ASSAK   G GT 
K195 ASSAK*QR    GT 
K199 LK*CASLQK  G G GT 
K351 LAK*TYETTLEK   G G 
K432 NLGK*VGSK    G 
K436 VGSK*CCK    GT 
K525 K*QTALVELVK    GT 
K541 ATK*EQLK    GT 
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3.3.3 Investigation of covalent binding of diclofenac acyl glucuronide to 
serum albumin in the rat 
Following intravenous bolus administration of 60mg/kg diclofenac-AG to a single rat, 
albumin was isolated using affinity chromatography, and tryptic digests of the protein 
were analysed using a QStar mass spectrometer.  Following exhaustive analysis of 
spectra, no diclofenac-related modifications could be detected. 
3.3.4 Plasma clearance of diclofenac and diclofenac acyl glucuronide from 
the rat: non-compartmental analysis 
The leading hypothesis for the mitigation of AG metabolites forming covalent adducts 
with proteins in vivo is their rapid elimination, and especially their rapid hydrolysis 
(Mizuma et al., 1999; Zhang et al., 2011).  Potentially this provides an explanation for 
the absence of detectable covalent HSA adducts in the rat that received bolus 
intravenous administration of a large (60mg/kg) dose of diclofenac-AG.  To test this 
hypothesis, the plasma clearance of diclofenac-AG administered as an intravenous 
bolus was investigated, and compared to that of diclofenac administered at a molar 
equivalent dose. 
Following bolus administration of diclofenac (Figure 3. 2) and diclofenac-AG  
(Figure 3. 3) to the rat, both compounds showed an exponential fall in plasma 
concentration typical of those seen following bolus administration of drugs (Clarke and 
Smith, 2001).  The mean plasma clearance of diclofenac-AG was found to be 
approximately 5.5 fold greater than that of diclofenac, resulting in plasma exposure of 
diclofenac as calculated by the mean AUC0-120 and AUC0-∞ to be 5.4 and 6.2 fold higher 
than that of diclofenac-AG (Table 3. 3).   
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Although diclofenac-AG was found in mouse plasma at low concentrations following 
administration of the aglycone (Sparidans et al., 2008), metabolism of diclofenac to its 
AG could not be quantified at any time point throughout the experiment.  Dilutions of 
plasma samples, up to 1 in 40, were required for quantification of diclofenac.  Due to 
the possibility of overloading the mass spectrometer, more concentrated plasma 
samples were not run in the attempt to assess metabolism of diclofenac to diclofenac-
AG. 
In vivo hydrolysis of diclofenac-AG to diclofenac, however, represented a considerable 
elimination pathway, with plasma concentrations of diclofenac surpassing those of 
diclofenac-AG by 15 minutes following AG administration.  Plasma exposure of 
diclofenac following AG administration over the 120 minute experiment, as calculated 
by AUC0-120, was two-fold greater than that of the AG.   
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Figure 3. 2:  (A) Plasma clearance of diclofenac-AG in the rat (filled circles) following 
iv administration of 5mg/kg and its hydrolysis to diclofenac (hollow circles).  (B) 
These data shown on a log scale for comparison with published related studies of 
drug and drug-AG clearance in rats (Watt et al., 1991; Iwaki et al., 1995; Dong et al., 
2005).  Data presented as mean ± standard deviation (n=3). 
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Figure 3. 3:  (A) Plasma clearance of diclofenac from the rat following iv bolus 
administration of 3.36 mg/kg. (B) These data shown on a log scale for comparison 
with published related studies of drug and drug-AG clearance in rats (Watt et al., 
1991; Iwaki et al., 1995; Dong et al., 2005).  Data presented as mean ± standard 
deviation (n=3).  
Chapter 3 – The Use of a Rat Model to Study Acyl Glucuronide Reactivity 
Page 155 
 
Table 3. 3:  Pharmacokinetic parameters derived from non-compartmental modelling 
of data displayed in Figure 3. 2 and Figure 3. 3.  Statistically significant differences 
between the pharmacokinetic parameters of diclofenac-AG and diclofenac following 
intravenous bolus administration of the compounds is analysed by either an unpaired 
t-test or a Mann-Whitney rank sum test (* p<0.05, ** p<0.01, *** p<0.001).  n/a 
represents not applicable. 
Drug 
administered 
Analyte 
t ½ 
(mins) 
AUC0-120 
(mmol min L-1) 
AUC0-∞  
(mMol min L-1) 
Plasma 
Clearance  
(ml min-1 kg-1) 
Diclofenac Diclofenac 
12.69  
(± 4.51) 
849.59  
(± 134.4) 
988.45  
(± 261.9) 
12.00  
(± 2.98) 
Diclofenac-
AG 
Diclofenac-
AG 
4.12  
(± 0.58)* 
154.6  
(± 26.7)*** 
160.3  
(± 33.1)** 
67.81  
(± 12.83)** 
Diclofeanc n/a 
344.07  
(± 275.2) 
n/a n/a 
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3.4 DISCUSSION 
The aims of this work were to investigate the adduction of RSA by diclofenac-AG, in 
vitro, ascertain whether these covalent adducts could be detected in vivo following 
bolus administration of diclofenac-AG to the rat, and finally determine the 
pharmacokinetic properties of diclofenac-AG following intravenous administration. 
As with the investigations of HSA adduction by diclofenac-AG in vitro as described in 
chapter 2, diclofenac-AG was found to modify both RSA and HSA specifically at lysine 
residues.  Despite exhaustive analysis of the mass spectra, no modifications 
(acylations) of serine or arginine residues were detected, as have been reported for 
reactions of benoxaprofen-AG and tolmetin-AG with HSA (Ding et al., 1993; Ding et al., 
1995; Qiu et al., 1998).  Reasons for these marked differences between adductions of 
HSA by AGs are not clear, but most likely they reflect in combination the electrophilic 
and steric properties of the conjugates (Berry et al., 2009; Potter et al., 2011).  
However, modifications of non-lysine residues were few in all of these experiments 
(Ding et al., 1995; Qiu et al., 1998); in every case, greater numbers of modifications of 
lysine residues were detected. 
On comparison of the modification of HSA and RSA by diclofenac-AG, it is clear to see 
that greater numbers of lysine residues were detected as modified on HSA (ten lysine 
residues) in comparison to RSA (four lysine residues) following incubation with 2mM 
diclofenac-AG.  Additionally, the lowest concentration of diclofenac-AG yielding 
detectable covalent modification of albumin was 10-fold lower for HSA (a glycation 
adduct detected at K199 following incubation with 40M AG) than for RSA (a glycation 
adduct at K199 and a transacylation adduct at K525 following incubation with 400M 
AG) (Table 3. 2, Table 3.3).  These findings may suggest that covalent modification of 
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HSA is preferential to modification of RSA, although definitive conclusions as to the 
selectivity of the modifications cannot be made due to the potential for differential 
ionisation of tryptic peptides as discussed in section 2.28.   
Few investigations have attempted to determine the relative reactivity of AG 
metabolites with HSA and RSA, however, Watt and Dickinson (1990) found a 74.7% 
greater modification of HSA compared to RSA following incubation with diflunisal-AG 
at a molar ratio of 0.16:1 (AG:HSA) compared with 0.3:1 (AG:RSA) (Watt and Dickinson, 
1990), suggesting the lesser modification of RSA is a real result.  Whilst little difference 
was observed following incubation at lower AG concentrations, this may have been 
due to the low concentrations used. 
HSA and RSA, and other mammalian serum albumins (Ahmad et al., 2011) are 
comprised of generally well-conserved amino acid sequences; HSA and RSA sharing 
80% sequence homology (Carter et al., 1989; Kosa et al., 1997).  However, variations in 
their non-covalent binding sites have been reported.  Whilst non-covalent interactions 
of the Sudlow Site I ligands warfarin and phenylbutazone were similar between RSA 
and HSA, interactions were greatly reduced for the Sudlow site II ligands ibuprofen and 
diazepam (Kosa et al., 1997).  Species differences in the non-covalent interactions of an 
unconjugated carboxylic acid with RSA and HSA have been reported for the leukotriene 
D4-antagonist MK-571, whose S- isomer preferentially formed non-covalent 
interactions with HSA, whereas the R- isomer preferentially interacted with RSA (Lin et 
al., 1990).  With hydrophobic sites shown to be important in the covalent modification 
of HSA by AGs, as described in chapter 2 and by others (Munafo et al., 1990; Williams 
and Dickinson, 1994; Ding et al., 1995; Qiu et al., 1998), species differences resulting in 
lower affinity for AGs at these sites are likely to have an effect on covalent 
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interactions.  With bovine serum albumin in vitro, the covalent modification of 
tolmetin-AG was much less than binding to HSA, although the rate of adduct formation 
was the same as with HSA (Munafo et al., 1990).  BSA lacks inter alia K195 and K199 
(Ahmad et al., 2011), both of which in HSA are adducted by tolmetin AG in vitro (Ding 
et al., 1995). 
However, the absence of 6 of the 10 lysine residues of HSA modified by diclofenac-AG 
from the primary sequence of RSA is the most likely explanation for the reduced 
identification of modified lysine residues in RSA (sequences from (Sargent et al., 1981; 
Minghetti et al., 1986)).  The absence of these six lysine residues (K137, K162, K190, 
K195, K432 and K541) from RSA is likely to have a drastic effect on the extent of 
covalent modification.  Consequently, the appropriateness of RSA as an adduction 
target in any attempt to predict the covalent binding of drugs and metabolites to 
plasma proteins in humans may be questioned. 
Despite this observation, qualitative assessments of modifications of RSA by 
carboxylate drugs and their AGs is still useful.  An identification of AG-derived glycation 
adducts on RSA in vivo may at least suggest corresponding adductions of HSA in vivo, 
pro rata with metabolic formation of the AG, will be more abundant and/or numerous, 
due to the generically slower rate of plasma clearance of drugs in humans than rats 
(Chiou et al., 1998) and the more numerous sites for covalent modification of HSA than 
RSA (Table 3. 2, Table 3.3).  Consequently, to investigate if diclofenac-AG can modify 
RSA in vivo, a single intravenous bolus dose of diclofenac-AG was administered to an 
anaesthetised rat, and isolated serum albumin was analysed using peptide mass 
spectrometry to detect any covalently modified residues.  With two covalent adducts 
detected on lysine residues K199 and K525 following in vitro incubation of 400µM 
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diclofenac-AG with 40µM RSA, which represented a relative molar exposure of 10:1 
(AG:RSA), it was decided to administer diclofenac-AG to the rat at a dose, which, 
ideally, would produce a similar exposure of the conjugate to RSA. 
Taking the estimated total plasma volume of the 264 g rat used here to be 10.22 ml 
(Bijsterbosch et al., 1981), a 60mg/kg bolus intravenous dose would theoretically result 
in a maximum plasma diclofenac-AG concentration of approximately 3.3mM.  With the 
plasma concentration of RSA estimated at 22.3mg/ml (337.8µM) (Papet et al., 2003), 
the molar ratio of diclofenac-AG to RSA immediately following bolus administration is 
estimated at 9.76:1 (AG:RSA).  This is approximately the relative exposure of AG that 
produced detectable covalent adducts of RSA during a 16 hour in vitro incubation 
(Table 3. 2). 
Despite exhaustive analysis of the tryptic digests of RSA isolated from plasma samples 
taken from the rat 2 hours following AG administration, no covalent adducts could be 
detected using QStar mass spectrometry.  This finding would appear to conflict with 
non-mass spectrometry studies suggesting AGs are able to form covalent adducts with 
plasma proteins in the rat following administration of the parent carboxylic acid 
(Sallustio and Foster, 1995; Liu et al., 1996).  It must be emphasised, however, that 
because these covalent binding assays rely on essentially indiscriminate alkaline 
hydrolysis of adducts, they do not permit attribution of the drug metabolites 
responsible for covalent modification of plasma proteins in vivo.   
Glucuronidation of xenobiotics is traditionally considered a process acting to nullify the 
adverse chemical and physiological activities of unusable compounds and hasten their 
elimination from the biological system (Caldwell, 1982; Miners and Mackenzie, 1991; 
Spahn-Langguth and Benet, 1992).  With their generic potential for covalent adduct 
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formation in vivo, AGs clearly do not represent model products of glucuronidation.  
Therefore the exceptionally rapid elimination of AG metabolites can be regarded as an 
essential counterbalance to the metabolite’s chemical reactivity, which mitigates their 
potential to exert toxicological effect.   
Despite assumptions of AG’s rapid elimination, measurements of AG clearance in vivo 
have not been undertaken extensively.  Most investigations into the rates of AG 
clearance in vivo employed measurement of the conjugate’s renal clearance in 
humans, following administration of the parent drug.  In all of these cases, renal 
clearance of the AG metabolite was found to be greater than for the parent drug 
(Smith et al., 1985; Castillo et al., 1995; Vree et al., 1995).  Experiments in the rat, 
where the AGs of benoxaprofen, flunoxaprofen, diflunisal and the R- and S- isomers of 
naproxen were directly administered as an intravenous bolus also reported rapid AG 
elimination in comparison with their parent carboxylates (Watt et al., 1991; Iwaki et 
al., 1995; Dong et al., 2005).  Consequently, it was decided to investigate whether 
plasma clearance of diclofenac-AG in the rat is also rapid, potentially providing an 
explanation for not detecting covalent adducts in vivo. 
As expected, the plasma clearance of diclofenac-AG was found to be significantly 
greater than that of diclofenac (by approximately six-fold), resulting in a shorter 
plasma half-life of diclofenac-AG of 4.12mins in comparison to 12.69mins for 
diclofenac (Table 3. 3).  The greater clearance of diclofenac-AG may be a result of its 
greater affinity for export transporters.  The major route of elimination of diclofenac in 
the rat has been shown to be biliary elimination (Peris-Ribera et al., 1991), with TR-/- 
(MRP2 deficient) rats revealing the importance of the export transporter MRP2 for the 
elimination of diclofenac acyl glucuronide from the rat (Seitz et al., 1998).  In knockout 
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mice not expressing MRP2, no statistically significant reduction of diclofenac biliary 
elimination could be detected.  However, elimination of the AG was vastly increased 
(Lagas et al., 2010); suggesting that elimination of the AG is dependent on export 
hepatic export transporters, whereas that of diclofenac is not.  Further evidence for 
this difference was derived from in vitro studies using transfected MRP-2 that 
suggested that diclofenac is not transported by this protein (Lagas et al., 2009). 
As a consequence of the greater rate of AG clearance in comparison to diclofenac, 
plasma exposure of the AG was significantly lower by 5.5-fold, supporting the 
hypothesis that rapid clearance of AGs, resulting in reduced AG exposure may be a 
mitigating factor in the covalent modification of endogenous macromolecules.  
The plasma clearance of diclofenac-AG (67.81 ± 12.83 ml min-1 kg-1, Table 3.3) being 
approximately double the 35.5 ± 5.2 ml min-1 kg-1 hepatic blood flow of urethane-
anaesthetised rats (Hiley et al., 1978) indicates that mechanisms other than hepatic 
metabolism and elimination contribute to the conjugate’s clearance from the 
circulation.  The major mechanisms which would be expected to account for extra-
hepatic AG eliminations would generally be considered to be renal elimination, or 
extra-hepatic AG hydrolysis.   
Whilst investigations into the renal and biliary elimination of AGs was not undertaken 
in these studies, extra-hepatic hydrolysis of diclofenac-AG to its parent carboxylate 
appeared to represent an important route of clearance in the rat.  This has also been 
shown for the AGs of benoxaprofen, flunoxaprofen, diflunisal and naproxen (Watt et 
al., 1991; Iwaki et al., 1995; Dong et al., 2005).  High variability in plasma or tissue 
hydrolysis of diclofenac-AG was detected in this experiment, most likely due to inter-
animal variation.  This explanation is represented by one animal having consistently 
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lower values for plasma hydrolysis than the other two in the experiment.  Whilst 
correlations between hepatic blood-flow and AG clearance, as described above, 
suggest that the detection of plasma diclofenac is largely as a consequence of extra-
hepatic hydrolysis, the contribution of enterohepatic circulation was not defined in this 
experiment.  The relative contributions of plasma and tissue hydrolases/esterases to 
the clearance of drug AG from plasma are still largely unknown (Fukami and Yokoi, 
2012).  Human plasma contains three esterases in high enough concentrations to 
contribute significantly to ester hydrolysis: butyrylcholinesterase, paraoxonase and 
albumin (Li et al., 2005). However, there are substantial species differences between 
esterase expression and hydrolase activity in mammalian plasma (Bahar et al., 2012), 
and carboxylesterase is absent from human plasma (Li et al., 2005).  Extensive 
enterohepatic recirculation of several NSAIDs including diclofenac has been found in 
the rat (Stierlin and Faigle, 1979; Lin et al., 1985; Dietzel et al., 1990).  However, the 
extensive hydrolysis of the AGs of flunoxaprofen and benoxaprofen in rats with 
cannulated bile ducts (Dong et al., 2005), which consequently were unable to undergo 
enterohepatic recirculation, combined with the extensive hydrolysis of AGs incubated 
in isolated plasma as shown in chapter 2 and by others (Ruelius et al., 1986; Volland et 
al., 1991; Williams et al., 1992; Akira et al., 2002; Shipkova et al., 2003; Karlsson et al., 
2010), suggest hydrolysis is primarily located in the tissues and/or plasma.  If this is the 
case, plasma hydrolysis of AGs does represent an additional elimination pathway, 
complimenting rapid direct elimination, reducing the risk of AG-mediated adduction of 
macromolecules in vivo. 
From this work, it is clear that species differences, expressed as a 20% variance in the 
primary structure between RSA and HSA (Sargent et al., 1981; Minghetti et al., 1986; 
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Carter et al., 1989; Kosa et al., 1997), result in a marked disparity of covalent adducts 
detected by QStar mass-spectrometry.  This finding is likely to be principally a 
consequence of the absence from RSA of 60% of the lysine residues of HSA known to 
be modified by diclofenac-AG in vitro.  Despite the identification of two covalent 
adducts following incubation of 400µM diclofenac-AG with 40µM RSA, no AG derived 
adducts were identified on RSA isolated from a rat administered diclofenac-AG at a 
dose estimated to produce the same exposure.  Rapid elimination of diclofenac-AG 
from plasma was hypothesised to be a mechanism mitigating covalent adduct 
formation by the AG metabolite in the rat.  To investigate this proposition, the plasma 
clearance of an intravenous bolus dose of diclofenac-AG was determined.  Plasma 
clearance of the AG was rapid, resulting in a measured half-life of clearance of only 4 
minutes, which was three fold faster when compared to diclofenac.  Hydrolysis of the 
administered AG represented a considerable elimination pathway, resulting in three-
fold higher exposure of diclofenac than the AG over the 120 minute experiment.  
Whilst it cannot be definitively identified in this experiment whether enterohepatic 
recirculation or plasma/tissue hydrolysis was primarily responsible for the extent of 
diclofenac-AG hydrolysis detected in rats, the incubations of AGs with isolated human 
plasma described in chapter 2 do suggest that plasma hydrolysis of diclofenac-AG 
would be extensive.  This would constitute a significant elimination pathway, greatly 
reducing the adduction of proteins by diclofenac-AG in vivo, and consequently, may 
also be considered a detoxification pathway.  
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4.1 INTRODUCTION  
The most convenient and widely used route for the administration of pharmaceuticals 
is via oral ingestion of either liquid or capsule formulations.  However a variety of 
other routes of drug administration are available and may be used when episodic oral 
administration is considered inappropriate or undesirable.  Continuous infusion allows 
continuous administration of drugs, usually into the circulatory system.  Clinically, 
various routes of continuous infusion are used, including skin patches, where infusion 
is maintained by an osmotic gradient as is used in rotigotine administration in the 
treatment of Parkinson’s disease (Sanford and Scott, 2011).  Alternatively, in a hospital 
setting continuous intravenous drug infusion may be used, allowing continuous and 
consistent drug plasma concentrations.  This is used for compounds including 
antibacterial agents, flucloxacillin (Leder et al., 1999; Howden and Richards, 2001), and 
chemotherapeutics such as 5-fluorouracil (Howell et al., 1997; Recchia et al., 2001).  
These routes of infusion allow consistent and careful control of drug plasma 
concentrations.  This is particularly important for compounds where consistent plasma 
concentrations are required for efficacy. 
Plasma kinetic profiles of drugs following continuous infusion usually follow 1st order 
kinetic principles, where drug clearance is proportional to drug plasma concentration.  
Following commencement of drug infusion drug plasma concentrations are low.  
Consequently clearance is low, and below that of the rate of infusion, resulting in a rise 
in drug plasma concentration.  As drug plasma concentration increases, so does the 
rate of drug clearance.  This continues until the rate of drug clearance matches that of 
drug infusion.  At this point plasma drug concentrations remain constant, and are 
consequently maintained (steady-state pharmacokinetics are said to have been 
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reached) until cessation of drug administration (Clarke and Smith, 2001; Hill, 2004).  
Whilst continuous intravenous infusion is a heavily used technique in the delivery of 
drugs in a clinical setting, and consequently the pre-clinical model is well-established in 
development of these drugs, application of the continuous intravenous infusion model 
to in vivo toxicology studies is not. 
Commonly, pre-clinical investigations of drug pharmacokinetics and drug safety are 
undertaken in rat models.  The quicker rate of drug elimination in rats vs man is a 
major limitation.  With 52 of 54 drugs tested showed a faster rate of plasma clearance 
in the rat than man, ranging from 1.3 times faster for ketoprofen to 123 times faster 
for diazepam.  Only cyclosporine and nifedepine are cleared faster in man than the rat 
(Chiou et al., 1998). Consequently, even repeat drug administrations in the rat are 
unlikely to suitably model the clinical situation, as increased drug clearance may result 
in periods of ‘drug holiday’ of minimal drug exposure which is not observed in man.  
Consequently, it is hypothesised that continuous drug infusion, reaching steady state 
drug exposure may better model the clinical situation. 
Alternatively, continuous intravenous infusion may also be considered a useful tool in 
toxicological investigations of compounds.  Whilst allowing better correlation with 
clinical exposure, continuous infusion may also be used as a technique allowing 
‘forced’ increased drug (and potentially) metabolite exposure.  This increased drug 
and/or metabolite exposure may unmask mechanisms of toxicity not detectable 
following bolus drug administration techniques which are currently frequently used in 
current drug toxicity studies.  Acute dosing of compounds also has the potential to 
produce toxicities in secondary organs to the primary ones being studied.  Diclofenac 
represents a good example of this, where the dose-limiting toxicity is damage to the 
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gastrointestinal tract (Menasse et al., 1978; Seitz and Boelsterli, 1998), which limits 
doses which may be used for investigation of hepatotoxicity.  Continuous infusion may 
present a model by which these secondary toxicities may be avoided or managed to 
allow further investigation of toxicities of intended interest. 
To test the applicability of continuous infusion in a toxicological setting, diclofenac was 
chosen.  For some disorders including rheumatoid and osteo-arthritis diclofenac may 
be administered daily over many years, with dosing only ceased on suspicion of a 
serious ADR.  Due to the necessity of continuous drug efficacy, diclofenac is often 
administered either twice or three times a day, at daily doses reaching 150mg, 
sometimes in slow release formulations.  Further to this, the rat exhibits 3.7 times 
faster plasma clearance of diclofenac than man (15.7ml/min/kg against 4.2 ml/min/kg 
respectively) (Chiou et al., 1998).  Consequently, as described above, single bolus drug 
administrations or repeat bolus drug administration studies in the rat are unlikely to 
represent the clinical situation. 
Diclofenac is associated with the generation of idiosyncratic hepatotoxicity, with 
approximately 6.3 patients out of 100,000 requiring hospital treatment (de Abajo et 
al., 2004).  Further to this, transient ALT rises are observed in patients receiving drug 
treatment in approximately 15% of patients, with approximately 3-5% of patients 
experiencing ALT rises above 3x the upper limit of normal (Banks et al., 1995; Laine et 
al., 2009).  To date, no in vivo models have allowed prediction or mechanistic 
understanding of either of these two types of drug toxicities. 
Incubations with human liver microsomes supplemented with UDPGA has suggested 
that approximately 75% of a dose of diclofenac is directly glucuronidated, forming its 
acyl glucuronide metabolite, with the remaining dose oxidised by CYP2C9 into its 4-OH 
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metabolite (Leemann et al., 1993; Tang et al., 1999c; Kumar et al., 2002).  The acyl 
glucuronide metabolite can be further oxidised into 4-OH diclofenac catalysed by 
CYP2C8 (Kumar et al., 2002).  Alternatively diclofenac may be oxidised by CYP3A4 into 
its 5-OH metabolite (Shen et al., 1999).  Both the 4-OH and 5-OH diclofenac 
metabolites have been reported to be further oxidised into quinone-imine metabolites 
(1’, 4’-quinoneimine and 2’, 5’-quinoneimine metabolites respectively) (Poon et al., 
2001).  CYP2B, 2C and 3A isoforms have been implicated with oxidative metabolism in 
the rat (Tang et al., 1999a).  Bioactivation of diclofenac into its reactive metabolites 
has been postulated to play a key role in the eliciting of idiosyncratic ADRs associated 
with the parent drug (Boelsterli, 2003; Aithal, 2004).  
Presentation of hepatotoxic ADRs associated with diclofenac is usually delayed, with 
76% of cases presenting after 1 month following introduction to the compound (Banks 
et al., 1995).  This combined with case reports of liver failure following diclofenac re-
administration to patients already suffered a delayed hepatotoxic reaction to the drug 
(Helfgott et al., 1990; Greaves et al., 2001) suggest an immunological pathogenesis.  
Whilst production of drug-protein adducts is hypothesised to be a critical process in 
the pathogenesis of immune-mediated ADRs, the provision of ‘danger signals’ from 
stressed, necrotic or apoptotic cells is also required for immune stimulation 
(Matzinger, 1994; Curtsinger et al., 1999).  Mechanisms for generation of danger 
signals in drug, and diclofenac-induced liver injury are largely undefined.  Several 
mechanisms have been hypothesised for the production of danger signals, including 
translocation of bacteria or endotoxins from the GI tract to the liver (Deng et al., 2006; 
Deng et al., 2008) and cytokine release as a result of cell-death elicited as a 
consequence of underlying disease, including osteoarthritis (Banks et al., 1995).  
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Alternatively, with transient plasma ALT rises detected in 3-5% of patients receiving 
diclofenac therapy (Banks et al., 1995; Laine et al., 2009), it can be hypothesised that 
danger signal release may be a direct response to drug exposure.  We hypothesise that 
continuous infusion of diclofenac to the rat would unmask these mechanisms of 
hepatotoxicity, as a result of forced-increased drug-exposure. 
Individual variations in phenotype, resulting in increased drug exposure have also been 
associated with increased susceptibility to off-target hepatotoxicity associated with 
diclofenac.  Genotyping studies have revealed an increased abundance of 
polymorphisms in the ABCC2 gene in patients who have retrospectively experienced 
an off-target ADR to diclofenac treatment, with an odds ratio of 5.0 (p=0.05).  This 
gene encodes the hepatobiliary export pump MRP2.  Whilst the functional outcome of 
the 24C>T ABCC2 polymorphism is not fully defined (Daly et al., 2007), it has been 
associated with identified associated with reduced mRNA expression of the gene 
(Haenisch et al., 2007), suggesting that increased drug or metabolite exposure may 
play a role in the clinical onset of diclofenac induced liver injury.   
Further associations with polymorphisms in the genes encoding CYP2C8 and UGT2B7 
were also found to produce increased risk of developing idiosyncratic hepatotoxicity 
following treatment with diclofenac (Daly et al., 2007), further suggesting 
accumulation of drug metabolites may represent a mechanism for the pathogenesis of 
idiosyncratic hepatotoxicity towards diclofenac.  Continuous infusion of diclofenac 
provides a tool by which this may be more closely modelled. 
Through this chapter we investigate the use of the continuous intravenous infusion 
system for its applicability for toxicological assessment of diclofenac hepatotoxicity in 
the rat.  This chapter aims to investigate whether diclofenac reaches steady state 
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following continuous intravenous infusion, and consequently if this results in initiation 
of hepatotoxicity in the rat, and possibly identification of mechanisms responsible. 
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Medfusion 3500 syringe pump (Smiths Medical, Ashford, Kent, UK), PhysioCath small 
animal vascular catheter (Data Sciences International, Minnesota, USA), Covance 
infusion harness (Instech Laboratories, Pennsylvania, USA), Vet-bond adhesive (3M, 
Minnesota), Water for injections (Hameln Pharmaceutical, Gloucestershire, UK and 
Freseniuis Kabi, Cheshire), Sterile 0.9% (w/v) saline and Sterile 5% (w/v) Manitol 
(Fresenius Kabi, Runcorn, UK), Vet-bond adhesive (3M Animal Care, Minnesota, USA), 
Diclofenac sodium salt (Sigma-Aldrich, Dorset, UK), Roche P modular analyser and 
standard Roche reagents (Roche Diagnostics, West Sussex, UK),  Bio Rad Bradford 
reagent (Bio Rad, Hertfordshire, UK), MRX microplate reader with Max Revelations 
3.04 software (Dynotech Laboratories, West Sussex, UK).  3,3’-diaminobenzidine, 
Background Blocker with Casein and X-cell plus polymer HRP (A.menarini diagnostics, 
Berkshire, UK), Carazzi’s Hematoxylin, polyclonal rabbit anti-catalase (2363-1, 
Epitomics, California, USA), Rabbit anti-SuperOxide Dismutase-2 (ab:13534, Abcam, 
Cambridgeshire, UK), polyclonal rabbit anti-CYP2C19 (HPA015066, SigmaAldrich, 
Dorset, UK), goat anti rat CYP1A1 (423635, Daiichi Pure Chemicals, Japan), rabbit anti-
BSEP (PC-064, Kamiya, Washington, USA), mouse anti-MRP2 (ab3373, Abcam, 
Cambridgeshire, UK), biotinylated rabbit anti mouse secondary (E0464, Dako, 
Calafornia, USA).  All other reagents were purchased from Sigma-Aldrich (Dorset, UK) 
unless otherwise stated.  
4.2.2 Animals   
Male rats of Wistar Hannover substrain RccHan:WIST of 10weeks of age were provided 
from Harlan Laboratories, UK.  Animals were housed in groups and acclimatised to 
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their surroundings for a minimum of 5 days prior to surgery for cannulation.  Following 
surgery, animals were housed singly.  Food and water was provided ad libitum to all 
animals throughout the study.  Experiments undertaken were in accordance with the 
criteria outlined in a licensed granted under the Animals (Scientific Procedures) Act of 
1986.  All cannulation surgery and sampling was performed by trained animal surgeons 
and technicians at AstraZeneca, Alderley Park, UK.  All analysis and sample work-up 
was performed in Liverpool. 
4.2.3 Cannulation procedure 
Initial induction of anaesthesia of rats was achieved by placing animals in an 
anaesthesia chamber containing 3-4% isoflurane/100% medical oxygen.   Following 
anaesthesia induction, the dorsal scapula and left ventral groin regions of the animals 
were shaved.  A small incision was made at the scapula region to facilitate cannula 
exteriorisation.   Proprietary skin cleansers were used on the shaved regions and the 
animals were transferred to the surgical table. Each animal was placed on a homeo-
thermic operating table over a sterile cloth and placed under 2-3% isoflurane 
inhalation.  A sterile drape was placed over the animal and a small incision 
(approximately 1cm) is made in the inguinal region adjacent to the peritoneal cavity. 
Following blunt dissection the femoral vein was exposed through the incision ligatures 
used to control blood flow.   Following this, an incision in the femoral vein was made, 
through which a PhysioCath catheter was inserted to a distance where the cannula tip 
sits within the vena cava.  The catheter was tied in place using silk ligatures 
and flushing of the catheter was carried out to ensure blood flow. The free end of the 
catheter was led subcutaneously from the groin to the incision at the scapula 
region.  The groin and neck incisions were closed using surgical staples and vet-bond 
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adhesive.  The free end of the catheter was led through a steel spring protector 
attached to an animal infusion harness.  The animal was then placed in the harness 
and the catheter was attached to the syringe pump via an infusion tether and swivel 
joint.  Following surgery, animals were maintained on continuous infusion of sterile 
saline at a flow of 1ml/hour/animal for approximately 24 hours.  This was then 
reduced to 0.5ml/hour/animal until 24 hours before drug dosing.  24 hours before 
drug dosing, animals were administered 5% mannitol vehicle at a flow rate of 
2ml/kg/hour, prior to administration of the test compound. 
4.2.4 Dose escalation arm 
To allow selection of the most appropriate dose for the study, a dose raising 
investigation was undertaken to investigate the maximum tolerated dose.  Using 2 
animals per group, diclofenac infusion of 12mg/kg/day using a vehicle of 5% mannitol 
(w/v) was well tolerated in animals.  A subsequent increase in dose to 24mg/kg/day 
was poorly tolerated.  Consequently, a 12mg/kg/day infusion of diclofenac was used 
for the main study. 
4.2.5 Continuous intravenous infusion of diclofenac at a dose of 
12mg/kg/day 
A 0.25mg/ml solution of diclofenac was made up in 5% (w/v) sterile mannitol solution, 
and was administered to rats at a rate of 2ml/kg/hour.  This equates to a dose of 
12mg/kg/day.  A control group was administered 5% (w/v) sterile mannitol solution at 
the same rate of infusion.  Drug infusion was maintained for 48hours.  Following the 48 
hour time point animals were disconnected from infusion equipment and cannulae 
were tied off.  Animals were subsequently maintained for 72 hours before termination 
of the study.  At desired time points, blood samples were obtained from animals 
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through tail vein knicks.  A composite sampling approach was chosen to ensure blood 
sampling is maintained below the 20% blood volume throughout the in-life phase of 
the study in accordance with the criteria in the Home Office Project License.  Group 
sizes were selected at n=8 for diclofenac infusion and n=6 for vehicle infusion.  Large 
group sizes were selected to allow for non-drug related losses from the study which 
are known to occasionally occur in continuous infusion experiments, including escape 
of animals from infusion equipment and development of blood clots in cannulae, 
preventing infusion.  The vehicle control group contained two less animals due to 
technical difficulties in the surgery procedure.  The diclofenac group contained one less 
animal than intended as one received its 24 hour dose in 24 minutes, and hence data 
achieved from this animal was discounted from analysis.  At the end of the in-life 
phase of the study, animals were killed by administration of halothane.  At the end of 
the experiment, a 3-5mm transverse section of the left lateral lobe of the liver was 
removed and stored in 10% buffered formalin and prepared for light microscopy 
assessment.  A further 3-5mm section from the left lateral lobe was isolated and 
immediately snap-frozen in liquid nitrogen and stored at -80°C for assessment of 
glutathione content.   
Table 4. 1: Blood sampling time points and volume (ml) for animals in diclofenac 
continuous infusion study. 
Dose group 
Number 
of 
animals 
in group 
Predose 1hr 2hr 6hr 24hr 48hr 72hr 96hr 
Terminal 
sample 
(120hr) 
Vehicle 
infusion 
3 0.2  0.2  1.2  1.8  3 
3 0.2 0.2  0.2  1.4  1.8 3 
Diclofenac 
12mg/kg/day 
4 0.2  0.2  1.2  1.8  3 
3 0.2 0.2  0.2  1.4  1.8 3 
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4.2.6 Isolation of plasma from blood samples  
Blood samples were collected from animals using tail vein knicks into heparinised 
tubes (Table 4. 1).  Plasma was isolated from these blood samples through 
centrifugation at 2100g for 10 minutes at 4°C.   
4.2.7 Analysis of diclofenac and diclofenac acyl glucuronide in plasma 
samples 
48µl of plasma were collected at 1hr, 2hr, 6hr, 24hr, 48hr, 72hr and 96hr following 
initiation of infusion, as well as immediately before sampling, using a composite 
sampling approach as outlined in Table 4. 1.  Plasma was immediately acidified through 
the addition of 2µl of 2M acetic acid in dH2O (4% v/v) to stabilise any acyl glucuronide 
metabolite.  Samples were subsequently immediately stored at -80°C until analysis 
(Sparidans et al., 2008). 
Plasma concentrations of diclofenac and diclofenac-AG were quantified as described in 
chapter 3. 
4.2.8 Pharmacokinetic analysis 
Non-compartmental analysis of diclofenac pharmacokinetics was assessed using 
Phoenix Winnonlin (Version 5.2, Pharsight, Missouri).  This allowed the area under the 
curve to be calculated. 
4.2.9 Clinical chemistry assessment 
Clinical chemistry assessment was undertaken at AstraZeneca, AlderleyPark, UK.  In 
brief, 600µl heparinised blood samples were isolated from animals at 72hr, 96hr and 
terminal (120hr) time points, and analysed for plasma ALT, glutamate dehydrogenase 
(GLDH), bile acid, total bilirubin, conjugated bilirubin and unconjugated bilirubin using 
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a Roche P modular analyser  and standard Roche reagents, as defined by 
manufacturer’s instructions.  
4.2.10 Histopathological assessment of hepatotoxicity  
Immunohistochemical preparation of slides was undertaken at AstraZeneca, Alderley 
Park UK.  All immunohistochemistry was performed on formalin-fixed paraffin-
embedded sections.  From these paraffin-embedded section 4µm sections were cut, 
mounted on glass slides, dewaxed, and rehydrated.  All antibody washes and dilutions 
were undertaken utilising Tris Buffered Saline (TBS) containing 0.1% Tween (v/v).  To 
allow visulalisation of antibodies, sections were incubated with 3,3’-diaminobenzidine 
and counterstained with Carazzi’s Hematoxylin.  Sections were subsequently 
dehydrated, cleared and mounted.  Appropriate positive and negative controls were 
utilized for analysis. 
For catalase and superoxide dismutase immunohistochemistry, heat-induced epitope 
retrieval was performed using 0.01M citrate buffer pH 6.0.  Endogenous peroxidase 
was blocked using 3% H2O2 (v/v) for 10 minutes.  Non-specific immunoglobulin (Ig)-
binding sites were blocked using Background Blocker with Casein for 20 minutes at 
room temperature (RT).  Sections were incubated in either polyclonal rabbit anti-
catalase (1:100 dilution) or Rabbit anti-SuperOxide Dismutase-2 (1:2000 dilution) for 
60 minutes at room temperature.  Following primary antibody incubation, sections 
were washed and incubated with a ready-to-use peroxidase-labelled secondary 
reagent, X-cell plus polymer HRP for 15 minutes at RT and subsequently washed again. 
For CYP2C19 immunohistochemistry, heat-induced epitope retrieval was achieved 
following incubation with proteinase K for 2 minutes.  Endogenous peroxidase was 
blocked using 3% H2O2 (v/v) for 10 minutes.  Non-specific Ig-binding sites were blocked 
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using Background Blocker with Casein for 20 minutes at RT.  Sections were incubated 
in either polyclonal rabbit anti-CYP2C19 (1:500 dilution) for 60 minutes at room 
temperature.  Following primary antibody incubation, sections were washed and 
incubated with a ready-to-use peroxidase-labelled secondary reagent, X-cell plus 
polymer HRP for 15 minutes at RT and subsequently washed again.  
For CYP1A1 staining, sections were immersed in 0.01M citrate pH 6.0 buffer and 
heated to 100◦C in RHS-2 processor for 5 minutes.  Endogenous peroxidase was 
blocked with 3% H202 for 10 minutes, and non-specific Ig-binding sites were blocked 
using Background blocker with Casein for 20 minutes at RT.  Sections were incubated 
in goat anti rat CYP1A1 (1:3000) for 60 minutes at RT.  Following this, a goat probe and 
goat HRP-polymer (Biocare Medical GHP516H) were applied for 15 minutes each, with 
sections then washed. 
For BSEP, heat-induced epitope retrieval was achieved following incubation of sections 
with 10mM EDTA, pH 8.0.  Endogenous peroxidase was blocked with 3% H2O2 for 10 
minutes, and non-specific Ig-binding sites were blocked using Background Blocker with 
Casein for 20 minutes at RT.  Sections were incubated in rabbit anti-BSEP (1:30 
dilution) for 60 minutes at RT.  Following primary antibody incubation, sections were 
washed and incubated with a ready-to-use peroxidase-labelled secondary reagent, X-
cell plus polymer HRP for 15 minutes at RT.  Thereafter, sections were washed again.   
For MRP2, heat-induced epitope retrieval was again achieved following incubation of 
sections with 10Mm EDTA, pH 8.0.  Endogenous peroxidase was blocked with 3% H2O2 
for 10 minutes, and non-specific Ig-binding sites were blocked using Background 
Blocker with Casein for 20 minutes at RT.  Sections were incubated with mouse anti-
MRP2 (1:300 dilution, Abcam: ab3373) for 60 minutes at RT.  A biotinylated rabbit anti 
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mouse secondary (1:400 dilution) was then applied for 30mins. Following secondary 
antibody incubation, sections were washed and incubated with X-cell plus polymer 
HRP for 15 minutes at RT.    Thereafter, sections were washed again in buffer.   
Sections were kindly read by John Foster, AstraZeneca, and scored on a scale from 
Grade 1 to Grade 4, as defined by Table 4. 2. 
Table 4. 2:  Scoring method used for histopathological analysis of sections 
Grading Severity 
Grade 1 Minimal / Very few/ Very small 
Grade 2 Slight / Few / Small 
Grade 3 
Moderate / Moderate number / Moderate 
size 
Grade 4 Marked / Many / Large 
  
4.2.11 Hepatic glutathione concentration 
Hepatic total glutathione levels (reduced glutathione (GSH) + oxidised glutathione 
(GSSG)) were determined using a microtitre plate assay.  In brief, approximately 50mg 
of hepatic tissue isolated from the medial lobe were isolated, and homogenised in 
200µl of 6.5% 5-sulphosalicylic acid (w/v) and 800µl glutathione stock buffer (143 mM 
NaH2PO4, 6.3mM EDTA, pH7.4 using 5M NaOH).  Homogenised tissue was incubated 
on ice for 10 minutes before centrifugation at 14,000 rpm for 5 minutes.   The 
supernatant was removed and used to determine total glutathione content 
spectophotometrically at 412nm using 5,5’-dithio-bis(2-nitrobenzoic acid), NADPH and 
GSH reductase, as described by (Vandeputte et al., 1994).  The results were compared 
to GSH standards (0-40 nMol/ml), and were normalised to protein content in the 
protein pellet. 
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4.2.12 Hepatic protein concentration for glutathione normalisation 
Protein concentration in pellets achieved from centrifugation in the glutathione assay 
was achieved using BioRad protein assay reagent as described by (Bradford, 1976).  
Protein standard curves were prepared using bovine serum albumin fraction V 
(0.5mg/ml). 
4.2.13 Statistical analysis 
To test if a significant difference could be observed in plasma diclofenac concentration 
between the 24hour and 48 hour time points (Figure 4. 1) the data were first assessed 
for normality using a Shapiro-Wilk test.  As this found that the data could be described 
using  a normal distribution, an unpaired t-test was used to investigate statistical 
significance. 
To test if a significant difference between vehicle control and diclofenac infused 
animals for clinical chemistry assays at each time point (Figure 4. 2), data was tested 
for normality using a Shapiro-Wilk test.  If data was found to follow a normal 
distribution an unpaired t-test was used to investigate significance, and a Mann-
Whitney Rank Sum test was used to test significance for non-normal data.  
For both tests a statistical significance was adjudged to have been found if p<0.05.  
Statistical analyses were assessed in SigmaPlot for Windows Version 11.0. 
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4.3 RESULTS 
4.3.1 Investigation into the maximum tolerated dose to be used for 
continuous intravenous infusion of diclofenac to the rat using a dose 
raising study 
To allow the best opportunity for hepatotoxicity and detection of covalent adducts to 
plasma proteins, an initial dose-raising study was run to ascertain the maximum 
tolerated dose of diclofenac infusion. 
An estimated maximum tolerated continuous intravenous dose of diclofenac was 
derived from the literature.  It is widely reported that the dose limiting toxicity of 
diclofenac is due to gastro-intestinal toxicity.  The LD50 following an oral dose of 
diclofenac to the rat was reported at 250mg/kg (Menasse et al., 1978).  With the 
bioavailability of diclofenac in the rat following an oral dose being reported at 79% 
following an oral dose of 1.25mg (Peris-Ribera et al., 1991), it was estimated that the 
LD50 of an intravenous dose of diclofenac would be 197.5 mg/kg.  Therefore, for an 
initial dose in a dose finding continuous intravenous infusion study it was decided to 
use a dose at least 10 times less than this.  A dose of 12mg/kg/day was used for the 
first investigation. 
This dose of 12mg/kg/day was well tolerated, with both animals in the test group 
surviving to the end of the in-life phase.  No clinical signs of adverse effects due to drug 
treatment were observed during the in-life phase of the study.  Upon necropsy, dark 
brown/black discolouration of areas of the cecum was observed, however, the dose 
was generally considered to be well tolerated.  Therefore, a higher dose of 
24mg/kg/day was investigated. 
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This higher dose of 24mg/kg/day was not tolerated in one of the two animals 
investigated.  This animal was prematurely removed from the study approximately 28 
hours into the 48 hour infusion.  This is due to exhibition of piloerection, reduced 
motor activity and reduced respiration rate combined with increased respiration 
depth.  On necropsy, dark red discolouration of the jejenum and black colouration of 
the cecum were observed.  The second rat in this group completed the infusion 
protocol, but exhibited piloerection, weight loss and low food consumption.  The 
24mg/kg/day dose was not considered to be tolerated, and a 12mg/kg/day infusion 
dose was selected for the main study. 
4.3.2 Investigation into plasma pharmacokinetics of diclofenac and 
diclofenac-AG following continuous intravenous infusion of 12mg/kg 
diclofenac/day. 
Plasma concentrations of both diclofenac and its AG metabolite were monitored 
throughout the study, using the same analytical assay described in Chapter 3, meaning 
that the lower limit of quantification was maintained at 50nM for diclofenac and 30nM 
for diclofenac-AG.  Lowest limits of detection were below 10nM for both diclofenac 
and diclofenac-AG. 
Plasma concentrations of diclofenac rose rapidly following initiation of infusion  
(Figure 4. 1), reaching a concentration of 1.19 ± 0.37µM over the first 6 hours of the 
experiment.  Plasma diclofenac concentrations subsequently appeared to stabilise 
between the 6 and 24 hour time points (24 hour concentration was 1.22 ± 0.20µM), 
with no statistical difference detected between the plasma concentration between 
these timepoints.  A statistically significant decrease in plasma diclofenac 
concentration was observed between the 24 and 48 hour time points, with plasma 
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concentration decreasing to approximately 423 ± 101 nM.  This reduction in plasma 
concentration whilst infusion was maintained suggests an adaptive change in animals 
resulting in enhanced drug clearance.  This is supported by plasma clearance of 
diclofenac increasing by a multiple of 1.76 (from 13.37ml kg-1 min-1 for 0-24hr time 
points to 23.48 ml kg-1 min-1 for the 0-48hr time points, Table 4. 3).  Following 
cessation of dosing, diclofenac concentrations remained above the lower limit of 
quantification at the 72 hour and 96 hour time points (119.83 ± 9.64nM and 76.08 ± 
23.14 nM (mean ± stdev) respectively).  
Throughout the experiment, diclofenac-AG could not be detected in plasma from the 
dose rats.  Due to the dilutions required for quantification of plasma diclofenac 
concentrations, it was not possible to use less diluted samples to investigate whether 
very low levels of diclofenac-AG might have been present, due to the need to avoid 
possible overloading of the HPLC-MS/MS with diclofenac.  
No diclofenac or diclofenac-AG could be detected in any plasma samples isolated from 
vehicle control animals. 
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Figure 4. 1:  Pharmacokinetic profile of diclofenac following continuous intravenous 
infusion to the rat for 48 hours (mean ± stdev).  * represents significant difference 
between the two points (p≤0.001) assessed using an unpaired t test. 
 
Table 4. 3: Pharmacokinetic parameters of diclofenac following continuous 
intravenous infusion to the rat.  Due to composite sampling used in the study, data 
was analysed from mean parameters 
Infusion 
timepoint 
Dose 
(nmol/kg) 
AUC 
(nmol hr L-1) 
Plasma clearance  
(ml kg-1 min-1) 
Diclofenac0-24 37724 47030.4 0.802 
Diclofenac0-48 75448 53544.7 1.409 
Diclofenac0-96 75448 55893.5 1.350 
Diclofenac0-∞ 75448 58022.0 1.300 
  
4.3.3 Assessment of hepatotoxicity induced by continuous intravenous 
infusion of diclofenac  
A combination of histopathology, immunohistochemistry and plasma clinical chemistry 
assays were used to assess whether continuous infusion of diclofenac resulted in 
hepatotoxicity.   
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Plasma samples taken at 72, 96 and 120 hour time points (all after cessation of dosing) 
were analysed for alanine transaminase, lactate dehydrogenase, total bile acid 
concentration, concentrations of both free and conjugated bilirubin, and glutamate 
dehydrogenase.  No statistically significant differences between diclofenac and vehicle 
treated animals could be detected for any of these clinical chemistry assays at any time 
point assayed throughout the investigations (Figure 4. 2).  These studies therefore did 
not provide evidence that administration of diclofenac had elicited hepatotoxicity.  
Following the end of the in-life phase of the study, livers were isolated from animals 
and assessed for hepatic glutathione content.  No difference between diclofenac and 
vehicle treated animals was detected (Figure 4. 2). 
Further liver sections were isolated at the end of the study, and prepared for 
histopathological and immunohistochemical analysis by a trained veterinary 
pathologist.  Haematoxylin and eosin (H & E) staining was used for assessment of 
alterations between diclofenac and vehicle treated animals.  Intrahepatocyte depletion 
of glycogen stores was observed in 4 out of 7 diclofenac treated animals in the study, 
as observed by the loss of intrahepatocyte vacuoles in H&E sections.  Glycogen 
depletion was graded as grade 2 severity in 3 animals, and grade 1 severity in 1.  
Glycogen depletion was not observed in any of the animals receiving vehicle infusion.   
On necropsy a growth was observed on the liver of one diclofenac treated animal, 
which (approximately 10mm width x10mm length x10mm height).  Upon 
histopathological staining, this was identified as an adhesion encapsulated 
haematoma.  In addition, the right medial lobe of the same animal appeared large 
upon necropsy.  Following H&E assessment, the lobe was identified as being 
hypertrophied.  Furthermore, this animal along with one other diclofenac treated 
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animal also showed an area of inflammatory cell infiltration and one further distinct 
diclofenac treated animal showed an area of necrosis with inflammatory cell 
infiltration (Table 4. 4).  
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Figure 4. 2:  Plasma biomarker assessment of hepatotoxicity and hepatic glutathione 
content.  Black filled in figures represent vehicle control, hollow white figures 
represent diclofenac infusion (mean ± stdev).  (A) Plasma ALT activity (B) Plasma GLDH 
activity (C) plasma LDH activity (D) plasma bile acid concentration (E) total plasma 
bilirubin concentration (F) hepatic glutathione content from livers isolated from 
animals at the end of the study (120 hrs following commencement of diclofenac 
infusion).  No statistical significance was observed between diclofenac or vehicle 
control treated animals.   
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Table 4. 4: Histopathological assessment of livers sections, allowing comparison 
between vehicle control and diclofenac infused animals. 
Histopathological finding 
Vehicle (5% mannitol) 
infusion 
Diclofenac continuous 
infusion (12 mg/kg/day) 
Glycogen depletion 
Not detected in any 
animals 
Grade 1 : 1 animal 
Grade 2 : 3 animals 
Necrotic foci with 
inflammatory cells 
Not detected in any 
animals 
Grade 2 : 1 animal 
Mixed inflammatory cell 
infiltration 
Grade 1 : 2 animals Grade 1 : 2 animals 
Hypertrophied right 
median lobe 
Not detected in any 
animals 
1 animal 
Adhesion encapsulated 
haematoma 
Not detected in any 
animals 
1 animal 
   
4.3.4 Immunohistochemical assessment of liver sections 
It was hypothesised that either induction of cytochrome P450 enzymes or hepatic 
export transporters could have contributed to the reduced plasma concentrations that 
were evident at time intervals beyond 24 h of continuous infusion.  Consequently, 
hepatic sections were immunohistochemically stained to assess expression of the 
cytochrome P450 isozymes CYP1A1 and 2C19 as well as the hepatic export 
transporters MRP2 and BSEP.   
Following analysis of sections, no consistent induction of the CYPs 1A1 or 2C19 could 
be found.  In addition, no consistent induction of the export transporters MRP2 and 
BSEP could be ascertained as reported in Table 4. 5. 
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Table 4. 5: Scored results of sections stained for immunohistochemistry.  6 animals 
were in the vehicle control group, and 7 animals were in diclofenac treated animals.  
Hepatic staining 
Vehicle (5% mannitol) 
infusion 
Diclofenac continuous 
infusion (12 mg/kg/day) 
CYP1A1 IHC 
Grade 1 : 3 animals 
Grade 2 : 3 animals 
Grade 1 : 4 animals 
Grade 2 : 3 animals 
CYP2C19 IHC 
Grade 1 : 1 animal 
Grade 2 : 2 animals 
Grade 3 : 3 animals 
Grade 1 : 1 animal 
Grade 2 : 5 animals 
Grade 3 : 1 animal 
BSEP IHC 
Grade 1 : 2 animals 
Grade 2 : 4 animals 
Grade 1 : 5 animals 
Grade 2 : 2 animals 
MRP2 IHC 
Grade 1 : 0 animals 
Grade 2 : 6 animals 
Grade 1 : 5 animals 
Grade 2 : 2 animals 
Catalase IHC 
Grade 1: 5 animals 
Grade 2 : 1 animal 
Grade 1 : 1 animals 
Grade 2 : 6 animals 
Superoxide dismutase-2 
IHC 
Grade 1 : 5 animals 
Grade 2 : 1 animal 
Grade 3 : 0 animals 
Grade 1 : 1 animal 
Grade 2 : 1 animal 
Grade 3 : 5 animals 
  
Diclofenac and its oxidative metabolites have been shown to elicit mitochondrial stress 
following incubation with isolated mitochondria and hepatocytes (Bort et al., 1999; 
Gomez-Lechon et al., 2003a; Gomez-Lechon et al., 2003b; Lim et al., 2006).  To test 
whether induction of oxidative stress had occurred in livers from rats dosed with 
diclofenac by continuous infusion, hepatic sections were stained for the expression of 
catalase and superoxide dismutase.  Continuous infusion of diclofenac resulted in 
expression of elevated levels of both of these enzymes, when compared to vehicle 
control animals (Figure 4. 3 and Figure 4. 4). 
Hepatic sections isolated from animals which had been infused with the dose vehicle 
infusion exhibited greater expression of SOD-2 in hepatocytes distributed around the 
central vein, although protein expression was also evident in in portal hepatocytes.  
Continuous infusion of diclofenac resulted in increased intensity of SOD-2 
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immunostaining around the vasculature.  This may be an indicator of oxidative stress.  
Conversely, midzonal hepatocytes appeared to have reduced SOD2 expression 
following diclofenac infusion, when compared to centrilobular or periportal 
hepatocytes. 
Catalase expression in rats receiving vehicle was evident primarily in portal areas, with 
reduced intensity of staining in centrilobular regions.  Intracellular catalase intensity 
was highest around peroxisomes (Figure 4. 3C).  Catalase staining in animals receiving 
diclofenac infusion was not apparent in portal areas, but was induced in centrilobular 
hepatocytes.  It was also noted that following diclofenac treatment, peroxisomes 
appeared enhanced in size (Figure 4. 3D). 
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Figure 4. 3: Continuous infusion of diclofenac induces expression of catalase in the 
liver.  (A+C) vehicle control animal (B+D) diclofenac infusion 12mg/kg/day for 48 
hours.  CV represents central vein, PV represents portal vein.  (A+B) at 10x 
magnification (C+D) at 40x magnification. 
 
 
Figure 4. 4: Continuous infusion of diclofenac induces hepatic superoxide dismutase 
immunostaining in cetntral vein (CV) areas.  (A) vehicle control (B) diclofenac infusion.  
Both figures at 10x magnification. 
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4.3.5 Identification of protein binding following continuous intravenous 
infusion of diclofenac to the rat. 
No evidence of covalently modified rat serum albumin adducts could be detected in 
plasma from diclofenac treated rats, using LC-MS technology. 
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4.4 DISCUSSION 
Currently, no investigations of the continuous infusion of diclofenac to the rat have 
been reported in the literature.  However, continuous intravenous infusion of 
diclofenac to humans, at a dose of 0.96mg/kg/day, has been reported to control fever 
in patients with acute cerebral damage and in neurosurgical critical care (Cormio et al., 
2000; Cormio and Citerio, 2007). 
Continuous intravenous infusion of diclofenac to the rat followed first order kinetics 
over the first 24 hours of infusion.  A rapid increase in diclofenac plasma concentration 
was observed initially, which subsequently slowed, culminating in steady-state 
diclofenac exposure between the 6 and 24 hour time points following commencement 
of infusion (Figure 4. 1).  Similar pharmacokinetic profiles have been observed for 
numerous other compounds following continuous intravenous infusion to either the 
rat or man, where the infusion has been maintained for sufficient time for plasma 
concentration to induce a rate of clearance matching that of continuous infusion  
(Bowersox et al., 1997; Arens and Pollack, 2001; Boselli et al., 2003) 
 Subsequently, between the 24 and 48 hour time points a statistically significant 
decrease in plasma diclofenac concentrations was found.  Plasma diclofenac 
concentrations declined by 65% (from 1.220 ± 0.195µM to 0.423 ± 0.102µM 
respectively).  This decline occurred whilst continuous intravenous infusion of 
diclofenac was maintained.  The pharmacokinetic analysis indicated that this decrease 
in plasma diclofenac concentration was indicative of a 76% increase in diclofenac 
plasma clearance, from the 0-24hr clearance of 13.37 to 23.48 ml kg-1 min-1 to  
0-48hours.  Little evidence of equivalent pharmacokinetic changes following 
continuous infusion of other compounds could be identified in the literature, with 
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most drugs being found to maintain steady-state plasma concentrations until infusion 
was ceased.  This suggests that this increased clearance is not a result of the infusion 
technique, but rather is likely to be due to an adaptive change resulting from 
continuous diclofenac exposure. 
The primary mechanisms for drug plasma clearance are drug metabolism and drug 
export via active transport.  Consequently, it was hypothesised that continuous 
infusion of diclofenac induced either drug metabolism or drug clearance, resulting in 
its enhanced plasma clearance between the 24 and 48hour timepoints. 
Diclofenac is metabolised into 3 primary metabolites in most species, including the rat 
and man, namely CYP mediated oxidation into the 4-OH and 5-OH metabolites and 
diclofenac-AG.  In the rat, the CYP enzymes 2B, 2C and 3A isoforms have been 
associated with diclofenac oxidation (Tang et al., 1999b), with glucuronidation 
catalysed by UGT2B1 (King et al., 2001).  Diclofenac-AG is transported into bile via the 
active biliary efflux transporter Multi-Drug Resistance Protein Type 2 (Mrp2), following 
which it is eliminated via bile in faeces, is hydrolysed to liberate parent diclofenac 
which undergoes enterohepatic cycling and /or is metabolized by CYPs to hydroxy-AG 
metabolites (Seitz et al., 1998).  On analysis of hepatic sections immunohistochemically 
stained using an MRP2 antibody, no induction could be identified on comparison 
between diclofenac and vehicle infused animals.  In the literature, whilst MRP2 has 
been shown to be inducible (Courtois et al., 1999; Payen et al., 2001; Choi et al., 2007), 
its induction by diclofenac has not been reported.  Genetic associations with mutations 
in the ABCC2 gene encoding MRP2 have suggested that reduced function of MRP2 is a 
risk factor in developing diclofenac hepatotoxicity (Daly et al., 2007), suggesting 
accumulation of diclofenac or its metabolites may be involved in the pathogenesis of 
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hepatotoxicity, and consequently, induction of this enzyme on exposure to diclofenac 
may be desirable cellular defence pathway.  However no identification of its induction 
could be detected in this study. 
Staining was also added to investigate whether diclofenac infusion resulted in hepatic 
induction of the bile salt export pump (BSEP).  Several case-reports of off-target 
hepatotoxicity elicited by diclofenac have been associated with generation of 
cholestasis in patients (Dunk et al., 1982; Banks et al., 1995; Hackstein et al., 1998), 
however it is not clear whether diclofenac induced cholestasis is a causative factor in 
diclofenac hepatotoxicity, or is a consequence of other hepatotoxic mechanisms of the 
drug.  To investigate the potential for diclofenac to elicit obstructive cholestasis plasma 
bile salt and bilirubin concentrations were assessed combined with investigation of 
induction of BSEP transcription.  Through this experiment, no evidence of BSEP 
induction or induction of cholestasis could be found. 
Induction of oxidative metabolism was also hypothesised to be a mechanism 
responsible observed increased plasma clearance of diclofenac.   Many CYP enzymes 
have been found to be inducible, usually following a drugs activation of gene pathways 
resulting in the stimulation of RNA synthesis (Guengerich, 2001).  
Oxidative metabolism of diclofenac is catalysed by CYP2B, 2C and 3A families, with 
CYP2C11 and CTP2C7 identified as subtypes involved in diclofenac metabolism (Tang et 
al., 1999a).  As no synthetic standards of 4-hydroxy and 5-hydroxy diclofenac were 
available to allow accurate method development and mass-spectrometric 
quantification, immunohistochemical staining of liver sections for the CYP isoforms 
1A1 or 2C19 were used to investigate induction of these enzymes as a possible 
mechanism for enhanced plasma diclofenac clearance following its continuous 
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intravenous infusion.  No CYP3 family immunoshistochemical stains were available for 
the investigation of CYP induction.   
No consistent induction of CYP enzymes could be identified in hepatic sections isolated 
from diclofenac infused animals when compared with vehicle controls (Table 4. 5).  
This is consistent with published literature where no induction of either CYP enzymes 
or UGTs by diclofenac has been reported using either in vitro or in vivo assays.  
Whether this reflects an absence of investigation into diclofenac’s ability to induce CYP 
enzymes remains unclear.  
For these immunohistochemical studies, however, it should also be noted that the 
timepoint for isolating the liver for stabilisation and immunohistochemical stabilisation 
was 72 hours following cessation of diclofenac delivery.  During this 3 day period it is 
possible that hepatocytes may have recovered, subsequently degrading induced CYP 
protein, with the cell returning to a normal phenotype.  It should also be noted that 
the absence of CYP2B and 3A immunohistochemistry, that induction of these enzymes 
may also have been responsible for increased diclofenac clearance following infusion.  
However, no evidence for their induction by diclofenac either has been reported in the 
literature.  Consequently no evidence was attained identifying induction of metabolism 
as a mechanism for increased diclofenac plasma clearance. 
Plasma concentrations of diclofenac acyl glucuronide were monitored throughout the 
experiment; however this metabolite could not be detected in plasma at any time 
point of sampling.  It should be noted that samples were diluted either 1 in 2, or 1 in 4, 
prior to analysis.  Consequently the lower limit of AG detection at these dilutions 
would be 20nM or 40nM.  Undiluted samples could not be assayed due to the 
sensitivity of the mass-spectrometer.  Due to the known concentration of diclofenac in 
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these samples, there was a high chance of overloading the system if undiluted samples 
had been analysed. 
In vitro investigations using liver microsomes have predicted that acyl glucuronidation 
accounts for approximately 70% of the clearance of diclofenac in the rat (Kumar et al., 
2002), however the rate of acyl glucuronidation by rat UGT2B1 is 3 time slower than 
that of human UGT2B7 (King et al., 2001).  
AG metabolites have been detected in plasma following single bolus administrations of 
the aglycone to the rat for several compounds including diflunisal and suprofen 
(Dickinson et al., 1989; Smith and Liu, 1995), potentially continuous intravenous 
infusion of diclofenac at a rate of 0.5mg/hour may be insufficient to allow turnover by 
UGTs to form the for AG metabolism in the rat to levels detectable in the plasma.  AG 
metabolites are largely biliary excreted in the rat (Peris-Ribera et al., 1991), with TR-/- 
rats deficient in MRP2 showing the importance of this transporter in the efflux of 
diclofenac-AG across the cannalicular membrane (Seitz et al., 1998).  This export pump 
driven efflux of AG metabolites has been associated with eliciting high up-
concentrations of AG metabolites along the cannalicular membrane and away from the 
basolateral membrance (Sallustio et al., 2000), resulting in reports of biliary 
concentrations of gemfibrozil-AG 50 to 5000 times higher than the circulatory 
perfusate (Sabordo et al., 1999; Sabordo et al., 2000).  Active up-concentrations of AG 
metabolites are also thought to be maintained by active transport across the 
basolateral membrane back from the blood into the hepatocyte (Sallustio et al., 2000).  
Consequently for AGs to reach the plasma, it is likely that they would need to be 
formed in concentrations sufficient to overwhelm this hepatic concentration-driven 
efflux.   
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It was further hypothesised that continuous intravenous infusion of diclofenac, 
resulting in continuous exposure of the drug and/or its metabolites might elicit 
hepatotoxicity in the rat.  However, throughout the study, no identification of 
diclofenac hepatotoxicity could be identified using either clinical chemistry assessment 
(Figure 4. 2) although possible diclofenac induced alterations in liver histopathology 
were observed in some diclofenac treated animals following assessment of H&E 
stained liver sections (Table 4. 4).  Restriction of blood sampling volumes, as dictated 
by the project license and the desire for close monitoring of plasma diclofenac 
concentrations, meant that time points for clinical chemistry assessment of 
hepatotoxicity were not ideal.  Since the half-life of alanine transaminases has been 
estimated to be 8 hours in the rat (Ennulat et al., 2010), it cannot be ruled out that 
raised ALTs may have occurred in diclofenac treated animals at time intervals been 
cleared before clinical chemistry sampling at the 72 hour time point.  No evidence of 
cell death was evident on examination of H&E stained liver sections.  This observation 
is in line with the findings of Sallustio, who found no induction of hepatotoxicity 
following daily oral administration of diclofenac at a dose of 15mg/kg (Sallustio and 
Holbrook, 2001).  With the reported bioavailability of diclofenac at 79% (Peris-Ribera 
et al., 1991), Sallustio’s bioavailable dose is calculated at 11.85mg/kg, close to our 
12mg/kg/day dose.  Intraperitoneal administration of diclofenac at bolous doses of 
100mg/kg to the rat and 80mg/kg to the mouse has been shown to elicit 
hepatotoxicity (Gomez-Lechon et al., 2003b; Deng et al., 2008).  These doses far 
exceed the 24mg/kg dose of diclofenac received by rats over the 48 hour period of this 
infusion study.   
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Translocation of bacteria and endotoxins from the GI tract has been suggested to play 
a key role in heightening immune responses and exacerbating toxicity.  Evidence of this 
for diclofenac has been shown from the attenuation in plasma ALTs by 
pharmacological sterilisation of a rat’s GI tract prior to diclofenac administration (Deng 
et al., 2006).  The dose selected for this infusion was designed to elicit minimal 
toxicological stress on the gastro-intestinal tract of rats, translocation of gastro-
intestinal bacteria and endotoxins to the liver may have been abated, and may provide 
an explanation by which hepatotoxicity observed in the single large doses reported in 
the literature was abated.  However, clinical evidence supporting this ‘germ theory’ is 
lacking, as histopathological examination of liver biopsies from patients undergoing an 
idiosyncratic adverse drug reaction to diclofenac as yet has not revealed bacterial 
hepatic translocation.   
Despite this, the immune system does appear to have a critical role in the eliciting of 
diclofenac induced hepatotoxicity.  Pharmacogenetic studies have revealed a 5-fold 
increased risk in development of diclofenac induced hepatotoxicity in patients 
expressing polymorphisms in genes encoding the interleukins IL-4 and IL-10 (Aithal et 
al., 2004), and associations with HLA11 (Berson et al., 1994).  Detection of circulating 
antibodies recognising diclofenac-modified rat heptic proteins in 100% of patients 
experiencing diclofenac induced hepatotoxicity, and 60% of patients receiving 
diclofenac therapy without hepatotoxicity, combined with identification of diclofenac-
modified hepatic proteins in a liver isolated from a patient experiencing diclofenac 
induced hepatotoxicity provide good evidence for the immune system and the role of 
drug-protein adducts.  Further evidence has been achieved from mouse models, where 
lymph nodes isolated from diclofenac sensitised mice were stimulated on ex vivo 
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exposure to the hydroxyl metabolites of diclofenac (Naisbitt et al., 2007), and selective 
killing of diclofenac-exposed hepatocytes by splenocytes isolated from mice sensitised 
to diclofenac (Kretz-Rommel and Boelsterli, 1995).  The source of danger signals, which 
are hypothesised to be necessary for propagation of delayed ADRs to diclofenac, 
however remain unclear. 
In vitro investigations have associated diclofenac with eliciting cell death through 
perturbation of mitochondrial function.  Two separate mechanisms have primarily 
been hypothesised in eliciting diclofenac mitochondrial disruption.  Due to its weakly 
acidic properties, combined with its lipophilic nature, diclofenac has been 
hypothesised to readily cross the outer membrane of mitochondria, acting to uncouple 
mitochondrial oxidative phosphorylation (OXPHOS) (Whitehouse, 1967; Boelsterli and 
Lim, 2007).  Further to this, the diphenylamine structure of NSAIDs including diclofenac 
has been suggested to be important in this function (Masubuchi et al., 1999; 
Masubuchi et al., 2000).  Oxidative metabolites of diclofenac have also been suggested 
to act synergistically to mitochondrial toxicity elicited through the parent compound 
through inducing increased cellular calcium concentrations, subsequently inducing 
mitochondrial permeability transition (mPT), and eliciting cell death (Lim et al., 2006).   
Experimental evidence for diclofenac eliciting mitochondrial stress to hepatocytes has 
only ever been shown following in vitro incubation, with no direct in vivo evidence.  
Further to this, diclofenac has only been identified as cytotoxic to hepatocytes 
following incubation at super-physiological concentrations, with the exception of one 
recent study where repeat administration of diclofenac to primary human hepatocytes 
to elicit hepatotoxicity at 6.5µM concentration (Mueller et al., 2012).  With 99.5% of a 
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dose of diclofenac plasma bound (Chamouard et al., 1985), the potential of diclofenac 
to elicit mitochondrial stress in vivo remains controversial (Boelsterli and Lim, 2007).  
Histopathological assessment of H&E stained liver sections however, did not reveal any 
mitochondrial swelling, indicative of mitochondrial stress as a consequence of opening 
of the mPT pore.  H&E staining however did reveal glycogen depletion from 
hepatocytes in 4 animals of the 7 receiving diclofenac infusion.  Glycogen depletion in 
three of these animals was classified as grade 2.  Metabolism of glycogen in stores may 
represent a mechanism for replenishing energy production lost as a consequence of 
diminished ATP provision due to mitochondrial stress.  To further test for 
mitochondrial stress, hepatic sections were immunohistochemically stained for 
catalase and superoxide dismutase as markers of reactive oxygen species released as a 
consequence of mitochondrial dysfunction.  
Immunohistochemical assessment of liver sections revealed an induction in both 
catalase and superoxide dismutase staining following continuous infusion of diclofenac 
(Figure 4. 3, Figure 4. 4 and Table 4. 5).  This suggests that diclofenac treatment may 
increase hepatic exposure to reactive oxygen species.  Both catalase and superoxide 
dismutase staining was found most intense in the areas surrounding the central vein.  
This is where cytochrome P450 enzymes are most abundantly expressed (Lindros, 
1997), potentially providing further evidence of the importance of oxidative 
metabolism in eliciting mitochondrial stress.  
In summary, following continuous intravenous infusion of 12mg/kg/day for 48 hours, 
no hepatotoxicity could be detected using clinical chemistry assays and 
histopathological assessment of hepatic sections.  Induction of mitochondrial stress 
was suggested by depletion of glycogen stores and induction of the ROS scavenging 
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enzymes superoxide dismutase and catalase.   These adaptive mechanisms appear to 
be protective mechanisms, abating cell death.  Further to this, protection against 
hepatotoxicity also appears to have been elicited through induction of unidentified 
mechanisms 24hours following commencement of diclofenac infusion, resulting in 
enhanced plasma clearance of the parent drug.    
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5.1 INTRODUCTION 
The biotransformation of drugs to reactive intermediates, able to covalently modify 
endogenous macromolecules, is hypothesised to play a key role in the pathogenesis of 
delayed hypersensitivity reactions and other off-target ADRs (Kalgutkar and Soglia, 
2005; Park et al., 2005; Park et al., 2011).  Consequently, pharmaceutical companies 
will usually preferentially avoid the incorporation of chemical structures capable of 
being metabolically bioactivated into CRMs in drug design, and routinely incorporate 
screens into pre-clinical drug development and candidate selection to assess a 
molecule’s covalent binding towards macromolecules (Evans et al., 2004; Kalgutkar 
and Soglia, 2005; Nakayama et al., 2009; Thompson et al., 2012).  However, covalent 
binding assays using radiolabelled compounds almost invariably have a major 
mechanistic limitation: if they employ simple hepatic microsomal incubations to 
generate reactive metabolites, they are usually restricted to assessing oxidative 
bioactivations (Evans et al., 2004); if they employ complex preparations, such as 
isolated hepatocytes (Thompson et al., 2012), which should express all of the various 
bioactivation pathways, they invariably create a substantial requirement for additional 
studies if the metabolic basis of a positive finding is to be identified. 
Metabolic activation of carboxylate compounds to intermediates able to covalently 
modify proteins is also considered a critical stage in the pathogenesis of off-target 
ADRs associated specifically with this class of compounds (Boelsterli, 2002; Skonberg et 
al., 2008; Aithal, 2011).  The covalent binding of carboxylate compounds in vivo is well 
established, as shown by their modification of plasma proteins in volunteers and 
patients (Smith et al., 1986; Hyneck et al., 1988; Volland et al., 1991; Munafo et al., 
1993; Dickinson et al., 1994; Castillo et al., 1995) and in experimental animals (Smith et 
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al., 1990b; Sallustio and Foster, 1995; Liu et al., 1996; Dong et al., 2005).  Modification 
of hepatic proteins has also been revealed in both humans (Aithal et al., 2004) and 
animals (Pumford et al., 1993; Hargus et al., 1994; Wade et al., 1997; Wang and 
Dickinson, 1998; Wang and Dickinson, 2000; Wang et al., 2002; Aithal et al., 2004).  
However, none of these investigations determined either the precise structural type or 
the location of the covalent modification.  Proof of the adduction of plasma proteins 
rested solely on liberation of the parent drug from the unfractionated protein samples 
by non-specific alkaline hydrolysis.  This method is assumed to release the carboxylic 
acid and any oxygenated metabolites (Hermening et al., 2000) selectively from (i) 
amine and ester (acylation/transacylation) adducts and (ii) ester linkages within 
glycation adducts derived exclusively from AG metabolites (Figure 2.2), and thereby 
assays acylation and glycation adducts collectively and indiscriminately (Smith et al., 
1990a).  While these assumptions are reasonable in respect of the parent carboxylate, 
oxygenated metabolites released by alkaline hydrolysis might have been adducted via 
alkylation reactions to cysteine residues through thioether bonds (Deng et al., 2011).  
Limited identification and quantification of modified hepatic proteins was achieved 
using Western blotting with anti-drug antibodies (Wade et al., 1997; Wang et al., 2001; 
Aithal et al., 2004).  Radiotracer experiments in rats confirmed the covalent binding of 
carboxylate drugs – including diclofenac – to plasma and hepatic proteins (Masubuchi 
et al., 2007; Takakusa et al., 2008) but did not provide any additional insights into 
either the mechanisms or sites of bioactivation or the sites of protein adduction.  
Nevertheless, it should be noted that several drugs not known to form AGs also 
adducted plasma proteins. 
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The importance of haptenation in eliciting immune responses has been shown 
specifically for carboxylate compounds.  Circulating antibodies to diclofenac 
metabolite-modified liver protein adducts were found in all patients diagnosed with 
diclofenac-induced liver injury, 60% of patients receiving diclofenac therapeutics, but 
in none of the healthy controls (Aithal et al., 2004).  The specific killing of hepatocytes 
exposed to diclofenac (and showing protein modifications) by lymphocytes derived 
from spleens isolated from diclofenac-immunised mice provides further evidence for 
the importance of covalent modification in immune-mediated off-target ADRs 
associated with carboxylate compounds (Kretz-Rommel and Boelsterli, 1995). 
Direct glucuronidation of carboxylate compounds to AGs has received the most 
attention as the bioactivation pathway potentially responsible for generation of these 
off-target ADRs.  Many AGs have been shown to be chemically unstable (Table 2.1) and 
protein reactive (Munafo et al., 1990; Volland et al., 1991; Spahn-Langguth and Benet, 
1992; Ding et al., 1993; Ding et al., 1995; Qiu et al., 1998; Ebner et al., 1999; Iwaki et 
al., 1999; Mortensen et al., 2001; Walker et al., 2007) during in vitro incubation.  With 
evidence of the covalent binding of carboxylate compounds to plasma proteins in 
volunteers and patients correlating to AG plasma exposure (Smith et al., 1986; Hyneck 
et al., 1988; Volland et al., 1991; Benet et al., 1993; Munafo et al., 1993; Dickinson et 
al., 1994; Castillo et al., 1995), acyl glucuronidation has been designated a metabolic 
pathway of toxicological concern, producing uncertainty in the pharmaceutical 
industry as to how to progress AG-forming compounds safely (Faed, 1984; Spahn-
Langguth and Benet, 1992; Boelsterli, 2002; Shipkova et al., 2003; FDA, 2008). 
As a result of this anxiety, pharmaceutical companies often feel the need to provide 
evidence mitigating the potential risk of drugs found to form AGs in humans, often 
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deriving reassurance from the identification of AGs that are relatively stable in vitro 
and thereby possess low protein reactivity (Benet et al., 1993).  For example, following 
the identification of citalopram’s metabolism to a carboxylic acid which undergoes acyl 
glucuronidation, the authors felt the need to emphasise that the drug was 
administered at low doses (<40mg daily) and the AG was not a major metabolic 
product (Dalgaard and Larsen, 1999).  Following identification of the extensive 
metabolism of the ester pro-drug BIBF 1120 to an AG, reassurance was derived from 
the conjugate’s long degradation half-life at pH 7.4 (10.5 hours), and consequently it 
was claimed that the AG ‘has a low tendency to form covalent adducts to protein due 
to its higher stability [in vitro] and thus should not be the cause of safety concerns’, 
despite the identification of its acyl migration isomers circulating in plasma (Stopfer et 
al., 2011).   
Further to these experiences, efforts have been made to investigate the applicability of 
pre-clinical tests to predicting the clinical risks of carboxylic acid drugs and their AG, 
with correlations between drug risk and AG instability in vitro (Sawamura et al., 2010), 
predictions of AG instability and protein adduction (Bolze et al., 2002; Wang et al., 
2004; Karlsson et al., 2010) and extensive investigations into structure-activity 
relationships of AG (Vanderhoeven et al., 2004a; Vanderhoeven et al., 2004b; Baba 
and Yoshioka, 2009a; Baba and Yoshioka, 2009b; Yoshioka and Baba, 2009) being 
undertaken.  Medicinal chemists are also investigating mechanisms to remove 
carboxylic acid structures from the pharmacophore (Crosignani et al., 2011a), or 
incorporating α-carbon moieties to sterically hinder acyl glucuronidation or provide 
increased stability  to the resulting AG (Crosignani et al., 2011b; Gallant et al., 2011).   
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Anxiety over drug acyl glucuronidation, however, may be unjustified.  To date, no 
evidence has been reported showing covalent modification of protein in vivo is 
definitely attributable to AGs, either in animal models, or in man.  Moreover, rates of 
renal and biliary clearance of AGs in man are high (Smith et al., 1985; Verbeeck et al., 
1988; Castillo et al., 1995; Balani et al., 1997; Hofmann et al., 2005; Wang et al., 2006), 
with the conjugate’s clearance from biological systems further increased by their 
spontaneous and enzymatic hydrolysis in both plasma (Ruelius et al., 1986; Volland et 
al., 1991; Williams et al., 1992; Akira et al., 2002; Karlsson et al., 2010) and tissues, 
including the liver (Brunelle and Verbeeck, 1996; Iwamura et al., 2012).  Consequently 
in vivo blood exposure of AGs may actually be relatively low in many cases, and 
certainly considerably reduced in comparison with exposures predicted by liver 
microsome incubations (Table 2.1).  These factors have led to debate as to whether AG 
metabolites actually do form covalent protein adducts in vivo, and consequently 
whether they actually are of toxicological concern (Bailey and Dickinson, 2003; 
Shipkova et al., 2003; Regan et al., 2010).  The most compelling evidence of protein 
modification by a xenobiotic AG in a complex biological system is the observation that 
covalent binding of diclofenac to proteins in isolated rat hepatocytes was greatly 
reduced by inhibitors of glucuronidation but was not affected by inhibitors of P450 
(Kretz-Rommel and Boelsterli, 1993).  Nevertheless, metabolic AG formation does not 
translate inevitably into measurable covalent protein binding in either isolated 
hepatocytes or in vivo (Levesque et al., 2007). If AG metabolites do not produce 
protein adducts in vivo, it would have to be assumed that the adduction of plasma and 
hepatic proteins by carboxylic acid drugs was due entirely to reactions with the diverse 
electrophilic products of oxidative bioactivation (Chen et al., 2006; Masubuchi et al., 
Chapter 5 – Formation of Covalent Protein Adducts by Diclofenac Acyl Glucuronide 
Metabolites in Patients 
Page 221 
 
2007; Takakusa et al., 2008) and thioester conjugation (Grillo and Benet, 2002; Grillo, 
2011) that many such drugs, including diclofenac (Shen et al., 1999; Poon et al., 2001; 
Grillo et al., 2003; Masubuchi et al., 2007; Grillo et al., 2008a; Grillo et al., 2008b; 
Waldon et al., 2010), are known to form. 
To address this issue HSA, isolated from patients receiving conventional therapeutic 
doses of diclofenac, was analysed in the form of tryptic peptides, using tandem mass 
spectrometry.  Survey scanning was used to search specifically for acylation adducts 
and adducts derived exclusively from AG metabolites; namely the simple, predictable, 
glycation adducts of lysine residues that were found following incubation of the 
protein with synthetic 1-β diclofenac-AG (chapter 2).  In addition to glycating HSA in 
simple buffered incubations, diclofenac-AG has also been shown to glycate proteins in 
the much more complex environment of rat liver microsomes (Kretz-Rommel and 
Boelsterli, 1994). However, HSA was pragmatically selected for investigation of AG 
binding in these studies as it has a well characterised structure (Ghuman et al., 2005), 
is accessible and abundant, and has a long residence time in the circulation (Nicholson 
et al., 2000; Tornqvist et al., 2002), which favours accumulation of adducted protein 
(Zia-Amirhosseini et al., 1994), but it is also a physiologically relevant target for 
covalent modification by drug AG because these metabolites frequently circulate in 
plasma (Volland et al., 1990; Benet et al., 1993; Zia-Amirhosseini et al., 1994; 
Hermening et al., 2000; Zhang et al., 2011; Klepacki et al., 2012).  HSA has a significant 
experimental advantage in that it can be readily extracted from plasma and greatly 
enriched by affinity chromatography (Greenough et al., 2004; Jenkins et al., 2009b).  
Additionally, even relatively unsophisticated analyses of circulating HSA for adducts of 
drug and non-drug xenobiotics and their metabolites have identified HSA as a common 
Chapter 5 – Formation of Covalent Protein Adducts by Diclofenac Acyl Glucuronide 
Metabolites in Patients 
Page 222 
 
and tractable target of diverse acylating and alkylating species (Noort et al., 1999; 
Johannesson et al., 2001; Johannesson et al., 2004; Damsten et al., 2007; McCoy et al., 
2008).  HSA has an established place in protein adductomics: the assessment of 
exposure to exogenous and endogenous electrophiles through characterisation and 
measurement of adducts (Rappaport et al., 2012). In certain cases (Johannesson et al., 
2001; Johannesson et al., 2004), there is evidence that HSA is adducted selectively. 
Several undefined plasma proteins were modified by unidentified reactive metabolites 
of zomepirac and diflunisal in rats but the major modified protein was serum albumin 
(Bailey and Dickinson, 1996). While none of the studies that found carboxylic acid 
drugs bound covalently to circulating human plasma proteins identified the modified 
proteins, it is known that ketoprofen-AG, which circulates at relatively high 
concentrations versus the parent compound (Grubb et al., 1999), binds selectively to 
HSA in vitro (Dubois et al., 1993); there being no detectable covalent binding to 
fibrinogen and gamma globulins, and only low-level binding to alpha and beta 
globulins. These instances of selective adduction might be attributable to HSA’s 
abundance of nucleophilic side chains (Kristiansson et al., 2003). 
Due to tandem mass spectrometry of modified peptides enabling the sequence 
location and incremental mass of the modification to be identified simultaneously, 
even when only small samples of human protein are available (Jenkins et al., 2009b; 
Meng et al., 2011; Whitaker et al., 2011), it was anticipated this technique may allow 
the glycation pathway of adduct formation from diclofenac to be revealed in patients.  
Identification of HSA adducts formed through the glycation pathway would provide 
unequivocal proof that an AG metabolite is responsible for at least a fraction of any 
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adductions of the protein that occur in vivo, due to retention of a glucuronic acid 
residue in the adducts (Figure 2.2).    
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Acetonitrile (LC-MS grade), hydrochloric acid (HCl), methanol (LC-MS grade) and 
trifluoroacetic acid (LC-MS grade) were purchased from Fisher Scientific, 
Leicestershire.  Bio Rad Bradford reagent was purchased from Bio Rad, Hertfordshire, 
UK.  Modified trypsin was purchased from Promega, Hampshire, UK.  Acetic acid (LC-
MS grade), ammonium hydrogencarbonate, diclofenac sodium salt, dithiothreitol, 
formic acid (LC-MS grade), iodoacetamide, potassium phosphate (KH2PO4), potassium 
chloride (KCl), tris(hydroxymethyl)aminomethane (TRIS) and zomepirac sodium salt 
were purchased from Sigma-Aldrich, Dorset, UK. 
0.1M phosphate buffer, pH 7.4 was made using 0.3117% monosodium phosphate 
monohydrate, 2.0747% disodium phosphate, heptahydrate  w/v in distilled water. 
All other reagents were purchased from Sigma-Aldrich, Dorset, UK, unless otherwise 
stated. 
5.2.2 Recruitment of diclofenac patients, blood sampling and plasma 
stabilisation 
Six patients were recruited to the study by Guru Aithal and Ira Pande at the 
Nottingham Digestive Diseases Centre, NIHR Nottingham Digestive Diseases 
Biomedical Research Unit, University of Nottingham and the Department of 
Rheumatology respectively, both at Nottingham University Hospitals NHS trust.  The 
patients had taken combined 100-150mg doses of diclofenac per day for a minimum of 
one year (Supplementary tables 6 and 7).  Diclofenac was taken variously as twice- or 
thrice-daily at 50mg or 75mg doses.  Patients N01-N03 took their final dose of 
diclofenac in the clinic, and an 18ml blood sample was removed 1 hour later.  Patients 
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N08-N10 took their final dose of diclofenac at home, and an 18ml blood sample was 
removed at the hospital 2.5 to 3 hours later.  Blood samples were collected by Marie-
Josèphe Pradere, at the Departmental of Rheumatology, Nottingham University 
Hospitals NHS Trust, into heparinised tubes on melting ice to minimise AG degradation 
and therefore protein adduction ex vivo, and centrifuged at 2000g for 10 minutes at 
4°C.  It is known that AG can be stabilised effectively at physiological pH through 
cooling alone (Xue et al., 2006; Matthews and Woolf, 2008; Klepacki et al., 2012).  
Plasma aliquots (60µl) for mass spectrometric analysis of covalent modifications of 
HSA by diclofenac were immediately frozen at -80°C in cryovial tubes.  They were not 
acidified because mildly acidic conditions cause a selective loss of AG glycation adducts 
from serum albumin (Smith et al., 1990a).  100 µl plasma aliquots for analysis of 
diclofenac and diclofenac-AG were taken, and the AG was immediately stabilised by 
acidification (Kenny et al., 2004) through addition of 2M acetic acid, 4% (v/v) final 
concentration (Sparidans et al., 2008).  Based upon the behaviour of other NSAIDs and 
their AGs (Ojingwa et al., 1994), reversible protein binding of diclofenac and 
diclofenac-AGs in the plasma sample will have been decreased significantly by 
acidification. Acidified plasma samples were immediately frozen and stored at -80°C.  
All samples were frozen at -80°C within 1 hour of blood collection.  Sample 
stabilisation of samples N08, N09 and N10 was performed by Melanie Lingaya and 
Rawinder Bainwait, Nottingham Digestive Diseases Centre, NIHR Nottingham 
Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of 
Nottingham.  Plasma samples were transported to the University of Liverpool, buried 
in dry ice, and were immediately stored at -80°C until they were analysed.  The 
covalent binding samples were analysed between 3 and 39 weeks after blood 
Chapter 5 – Formation of Covalent Protein Adducts by Diclofenac Acyl Glucuronide 
Metabolites in Patients 
Page 226 
 
sampling, and the plasma samples for diclofenac and diclofenac-AG metabolite 
analysis were run between 12 and 13 weeks of blood sampling.  Control plasma was 
obtained from 3 healthy volunteers who had never taken diclofenac.   
5.2.3 Analysis of diclofenac and diclofenac-AG concentrations in plasma 
samples 
Stored plasma samples were thawed at room temperature and processed 
immediately.  To 50 µl aliquots of the acidified plasma 10µl of 3 µM zomepirac internal 
standard was added in acetonitrile-water (1:1, v/v) containing 0.1% formic acid.  
Protein was precipitated through addition of four times volume of ice-cold acetonitrile.  
Precipitated protein was pelleted by centrifugation at 14,000g for 5 minutes at 4°C.  
Supernatant was removed, and filtered through 0.45-µm low-binding hydrophilic PTFE 
filter plates (Millipore, Cork, Republic of Ireland) according to the manufacturer’s 
instructions to remove any remaining particulate material.  The filtrate was evaporated 
to dryness at 37°C under a constant stream of nitrogen, and reconstituted in 60µl of 
acetonitrile-water (1:1, v/v) containing 0.1% formic acid.  A 10 µl aliquot was injected 
onto the HPLC column.  Analyte separation was performed at room temperature using 
a Zorbax Eclipse XDB-C18 column (150 x 2.1 mm, 5µm; Agilent Technologies, Santa 
Clara, CA, USA) connected to a Dionex Ultimate 3000 Ultimate 3000 HPLC system 
(Dionex Ltd., Macclesfield, Cheshire, UK) and a 4000 QTRAP hybrid quadrupole mass 
spectrometer (AB Sciex, Foster City, CA, USA).  Samples were maintained at 4°C in the 
autosampler.  Analytes were eluted using a gradient of acetonitrile containing 0.1% 
formic acid against 0.1% formic acid in water: 50-95% over 10 minutes.  The eluent 
flow rate was 210µl/minute. Under these conditions diclofenac 1-β AG and its isomers 
eluted as a single peak at 2.7 minutes; zomepirac eluted at 5.2 minutes and diclofenac 
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at 7.0 minutes.  MS operating parameters for the multiple reaction monitoring (MRM) 
analyses of diclofenac and diclofenac-AG are shown in Table 5. 1.  No endogenous or 
artefactual materials interfering with analyte and internal standard signals in the 
selected MRM channels were detected in control plasma samples.  The lower limit of 
detection of diclofenac and the 1-β AG spiked into pooled human plasma obtained 
from healthy volunteers, as defined by a signal to noise ratio > 3, was below 10nM for 
both compounds.  Detection of analytes in the clinical samples was confirmed using 
enhanced product ion (EPI) scans (Hopfgartner et al., 2004); the MS/MS spectra 
obtained matched the spectra of the authentic compounds.  The corresponding lower 
limits of quantification, as defined by accuracy of between 80-120%, and precision 
(coefficient of variation) < 20% was 50nM for diclofenac (accuracy 93.2%, precision 
15.9%), and 30nM for diclofenac-AG (accuracy 108.7%, precision 3.9.).  Three 
validation assays were run prior to analyte analysis, with further validation assays run 
each time sample analysis was performed. 
Table 5. 1:  MRM parameters for analysis of diclofenac and diclofenac-AG in plasma 
samples.  *Parent ions are [M + H]+.  ** Internal standard 
Parameters Diclofenac-AG Diclofenac Zomepirac** 
Fragmentation 
transition (m/z)* 
472.0296.1 296.1215.1 292.0139.0 
Declustering 
potential (V) 
37.00 31.00 40.00 
Entrance potential 
(V) 
10.00 10.00 10.00 
Collision energy (eV) 14.00 41.00 27.00 
Collision exit 
potential (V) 
15.00 15.00 15.00 
Dwell time (ms) 200 200 200 
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5.2.4 Isolation of HSA from plasma obtained from diclofenac patients 
Stored plasma samples were thawed at room temperature.  HSA was immediately 
isolated from three 60µl aliquots of unacidified plasma samples from each of the six 
diclofenac patients using affinity chromatography at room temperature (Greenough et 
al., 2004; Jenkins et al., 2009a).  HSA from patients N01, N02, N03 and N08 and also 
HSA from the pooled control plasma was captured on a POROS anti-HSA affinity 
cartridge (Applied Biosystems, Foster City, CA, USA).  This cartridge expired before any 
more plasma samples could be processed, and could not be replaced because the 
manufacturer had discontinued production. Therefore HSA from patients N09 and N10 
was captured using an Affinity Removal System column (HSA only; 4.6 x 50mm; Agilent 
Technologies, Santa Clara, CA, USA).  Both columns were installed on a PerSeptive 
BioSystems Vision Workstation (Applied Biosystems).  HSA was eluted with HCl (12 
mM) for patients N01, N02, N03 and N08 (Greenough et al., 2004), and with a 
proprietary acidic elution buffer (Agilent Technologies) for the N09 and N10 samples.  
Eluted protein fractions were immediately neutralised through addition of 0.1M Tris 
buffer, pH 7.  Protein fractions were precipitated immediately through vortex mixing 
with nine volumes of ice-cold methanol, and the precipitate was pelleted by 
centrifugation at 14,000 rpm.  The supernatant was removed, and the pellet washed 
three times with 60µl ice-cold methanol.  The precipitated protein was dissolved 
immediately in 50µl of 0.1M phosphate buffer, pH 7.4, reduced with dithiothreitol 
(10mM) for 15 minutes at room temperature and alkylated with iodoacetamide 
(55mM) for a further 15 minutes at room temperature.  The protein was then 
precipitated and washed with ice-cold methanol as before.  The protein pellet was re-
dissolved in ammonium hydrogencarbonate solution (50µM, 50µl), assayed for protein 
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content using the Bradford assay (Bradford, 1976), and 50 µl aliquots of 3.2mg/ml 
protein were digested with 5µg trypsin overnight.  On the following day, the tryptic 
peptides were subjected to ion exchange chromatography on a PolySULFOETHYL A 
strong cation-exchange column (200 × 4.6 mm, 5 µm, 300Å; PolyLC Inc, Columbia, MD, 
USA); a procedure that enhances substantially the sensitivity of the peptide analyses 
by LC-MS/MS (Jenkins et al., 2009b).  Peptides were eluted with a linear gradient (0-
50% over 75 min) of 10 mM KH2PO4 containing 1 M KCl and acetonitrile (3:1,v/v), pH 
<3, against 10 mM KH2PO4 and acetonitrile (3:1,v/v), pH <3, at a flow rate of 1 ml/min. 
The eluate was monitored at 214 nm. Approximately 15 peptide-containing fractions (2 
ml) were collected per elution. They were dried by centrifugation under vacuum 
before being desalted using a Macroporous Reversed-Phase C18 High-Recovery column 
(4.6 × 50 mm, Agilent Technologies) installed on a Vision Workstation and finally dried 
under vacuum for LC-MS/MS analysis.  These analyses were carried out within 1 week. 
5.2.5 Mass spectrometric characterisation of modified HSA isolated from 
patients receiving therapeutic doses of diclofenac 
Modified tryptic peptides were detected on a 5500 QTRAP hybrid triple-
quadrupole/linear ion trap instrument fitted with a Nanospray II source (AB Sciex).  
MRM transitions for peptides modified by diclofenac-AG by the transacylation or 
glycation pathways were selected as follows: the m/z values for all singly charged 
peptides with a missed trypsin cleavage at the modified lysine residue and mass 
additions of either 277 amu (for the transacylated peptide) or 453 amu (for the 
glycated peptide) were calculated.  These values were paired with the m/z values of 
the dominant fragment ions of diclofenac, namely m/z 215 and m/z 250 (Figure 2.6) to 
complete the MRM transitions.  Transitions for which a modified peptide was detected 
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in any of the experiments described here are listed in Supplementary tables 1 and 2, 
with cation exchange fractions shown in Supplementary table 3.  Other transitions 
representing peptides modified by a range of drugs in our laboratory but not observed 
here are listed in Supplementary tables 4 and 5.  Sample aliquots (2.4-5.0 pmol) were 
delivered into the mass spectrometer by an Ultimate 3000 HPLC System through a 5-
mm C18 nano-precolumn, a C18 PepMap column (75 µm × 15 cm; Dionex) and a 10-
µm i.d. PicoTip ionspray emitter (New Objective, Woburn, MA, USA). The ionspray 
potential was set to 2200-3500 V, the nebuliser gas to setting 19 and the interface 
heater to 150°C.  A gradient from 2% acetonitrile/0.1% formic acid (v/v) to 50% 
acetonitrile/0.1% formic acid (v/v) over 60 min was applied at a flow rate of  
300 nL/min. MRM transitions were acquired at unit resolution in both Q1 and Q3 to 
maximize specificity. Collision energies were optimised for each MRM transition and 
dwell times were 20 ms. MRM survey scans were used to trigger up to three enhanced 
product-ion scans of modified peptides according to the MIDAS technique (Unwin et 
al., 2005; Unwin et al., 2009), with Q1 set to unit resolution and with dynamic fill of the 
trap.  
Modified tryptic peptides were also analysed on an AB Sciex Triple TOF 5600 for 
confirmation.  The higher resolution and broader mass range of this instrument 
allowed for more confident assignments of some peptide sequences and hapten 
structures. Peptide aliquots (2.4-5.0 pmol) were delivered into the mass spectrometer 
via a 10-µm i.d. PicoTip (New Objective) by a direct-flow nano-LC system (Eksigent, 
Dublin, CA, USA): a NanoLC-Ultra chromatograph linked to a cHiPLC-Nanoflex docking 
station, ChromXP C18  trap column (200 m × 0.5 mm) and ChromXP C18 column (75 
µm × 15 cm). The ionspray potential was set to 2200-3500 V, the nebuliser gas to 
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setting 5 and the interface heater to 150oC.  A gradient from 2% acetonitrile/0.1% 
formic acid (v/v) to 50% acetonitrile/0.1% formic acid (v/v) in 90 min was applied at a 
flow rate of 300 nL/min. The instrument acquired data at 25 MS/MS spectra per cycle 
with an accumulation time of 100 ms each. The data were sorted in PeakView (AB 
Sciex) to highlight spectra with fragment ions of m/z 215 and m/z 250 and were then 
interpreted manually.  
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5.3 RESULTS 
5.3.1 Covalent binding of diclofenac to human serum albumin isolated from 
patients receiving therapeutic doses of the drug 
As found previously with in vitro incubations of benoxaprofen-AG and tolmetin-AG 
(Ding et al., 1993; Ding et al., 1995; Qiu et al., 1998), diclofenac was found to modify 
HSA in patients by both transacylation and glycation pathways, with representative 
mass spectra shown in Figure 5. 1.  Whilst the MRM transitions utilised in MIDAS 
analysis of the modifications were designed specifically for adducted HSA lysine 
residues, no modifications of other amino acid residues, such as the arginines and 
serines adducted by benoxaprofen-AG and tolmetin-AG (Ding et al., 1995; Qiu et al., 
1998), were identified by exhaustive analyses of selected cation exchange fractions on 
a 5500 QTRAP hybrid triple-quadrupole/linear ion trap mass spectrometer. 
Reactive metabolites of diclofenac were found to have modified the HSA isolated from 
all six patients analysed (Table 5. 2), with transacylation adducts detected in all 
samples.  Glycation adducts were detected in three of the six patient samples analysed 
(N01, N08 and N09).  The finding of these glycation adducts revealed definitively for 
the first time that AG metabolites can modify proteins in vivo.  None of these 
modifications were detected on tryptic peptides of the HSA isolated from pooled 
control plasma. 
Whilst diclofenac was found to have modified at least one amino acid residue of HSA 
isolated from each patient analysed, the number of lysine residues identified as 
modified and chemical pathways of modification varied greatly between patients.  The 
numbers of lysine residues modified through the transacylation pathway varied from 
one residue (K195) for patients N09 and N10, to five residues for patients N01, N02 
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and N08.   Transacylation adducts to residue K195 were identified in all 6 patient 
samples analysed.  K199 and K541 were the next most commonly modified lysine 
residues identified by the transacylation pathway in patients, N01, N02, N03 and N08. 
Glycation adducts, however, were only detected in three out of the six patient samples 
isolated.  Whilst four distinct lysine residues were identified as modified in HSA 
isolated from patient N08 (K195, K199, K432 and K525), only one modification was 
detected on albumin samples isolated from patients N01 (K199) or N09 (K195).   
From these data it is apparent that greater numbers of modifications by the 
transacylation pathway were detected compared to glycation, suggesting this may be 
the more favourable chemical pathway of adduct formation in vivo.  However, it 
cannot be discounted that differential ionisation of peptides, producing different lower 
limits of identification, may not allow accurate comparison. 
Almost all the modified lysine residues of HSA detected in the patient albumin samples 
were also detected following in vitro incubation of diclofenac-AG with HSA (Chapter 2).  
The only exception to this finding was the detected acylation of K436 (peptide 
433VGSKCCK439).  However, two of the eight lysine residues modified in vitro were not 
modified detectably in vivo, namely K137 and K351.  Only three of the eight lysines 
glycated by diclofenac-AG in vitro were adducted with the complete AG structure 
(Figure 2.2) in vivo: K195, K199 and K432.  All of these residues were transacylated 
both in vivo and in vitro. Two of the seven lysines transacylated and glycated in vitro 
were only transacylated in vivo: K190 and K541.  Uniquely in peptide 525KQTALVELVK534 
from the HSA of patient N08, K525, which was transacylated in vitro and in vivo and 
adducted with the complete AG structure in vitro, was adducted with glucuronic acid 
alone.  
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Figure 5. 1:  Examples of product-ion spectra demonstrating covalent modification of 
K199 in the tryptic peptide 198LKCASLQK205 of HSA isolated from a patient (N08) 
receiving diclofenac: modification by the transacylation (A) or glycation (B) 
pathways. The modified peptides were analysed on a 5500 QTRAP instrument. Ions 
produced by fragmentation of the diclofenac and diclofenac-AG residues are enclosed 
by red ellipses (see Figure 2.6).  The m/z values of the modified peptides and 
fragments correspond to the 35Cl2 isobars. C+iodo=cysteine residue alkylated with 
iodoacetamide. Note, the modified and unmodified peptides were not resolved 
completely by LC. The assignments of the ‘+453,’ ‘+277’, ‘+176’, and ‘+158’ ions are 
given in Figure 2.6.  The ‘+78’ ion was commonly seen on analysis of spectra glycated 
by the AG, but the fragment could not be definitively identified.  The MRM transitions 
for these peptides and the other adducted peptides are given in Supplementary tables 
1 and 2. 
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Table 5. 2: Identification of modified lysine residues of HSA isolated from patients 
receiving therapeutic doses of diclofenac and their chemical routes of modification. 
Patient 
identification 
number 
Time of blood 
sampling following 
last dose of 
diclofenac 
Chemical pathway 
of modification* 
Modified lysine 
residues** 
N01 1hr 
Transacylation 
K190, K195, K199, 
K432, K541 
Glycation K199 
N02 1hr Transacylation 
K190, K195, K199, 
K432, K541 
N03 1hr Transacylation K195, K199, K541 
N08 2 hr 52 mins 
Transacylation 
K195, K199, K436, 
K525, K541 
Glycation 
K195, K199, K432, 
K525 
N09 2hr 34 mins 
Transacylation K195 
Glycation K195 
N10 2hr 40mins Transacylation K195 
 
5.3.2 Detection and quantification of diclofenac-AG in plasma samples 
Plasma samples were also isolated and stabilised for qualitative analysis of diclofenac 
and diclofenac-AG and for quantitative analysis where possible.  LLOQ of the analyses 
were defined, as described in the methods section, at 50nM for diclofenac and 30nM 
for diclofenac-AG.  Sparidans et al. (2008) obtained corresponding figures of 68nM and 
42nM respectively (Sparidans et al., 2008).  Analytes were determined as detected but 
not quantified when their concentration was below the LLOQ provided the MRM peak 
eluting at the correct retention time had a signal-noise ratio of >3.  Further 
confirmation of analyte detection was provided through the use of multiple reaction 
monitoring-triggered EPI scans (Hopfgartner et al., 2004).  The survey scans triggered 
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MS/MS data capture automatically on detection of a signal for diclofenac (m/z 
296.1215.1) or diclofenac-AG (m/z 472.0296.1).  Analyte detection was confirmed 
by EPI scans if drug fragments were found in spectra captured at the known elution 
time of the analyte.  The known mass spectrometric fragments of diclofenac (MW 295 
for the 35Cl2 isobar) are m/z 215, 250 and 278.  The presence of diclofenac-AG was 
shown by identification of the known diclofenac fragments (the conjugate underwent 
conventional facile loss of the glucuronic acid residue), and occasionally by additional 
identification of the loss of water from diclofenac-AG giving an ion at m/z 454 (as 
shown by Figure 5. 2).  The lower limit of detection of diclofenac and diclofenac-AG 
was identified at <10nM for both analytes. 
Blood was taken from patients N01, N02 and N03 1 hour following the last 
administration of diclofenac.  Diclofenac-AG was not detected in plasma from N01 and 
N02 (Table 5. 3).  The concentrations of diclofenac from N01 and N02 were below the 
LLOQ.  Diclofenac-AG was detected in plasma from patient N03, and confirmed using 
EPI scans, although it remained below the LLOQ.  The plasma diclofenac concentration 
in this patient was 166.7nM.  
The time point of blood sampling from patients N08, N09 and N10 was extended to 
about three hours following the last dose of diclofenac.   Plasma concentration of 
diclofenac could be quantified in patients N08 and N10, at 423nM and 63.9nM, 
respectively, and the drug could be detected in patient N09.  The only patient in whom 
diclofenac-AG could be quantified in was patient N08, at 90.78nM, although it could be 
detected in the N09 and N10 plasma samples. 
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Table 5. 3:  Plasma diclofenac and diclofenac-AG concentration.  ND=not detected 
(MRM signal-to-noise ratio <3 at confirmed Rt of the analyte). NQ=not quantified 
(analyte concentration >LLOD,  <LLOQ). 
Patient 
ID 
Time of 
blood sampling 
Diclofenac AG 
(nM) 
Diclofenac (nM) 
N01 1 h ND NQ 
N02 1 h ND NQ 
N03 1 h NQ 166.7 
N08 2 hr 52 mins 90.78 423.3 
N09 2hr 34 mins NQ NQ 
N10 2hr 40 mins NQ 63.91 
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Figure 5. 2:  Representative total ion current scan (A), and EPI scans showing 
identification of diclofenac (B) and diclofenac-AG (C) in plasma isolated from patient 
N03. The protonated molecules (m/z 296 and m/z 472, respectively) and the fragment 
ions are enclosed by red ellipses (see Figure 2.6). The fragment ion of the AG at m/z 
454 is [M+H-H2O]
+.  
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5.4 DISCUSSION 
The main aim of this study was to investigate whether AG metabolites can form 
covalent adducts with a protein in patients receiving therapeutic doses of the drug, 
using mass spectrometric techniques proven in vitro for identification of the adducts.  
Identification of glycation adducts of HSA in plasma isolated from three of the six 
patients analysed (N01, N08 and N09) provides the first definitive evidence that AGs 
can form covalent adducts in humans.  This finding reinforces the toxicological 
concerns held over AG metabolites over the last 30 years (Faed, 1984; Benet et al., 
1993; Shipkova et al., 2003; Skonberg et al., 2008). 
Transacylation adducts were formed in all of the six patients tested.  Whilst AGs are 
known to covalently modify HSA through the transacylation pathway in vitro (Ding et 
al., 1995; Qiu et al., 1998), reactive ester metabolites other than AGs may also be 
responsible in vivo.  Greater numbers of modifications in the clinical samples had 
occurred by the transacylation pathway than glycation.  This is unlike the 16 hour 
incubations of diclofenac-AG with HSA, where modifications by glycation were 
detected at lower concentrations than transacylation (Table 2.7).  Nevertheless, 
because of the high plasma concentration of HSA (Anderson and Anderson, 2002), the 
low molar ratio of AG to protein in these incubations bears some resemblance to the 
situation in vivo.  It is hypothesised, because 1-β AGs form transacylation adducts 
exclusively and sequential acyl migration and aldehyde-amine condensation are 
required for formation of glycation adducts (Chapter 2) and (Smith et al., 1990a), that 
in vivo AGs may be cleared before extensive acyl migration and/or glycation occurs, 
resulting in increased transacylation adduct formation in comparison to glycation. 
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Clearance of AGs in humans has been shown to be rapid, with renal clearances of 
zomepirac-AG of 406 ± 110 ml/min (11.3 fold faster than its aglycone) in healthy 
volunteers, and ibuprofen-AG of 2.46 ± 0.82 ml/min/kg (307.5 fold faster than its 
aglycone) in elderly patients (Smith et al., 1985; Castillo et al., 1995).  Biliary clearance 
of AG metabolites (Verbeeck et al., 1988; Balani et al., 1997; Hofmann et al., 2005; 
Wang et al., 2006) and their extensive spontaneous and enzymatic hydrolysis as shown 
in chapter 2 and the literature (Ruelius et al., 1986; Volland et al., 1991; Williams et al., 
1992; Akira et al., 2002; Karlsson et al., 2010) might also contribute to rapid and 
extensive plasma clearances of AGs.  This suggests that 1-β AGs may consequently be 
cleared from the plasma before extensive rearrangement into their positional isomers 
occurs, resulting in greater plasma exposure of the 1-β AG isomer than the positional 
isomers individually or collectively, and potentially greater formation of transacylation 
adducts than glycation. 
Nevertheless, there are reports of AG positional isomers in human plasma (Hyneck et 
al., 1988; Stopfer et al., 2011).  The extent of AG isomerisation in a patient’s plasma in 
vivo may be assessed through the use of longer LC-gradient conditions, allowing 
complete separation of positional isomers, as was described in chapter 2.  In the 
present study, all AG positional isomers were co-eluted in metabolite analyses to 
increase assay sensitivity.  From these analyses, only plasma of one patient (N08) 
contained a sufficiently high AG concentration for a separation gradient to be run.  
Unfortunately time was not available to perform this assay. 
However, it cannot be discounted that acyl-coenzyme A thioester (acyl-CoA thioester) 
conjugates of carboxylate compounds, which can also form covalent adducts through 
the transacylation pathway, and transacylate glutathione (Grillo and Benet, 2002; 
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Sidenius et al., 2004) and protein (Olsen et al., 2003) in vitro, may also be responsible 
for transacylation adducts detected in patient samples.  Studies using isolated rat 
hepatocytes and selective conjugation inhibitors indicated adduction of intracellular 
proteins by xenobiotic carboxylic acids can be mediated by their acyl-CoA thioesters (Li 
et al., 2002; Li et al., 2003; Grillo and Lohr, 2009).  Indeed the modification of proteins 
in rat hepatocytes by phenylacetic acid occurred in the absence of detectable AG 
formation (Grillo and Lohr, 2009).  Unlike AG metabolites, which are considered to be 
relatively low reactivity CRMs but with high abundance, allowing them to leave 
hepatocytes, reaching the general circulation and extra-hepatic tissues, acyl-CoA 
thioester metabolites are generally considered to be high reactivity but low abundance 
CRMs (Boelsterli, 2002).  To date no evidence has shown acyl-CoA thioesters escaping 
the cell into plasma.  Consequently, if the diclofenac-CoA thioester is partly or entirely 
responsible for the transacylation adducts detected on albumin in this experiment, it 
would suggest protein modification is at least partly located in the liver.    
This hypothetical mechanism of HSA adduction in vivo would appear to conflict with 
the findings of early studies of plasma protein modification by carboxylate drugs, 
where modification was found to correlate with plasma AG exposure (Smith et al., 
1986; Hyneck et al., 1988; Benet et al., 1993).  Due to their ability to reach the blood 
stream in appreciable concentrations (Grubb et al., 1999; Dockens et al., 2000; 
Hermening et al., 2000; Stangier et al., 2007; Stopfer et al., 2011; Zhang et al., 2011), if 
protein modification does occur in the plasma, it would suggest that AG metabolites 
are more likely to be responsible for transacylation adducts detected in patients.  With 
extensive hepatic generation of albumin, at approximately 12g/day (Anderson and 
Anderson, 2002), its intrahepatic modification by transacylation or glycation before 
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secretion into the plasma cannot be discounted.  Although serum albumin is 
synthesized largely in the liver, albumin gene expression has been detected in several 
other tissues (Shamay et al., 2005).  In principle, any tissue that synthesizes the protein 
and glucuronidates diclofenac could produce modified albumin.  Finally, the relative 
contributions of AGs and acyl-CoA thioesters to protein adduction in vivo might differ 
between carboxylic acids; as seems to be the case in isolated hepatocytes (Li et al., 
2002; Li et al., 2003; Grillo and Lohr, 2009). 
Any attempt at analysing protein adduction by AGs has to be qualified by an 
appreciation that even the use of advanced LC-MS/MS techniques has potentially 
significant limitations.  In particular, the glycation reactions of sugar species are very 
complex and probably incompletely understood (Ahmed and Thornalley, 2002; Wa et 
al., 2007), and certainly not limited to the familiar lysine condensation reactions and 
Amadori rearrangements (Frolov and Hoffmann, 2010).  No practical analysis of 
protein modification by a drug AG can allow for all of the potential glycation products; 
for example, cross-linking adducts derived from Amadori (2-ketoamine) structures 
(Acharya et al., 1988).  Consequently, in comparison with the intrinsically simple 
acylation adducts, the number of glycation adducts formed in vitro and in vivo may 
have been underestimated.  
Whilst no experiments have ever investigated plasma AG exposure following 
diclofenac administration to humans, the reported Cmax of diclofenac is approximately 
1.93µg/ml (6.5µM) in volunteers, or 0.99µg/ml (3.3µM) in patients with rheumatoid 
arthritis (Crook et al., 1982), with the normal population range for the concentration of 
HSA in plasma between 35-50mg/ml (530-758µM) (Anderson and Anderson, 2002), 
although concentrations have been shown to be lower in patients with rheumatoid 
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arthritis (Ballantyne et al., 1971; Crook et al., 1982).  Consequently, as plasma 
concentrations of diclofenac-AG are unlikely to exceed those of the aglycone Cmax, the 
maximum expected molar ratio of AG : HSA in patient’s plasma will be between 
0.012:1 and 0.004:1.  By analogy with the glycation of plasma proteins by endogenous 
species (Bhonsle et al., 2012), low albumin levels in patients might be associated with 
increased AG-mediated glycation because albumin competitively inhibits the natural 
glycation of less abundant proteins. 
In vitro incubation of 400nM diclofenac-AG with 40µM HSA (molar ratio of 0.01 : 1) 
revealed only a single modification of HSA, through the glycation pathway, at K190.  In 
contrast to this, several lysine modifications were identified on HSA isolated from 
patient’s plasma samples.  Cation-exchange enrichment of tryptic peptides during 
sample preparation may have increased the sensitivity of detection, revealing 
modifications undetectable in its absence, despite in vitro incubation for 16 hours.  
Alternatively, the long turnover time of HSA of approximately 21 days (Anderson and 
Anderson, 2002) or 14.6 days in rheumatoid arthritis patients (Ballantyne et al., 1971), 
may allow accumulation of covalent modifications.  Reduction of plasma HSA 
concentrations by 23% (Ballantyne et al., 1971) or 16.6% (Crook et al., 1982) in 
patients with rheumatoid arthritis, resulting in an increased ratio of AG:HSA may also 
result in increased albumin modification.   
Attempts were made to quantify plasma diclofenac and diclofenac-AG concentrations 
in patient’s plasma samples.  Restrictions in place for ethical approval of the study 
meant only one time point could be selected for blood sampling, meaning in-depth 
pharmacokinetic analyses could not be undertaken.  Due to the long turnover time of 
serum albumin in human plasma (Anderson and Anderson, 2002), the time point of 
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sampling is not likely to greatly influence the detection of covalent modifications of 
albumin in patients who have taken diclofenac for many months.  Consequently, time 
points were selected with the aim of allowing quantification of diclofenac and 
diclofenac-AG.   
Previous studies of diclofenac pharmacokinetics in humans used the enteric coated 
formulation of the drug, with tmax shown to be highly variable in these studies, varying 
from 1 hour to 5 hours in different individuals, but with a mean of between 2.0 and 2.5 
hours (Willis and Kendall, 1978; Willis et al., 1979; Willis et al., 1980).     
Whilst no restrictions were placed on the formulation of diclofenac for patients 
recruited to the study, it was known that most of the patients would be receiving 
enteric coated diclofenac-sodium formulations. The enteric coating is a pH-sensitive 
polymer, which remains intact in the acidic environment of the stomach, protecting 
the contents of the tablet.  After passing through the stomach, the coating 
disintegrates in the alkaline environment of the small intestine.  With absorption of 
enteric coated formulations delayed until later in the gastro-intestinal tract, it was 
assumed that tmax of enteric coated formulations would be later than those of standard 
diclofenac sodium formulations.  Blood samples were collected from the first few 
patients (N01-N03) 1 hour following DCF administration. This was selected to ensure 
patient compliance. However, with AG only detected in one sample and only minimal 
DCF detected in all three, it was decided to extend this time-point to three hours, and 
allow patients to take their final dose of DCF out of the clinic. 
Diclofenac-AG could not be detected in plasma samples isolated from patients N01 and 
N02, who received enteric-coated diclofenac sodium.  Plasma diclofenac was below 
the LLOQ, but could be detected.  Patient N03, however, received a modified (slow) 
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release form of the enteric coated formulation of diclofenac.  At this 1 hour time point, 
diclofenac could be quantified at 166.7nM, and although the AG remained below the 
LLOQ, its identification was confirmed by an EPI scan.   
The time point of blood sampling was extended to 2.5-3 hours after the last 
administration of diclofenac for the second group of patients (N08-N10).  This time 
point was selected to be closer to the reported plasma tmax of enteric coated 
formulations, in an attempt to facilitate identification and quantification of diclofenac 
and its AG metabolite.  Diclofenac could be quantified in the plasma of two patients, 
namely N08 (at 423.3nM, following administration of enteric coated formulation) and 
N10 (at 63.39nM receiving diclofenac sodium).  Diclofenac-AG could also be quantified 
in patient N08 (90.8nM), and whilst it could not be quantified, the AG was identified in 
plasma from patients N09 and N10 samples (Table 5. 3).   
In each plasma sample assayed through this study, the diclofenac concentration was 
considerably lower than the Cmax reported in the literature.  Whilst the Cmax of 
diclofenac has been reported to be reduced in rheumatoid arthritis and elderly 
patients compared to healthy volunteers (Willis and Kendall, 1978; Crook et al., 1982), 
values measured in this study remain lower than expected.  The most likely reason for 
this disparity is the time point of blood sampling.  The extensive variation of tmax values 
in patients receiving the same enteric coated formulation (Willis et al., 1980) means 
that consistent quantification with only one time point of sampling is difficult.  Rapid 
absorption of diclofenac following an initial lag-time (Willis et al., 1979; Willis et al., 
1980) suggests that the window of sampling within which diclofenac is detectable 
before Cmax is reached may be small, although it remains unclear whether this 
phenomenon is specific to enteric coated formulations of diclofenac, or is a property of 
Chapter 5 – Formation of Covalent Protein Adducts by Diclofenac Acyl Glucuronide 
Metabolites in Patients 
Page 246 
 
diclofenac itself.  This study, however, does provide confirmation that diclofenac is 
metabolised to its AG metabolite in patients, and the AG metabolite is present in 
plasma. 
Through the detection of drug-derived glycation adducts of HSA isolated from patients 
receiving diclofenac therapy, these experiments have provided the first definitive 
confirmation that AG metabolites can form covalent protein adducts in vivo.  This re-
affirms the potential of these metabolites to act as haptens, potentially having a role in 
the initiation of delayed hypersensitivity ADRs associated with their parent carboxylate 
compounds.   
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6.1 INTRODUCTION 
ADRs, accounting for 6.5% of hospital admissions in the UK (Pirmohamed et al., 2004), 
represent a major challenge for clinicians and healthcare systems alike.  Representing 
the 2nd most common cause of attrition of NCEs before clinical trials (Kola and Landis, 
2004), ADRs also play a large role in the reduced productivity and consequential 
profitability of the pharmaceutical industry.  With an estimated cost for the 
development of an NCE into a marketed drug of $802 million (DiMasi et al., 2003), late-
stage drug withdrawal as a consequence of ADRs inflicts a massive financial burden on 
the pharmaceutical industry.  Consequently, to avoid this situation, pre-development 
(in silico) prediction and/or in-development identification of compounds likely to elicit 
ADRs in humans is essential.  Off-target ADRs, however, as a consequence of their low 
incidence and unpredictable nature are currently infrequently detected before the 
drug is exposed to large clinical populations (Park et al., 2000), after large financial 
investment has already been made in the compound. 
Covalent binding of drugs or their CRMs to proteins is widely recognised as a potential 
risk factor in the pathogenesis of ADRs (Kalgutkar and Soglia, 2005; Park et al., 2005), 
with many drugs associated with idiosyncratic liabilities undergoing covalent binding in 
vitro and in vivo (Nakayama et al., 2009; Park et al., 2011a).  This recognition has 
resulted in the incorporation of screens in pre-clinical drug development to assess 
covalent binding, and consequential decision trees into how drugs should be managed 
if they are found to bind extensively (Evans et al., 2004; Park et al., 2011a; Sakatis et 
al., 2012).   
Whilst the covalent binding of drugs or their CRMs to proteins critical for cellular 
function has been suggested to have a role in idiosyncratic reactions towards drugs 
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(Park et al., 2005), including the pathogenesis of immune-allergic ADRs, such as 
anaphylaxis and hepatotoxicity associated with carboxylate compounds, it is the 
covalent binding of drugs or their CRMs with proteins and their subsequent 
presentation to the immune system by MHC molecules that is thought to be associated 
with their pathogenesis (Pichler, 2003; Park et al., 2011b), although direct non-
covalent interaction of drugs at T-cell receptors has been suggested for some 
compounds (Pichler, 2002) including sulfamethoxazole (Schnyder et al., 1997).   
With 14% of the drug withdrawn from the market between 1960-1999 containing a 
carboxylic acid group (Fung et al., 2001), attention has been drawn to the possible 
consequences of drug bioactivation at this site (Skonberg et al., 2008).  Further to this 
background situation, many carboxylate drugs remaining on the market do so with 
black-box warnings to their safety (Skonberg et al., 2008; Stepan et al., 2011), usually 
as a consequence of their association with off-target anaphylaxis or hepatotoxicity.    
A common metabolic pathway of carboxylate compounds is their direct and often 
extensive glucuronidation at the carboxylic acid group (Table 2.1), forming acyl 
glucuronides (AG).  AGs have been shown to be chemically unstable and protein 
reactive in vitro (Benet et al., 1993; Stachulski et al., 2006).  With covalent binding of 
carboxylate compounds to serum albumin in humans and animals correlating to 
plasma AG exposure (Smith et al., 1986; Hyneck et al., 1988; Smith et al., 1990b; Benet 
et al., 1993; Castillo et al., 1995; Sallustio and Foster, 1995; Liu et al., 1996), it has been 
proposed that CRM’s derived from carboxylic acids can elicit ADRs.  Consequently, this 
perceived association has resulted in anxiety in the pharmaceutical industry over the 
progression of compounds found to be metabolised to AGs, and incorporation of the 
phrase:  
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‘Phase II conjugation reactions usually render a compound more water soluble and 
pharmacologically inactive, thereby eliminating the need for further evaluation.  
However, if the conjugate forms a toxic compound, such as an acyl glucuronide, 
additional safety testing may be needed (Faed, 1984)’  
 
into the FDA’s  guidance for industry in the safety testing of drug metabolites (FDA, 
2008).   
However, to date, no direct and compelling evidence has shown covalent binding of 
AG metabolites to proteins in vivo.  Furthermore, with the expected rapid clearance of 
phase II metabolites (Caldwell, 1982), whether AGs actually are responsible for the 
covalent binding of carboxylate compounds is unclear, and certainly undefined.  
Consequently, further investigations into and potential cessation of development of 
compounds extensively metabolised into AGs, as advised by the FDA may be 
unnecessary.   
To address this, the central aim of this thesis was to investigate whether AG 
metabolites could directly form detectable covalent adducts to serum albumin in vivo.  
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6.2 RISK ASSESSMENTS OF ACYL GLUCURONIDE REACTIVITY 
The first focus of this thesis was to investigate diclofenac-AG as a suitable tool for the 
investigation of AG reactivity in vivo for the studies undertaken in consequence 
chapters of the thesis.  The criteria set-out for the suitability of an AG was that 
concerns made over its acyl glucuronidation would be made if the drug was developed 
as a NCE today.  In accordance with the FDA’s guidance for industry, the extensive 
(75%) acyl glucuronidation of diclofenac-AG in isolated liver microsomes supplemented 
with UDPGA (Kumar et al., 2002) and detection in pre-clinical species (Stierlin and 
Faigle, 1979; Sparidans et al., 2008) suggests that ‘additional safery testing may be 
needed’ (FDA, 2001). 
Safety testing of AGs are focussed on the investigating the protein reactivity of the 
molecule.  The most commonly used mechanism in pharmaceutical studies for the 
investigation of AG protein reactivity is through investigation of their rate of 
degradation in phosphate buffer, pH 7.4 at 37°C (Ebner et al., 1999; Wang et al., 2004; 
Walker et al., 2007; Potter et al., 2011; Stopfer et al., 2011).  This follows the finding of 
excellent correlation (r2=0.995) between the rate of degradation and protein binding 
of 9 AGs following in vitro incubation under physiological conditions (Benet et al., 
1993), and allows correlation of the reactivity of different AG molecules to be assessed 
and compared (Shipkova et al., 2003; Stachulski et al., 2006). 
Incubations in Chapter 2 revealed diclofenac-AG to spontaneously degrade under 
these conditions, with a t½ of degradation of 0.79 hours.  Whilst some discrepancy was 
found between this value of degradation and the value previously reported by (Ebner 
et al., 1999), increased time-points at the early portions of the degradation curve and 
homology with the other reported degradation t½ of 0.7 hours (Sawamura et al., 2010) 
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provides increased confidence in this data.  This rapid degradation of diclofenac-AG 
places it amongst the most reactive AGs reported.  Further studies were undertaken to 
confirm that this intrinsic reactivity also represented protein reactivity.  Following 
incubations with human serum albumin, covalent binding of diclofenac-AG was shown 
using both an established alkaline hydrolysis technique as well as direct tandem mass 
spectrometric analysis of tryptic peptides of the modified protein.  This confirmation of 
the chemical instability and protein reactivity of diclofenac-AG, combined with its 
extensive acyl glucuronidation does suggest that if diclofenac was developed as a NCE 
today, it is most likely that concerns would be raised about potential risk over its acyl 
glucuronidation.   
Correlation of the rate of degradation of the 1-β AG as to the consequential perception 
of safety of the compound however is less assured.  A study correlating the marketable 
fate of 21 carboxylate drugs with the degradation t½ of their 1-β AGs did show a good 
separation between compounds classified as safe.  No separation however, could be 
achieved to separate drugs with warnings attached to their safety and those 
withdrawn due to safety concerns (Sawamura et al., 2010).  Drugs in this warning 
category include naproxen, probenecid, ibuprofen and diclofenac.  With NSAIDs some 
of the drugs most commonly exposed to man, (Aithal, 2011).  6% of the US population 
using a prescription NSAID and 24 % of the US population exposed to ibuprofen in a 
month (Paulose-Ram et al., 2003), and with diclofenac, ibuprofen and naproxen the 
most commonly prescribed NSAIDs by general practitioners in the UK (Langman et al., 
2001), potentially useful compounds whose risk is not particularly high may not be 
progressing through pre-clinical drug development as a consequence of their acyl 
glucuronidation.  
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6.3 CHEMICAL INTERACTIONS OF ACYL GLUCURONIDE METABOLITES WITH 
PROTEINS 
Secondary investigations in the thesis were undertaken in Chapter 2 to utilise methods 
developed in the validation of diclofenac-AG as a suitable AG for study to explore the 
chemistry of interaction between AGs and protein, and potentially to allow some 
prediction as to how the AG might behave in vivo. 
Incubations in phosphate buffer revealed diclofenac-AG to degrade primarily by acyl 
migration, with little hydrolysis detected.  The preferential degradation of by acyl 
migration rather than hydrolysis has also been reported for many other AGs (Watt and 
Dickinson, 1990; Iwaki et al., 1999; Corcoran et al., 2001; Akira et al., 2002; Berry et al., 
2009; Johnson et al., 2010; Karlsson et al., 2010).  Increased hydrolysis of  
diclofenac-AG was found following incubation with HSA at reduced (400µM) AG 
concentrations, with an absence of noticeable hydrolysis at higher concentrations of 
(2mM) AG in the incubation mixture.  This was hypothesised to reveal the weak 
esterase potential of AGs, as has previously been reported for other AGs (Watt and 
Dickinson, 1990; Sallustio et al., 1997; Iwaki et al., 1999; Mizuma et al., 1999; Akira et 
al., 2002) as well as other ester drugs (Ma et al., 2005).  Furthermore, extensive 
hydrolysis was revealed following incubation of the drug in isolated human plasma.  
This was considered to be a reflection of esterases known to reside in the plasma 
(Fukami and Yokoi, 2012), and again is reflective of the findings with other AGs (Watt 
and Dickinson, 1990; Dickinson and King, 1991; Dubois et al., 1994).  This esterase 
activity observed following incubation in isolated human plasma is likely to be 
reflected in in vivo studies, and in man may result in reduced plasma exposure to AGs, 
reducing their potential for covalent modification of protein.  This has been proven in 
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vivo where co-administration of zomepirac with the esterase inhibitor PMSF resulted 
in increased plasma exposure of zomepirac-AG, and a consequent increase in the 
covalent modification of protein (Smith et al., 1990b).   
These findings suggest that as well as the known extensive renal and biliary clearance 
of AGs in man, plasma hydrolysis of AGs in vivo, potentially by both HSA and plasma 
esterases may enhance the rate of clearance of AGs from the plasma, and 
consequently result in reduced AG exposure, consequently reducing the potential for 
AGs to modify plasma in vivo.   
Further experiments in Chapter 2 were directed to study the covalent modification of 
HSA by AGs.  An alkaline hydrolysis method was set-up to allow quantification of the 
covalent modification of HSA by protein, as commonly used in AG experiments.  This 
revealed modification to be both time and concentration dependent.  It is unclear from 
both this experiment and the literature as to whether following a maximum covalent 
modification of HSA by AGs being reached, whether a decline in the detection of 
binding is seen.  This is due to the consistent variation in the assay (Watt and 
Dickinson, 1990; Dickinson and King, 1991; Dubois et al., 1994).  Whilst not conclusive, 
a reduction in binding would mean that covalent modification of AGs is reversible, and 
although not extensive, may reduce the rate of covalent adduct accumulation in vivo. 
Direct tandem mass-spectrometric identification of the covalent modification of 
peptides was used to provide quantitative analysis of the interactions of diclofenac-AG 
with HSA.  These experiments confirmed that diclofenac-AG formed both glycation and 
transacylation adducts with HSA following in vitro incubation.  Covalent binding of the 
AG was primarily located in or around hydrophobic pockets on the HSA molecule, 
known to be important in the non-covalent interaction of many drugs with HSA 
Chapter 6 – Final Discussion 
Page 266 
 
(Ghuman et al., 2005).  Potentially this may suggest the importance of non-covalent 
interaction of AGs with protein for covalent binding with protein.  Further work in the 
investigation of the chemical interactions of diclofenac-AG with HSA revealed the 
differential role of the 1-β diclofenac-AG to form transacylation adducts.  Combined 
with the earlier work of (Smith et al., 1990a) who suggested that acyl migration was 
required for glycation adducts.  This may suggest that as a consequence of the 
expected rapid elimination of AGs from the plasma as expected by their rapid urinary 
and biliary clearance (Smith et al., 1985; Verbeeck et al., 1988; Castillo et al., 1995; 
Balani et al., 1997; Hofmann et al., 2005; Wang et al., 2006) and extensive hydrolysis in 
the plasma Chapter 2 and (Iwaki et al., 1999; Mizuma et al., 1999; Akira et al., 2002), 
AGs may be expected to be cleared before extensive acyl migration, and consequently 
if they do form covalent adducts in vivo, it may be suggested that these could be 
expected to be through transacylation.  
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6.4 APPLICABILITY OF THE RAT TO STUDY THE POTENTIAL OF ACYL 
GLUCURONIDE METABOLITES TO FORM COVALENT ADDUCTS IN VIVO 
Following the validation of diclofenac-AG as a useful tool to investigate the protein 
reactivity of AGs in vivo, it was subsequently decided to investigate the applicability of 
the rat as a model system to investigate AG protein reactivity towards serum albumin.  
Initial investigations were undertaken to ascertain the covalent modification of RSA by 
diclofenac-AG following in vitro incubation.  These experiments revealed a reduction in 
the detection of the covalent modification of RSA than HSA following incubation with 
diclofenac-AG.   Modification of HSA could also be detected at 10-fold lower AG 
incubation concentrations than RSA.  This suggests that RSA is less susceptible to 
covalent modification by diclofenac-AG, although, as a consequence of the potential 
for differential ionisation of tryptic digest peptides of RSA and HSA in the mass 
spectrometer, assertive assessment of a quantitative reduction of covalent binding 
cannot be made.  However, a 74.7% reduction in the covalent binding of diflunisal-AG 
to RSA, was shown following the use of an alkaline hydrolysis detection of modification 
(Watt and Dickinson, 1990).  Loss of 60% of the identified diclofenac-AG binding sites 
on HSA in RSA, as a consequence of the 20% sequence variance in the two proteins 
(Sargent et al., 1981; Minghetti et al., 1986; Carter et al., 1989; Kosa et al., 1997) is 
hypothesised to be the attributable for the apparent reduced covalent modification of 
RSA by diclofenac-AG when compared to HSA. 
Despite this apparent reduced modification of RSA by diclofenac-AG, reports in the 
literature have still associated AGs with the covalent modification of plasma proteins in 
the rat detected following administration of their parent aglycones (Sallustio and 
Foster, 1995; Liu et al., 1996), with Western blot analysis identifying RSA as a main 
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target in the plasma for modification (Bailey and Dickinson, 1996).  However, again, as 
a consequence of the inability of antibody and alkaline hydrolysis methods to identify 
metabolic species responsible for covalent adducts detected, it remains possible that 
these adducts are not elicited by AGs, and may be formed through other bioactivation 
pathways of the drugs tested.  
With access to relatively large quantities of synthetic diclofenac-AG, it was decided to 
investigate whether covalent adducts to plasma proteins could be detected following 
intravenous bolus administration of the AG to the rat.  However, despite selection of a 
dose estimated to allow similar instantaneous AG exposure to RSA in plasma, as 
allowed detectable covalent adducts in in vitro incubations, no covalent adducts could 
be detected.  This was hypothesised to be a consequence of rapid AG clearance of the 
rat, preventing sufficient exposure to allow detectable covalent adducts.  With the 
physiological role of glucuronidation to enhance a molecule’s polarity and affinity for 
export transporters, consequently resulting in its rapid clearance from biological 
systems and organisms (Caldwell, 1982; Miners and Mackenzie, 1991) it was 
hypothesised that diclofenac-AG would be eliminated rapidly from the rat, as has been 
shown for other AGs (Watt et al., 1991; Iwaki et al., 1995; Dong et al., 2005), 
potentially with plasma esterases also acting to hydrolyse the drug in vivo, further 
increasing plasma clearance, as predicted through incubations in Chapter 2.  This 
hypothesised rapid clearance may prevent AG exposure reaching sufficient levels to 
allow detectable covalent modification of RSA in vivo in the rat.  
To investigate this hypothesis, the plasma clearance of an intravenous bolus dose of 
diclofenac-AG was investigated, and compared to that of diclofenac.  Plasma clearance 
of diclofenac-AG was found to be over 460% faster than diclofenac, with a plasma half-
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life of the AG of 4.12 minutes, indicating this hypothesis of rapid and extensive 
clearance of diclofenac-AG from the rat is valid.  As predicted by in vitro investigations 
in Chapter 2, extensive hydrolysis of diclofenac-AG was detected in the rat.  It could 
not however be completely defined whether high concentrations of plasma diclofenac 
following administration of its AG were a consequence of plasma (or tissue) AG 
hydrolysis, or a consequence of enterohepatic recirculation of the aglycone, as has 
previously been proved to occur in the rat (Stierlin and Faigle, 1979; Fukuyama et al., 
1994).  Whilst elimination of AG through plasma esterases may be considered a 
process resulting in reduced AG exposure, enterphepaic recirculation of diclofenac 
may act to further increase exposure through subsequent re-glucuronidation of the 
aglycone. 
With the plasma clearance of pharmaceuticals from the rat known to be faster than 
man (Chiou et al., 1998), combined with suspected reduced affinity of AG modification 
of HSA, the rat does not represent a suitable in vivo tool for the investigation of serum 
albumin modification by AGs in man.  The short t½ of circulatory rat serum albumin of 
2.5 days, in comparison to 21 days for humans (Tornqvist et al., 2002) also suggests 
that repeat dose studies investigating whether adducts could accumulate would not be 
useful.  The increased biliary clearance of AGs in rats in comparison to man, as a result 
of a humans preferentially exporting larger molecules across the hepatobiliary plasma 
membrane, unlike rats (Boelsterli, 2003) may however suggest the rat may be more 
suitable to investigation of hepatic modification of peptides by AGs. 
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6.5 THE USE OF CONTINUOUS INTRAVENOUS INFUSION TO INVESTIGATE 
POTENTIAL MECHANISMS FOR THE PRODUCTION OF DANGER SIGNALS BY 
DICLOFENAC 
Whilst the covalent binding of haptens to proteins is considered critical for their 
presentation to the immune cell in the hapten hypothesis (Padovan et al., 1997; Park 
et al., 2001; Pichler, 2003; Posadas and Pichler, 2007; Park et al., 2011b), antigen 
presentation alone is not considered sufficient for the stimulation of immune 
responses.  Danger signals from apoptotic, necrotic or stressed cells are also 
considered mandatory (Matzinger, 1994; Pirmohamed et al., 2002; Li and Uetrecht, 
2010).  Currently, the range of endogenous molecules that may act as danger signals 
are largely unknown (Li and Uetrecht, 2010), but in theory they may be generated by 
any mechanism resulting in cell stress, for example cytotoxic action of a drug.  With the 
apparently critical role of danger signals in off-target immune mediated ADRs, 
identification of potential mechanisms for their provision would be useful in providing 
better understanding of the mechanisms involved in idiosyncratic ADRs, and 
potentially helping towards a better understanding of the risk of NCEs.  To address 
this, investigations were undertaken with diclofenac, a model drug used to study off-
target hepatotoxicity (Boelsterli, 2003; Aithal, 2004), to investigate whether 
hepatotoxicity could be elicited in the rat following its continuous intravenous 
infusion. 
Dose-limiting gastro-intestinal toxicity of diclofenac (Menasse et al., 1978) and its rapid 
clearance following intravenous bolus administration as shown by Chapter 3 and  
(Chiou et al., 1998; Peris-Ribera et al., 1991) represent a major challenge in the study 
of the potential for diclofenac to elicit hepatocellular stress in vivo.  In an attempt to 
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overcome these obstacles, a continuous intravenous infusion drug delivery system, 
hypothesised to allow continuous drug exposure throughout the 48 hour study was 
used.  This would negate the drug’s rapid clearance, whilst the intravenous route of 
administration allows reduced drug exposure to the gastro-intestinal tract, reducing 
risk for the development gastro-intestinal toxicity in rats.  Whilst the use of continuous 
intravenous administration of drugs allowing continuous exposure is well established 
and used clinically (Howell et al., 1997; Leder et al., 1999; Howden and Richards, 2001; 
Recchia et al., 2001), few reports of its use in a toxicology setting have been reported. 
However, despite infusion of a maximum tolerated dose of diclofenac to the rat for 48 
hours, no evidence of hepatotoxicity could be detected.  Instead, plasma 
measurements of diclofenac concentration revealed an adaptive response to 
diclofenac infusion in animals resulting in enhanced plasma clearance of the drug.  
Further to this, increased expression of the ROS scavenging enzymes, catalase and 
superoxide dismutase were detected.  Whilst time points of toxicological investigation 
were not ideal, due to Home Office license constraints on blood volume sampling, 
these findings suggest that absence of hepatotoxicity may be a consequence of these 
adaptive responses to drug exposure. 
Whilst the adaptive mechanisms responsible for enhanced plasma diclofenac clearance 
could not be revealed, it is possible that this increased clearance may reduce the 
potential for drug metabolite or CRM accumulation.  Cellular accumulation of drugs or 
their metabolites has been associated with the pathogenesis of many idiosyncratic 
ADRs (Park et al., 2011a).  With no idiosyncratic ADRs reported for drugs administered 
at a daily dose of below 10 mg per day (Uetrecht, 2003; Stepan et al., 2011), clearly a 
threshold of drug exposure is required before a risk of idiosyncratic liability is reached.  
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Cellular accumulation of drugs or their CRMs is likely to increase the threshold to these 
ADRs.  Consequently, if this adaptive response, resulting in increased drug clearance 
translates to patients receiving chronic drug therapy, failure of a patient to adapt 
leading to reduced efficiency for drug or CRM elimination compared with the rest of 
the population may represent an increased risk of the individual for development of an 
idiosyncratic reaction towards the drug.  Genetic polymorphis studies in man, 
associating MRP2, CYP2C8 and UGT2B7 with increased incidence of hepatotoxicity in 
patients receiving diclofenac (Daly et al., 2007) does suggest that accumulation of 
CRMs may have a role in the development of diclofenac-induced hepatotoxicity in man 
specifically.  Before these hypotheses can be made confidently, the absence of 
hepatotoxicity and mechanisms of increased clearance need to be confirmed.  This 
could be undertaken through repeating the infusion study, allowing consistent 
assessment of plasma biomarkers of hepatotoxicity throughout the time course.  Livers 
should be isolated from rats immediately following cessation of infusion for 
histopathologial assessment of hepatotoxicity and export transporter induction.  
Western blot analysis investigating the hepatic induction of metabolising enzymes and 
export transporters, as well as metabolising enzyme function assays using microsomes 
or hepatocytes isolated from rats in the study may be used to confirm any 
histopathological findings from immunohistochemical staining.  
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6.6 COVALENT MODIFICATION OF HSA ISOLATED FROM VOLUNTEER PATIENTS 
BY DICLOFENAC ACYL GLUCURONIDE 
6.6.1. Identification of the modification of HSA by diclofenac acyl glucuronide 
in patients receiving therapeutic doses of diclofenac 
With the inapplicability of the rat model to investigate covalent modification of serum 
albumin by AGs as outlined in section 6.4, it was decided to investigate if covalent 
modifications could be detected in patients receiving therapeutic doses of the drug.  
Collaboration with the Department of Rheumatology and the Nottingham Digestive 
Diseases Centre at the Queens Medical Centre in Nottingham provided access to 
plasma samples isolated from patients receiving therapeutic administration of 
diclofenac for at least a year.  Albumin was isolated from these plasma samples, and 
covalent binding was assessed using direct mass-spectrometric analysis of tryptic 
digests of isolated albumin. 
With the retention of glucuronic acid in the adduct, the identification of glycation 
adducts to serum albumin isolated from three out of the six patients tested showed for 
the first time, definitive evidence for the covalent binding of AG metabolites to HSA in 
vivo.  With the well-established associations of covalent binding with immunological 
ADRs, largely shown through investigations into penicillin hypersensitivity (Park et al., 
2011a), this identification of AG covalent binding in vivo clearly represents an area of 
toxicological interest (Faed, 1984; Spahn-Langguth and Benet, 1992; FDA, 2008).   
However, it must also be noted that glycation adducts could only be detected to HSA 
isolated from 50% of the patients analysed.  Whilst it is assured that transacylation 
adducts are elicited as a consequence of direct bioactivation at the carboxylic acid 
group, due to the covalent linkage with protein at this site, metabolites other than AGs 
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may also be responsible.  Coenzyme A thioester conjugates of carboxylate compounds 
have also been shown undergo transacylation reactions with protein (Li et al., 2002; 
Olsen et al., 2003), and glutathione (Grillo and Benet, 2002; Sidenius et al., 2004).  
Consequently, they have the potential to also transacylate proteins in vivo (Skonberg 
et al., 2008; Grillo, 2011).  However, as suggested in section 6.3, with the 1-β isomer 
primarily responsible for the formation of transacylation adducts (Chapter 2), and 
potentially increased 1-β AG isomer exposure when compared to the acyl migration 
isomers, as a consequence of rapid AG clearance, potentially before extensive acyl 
migration in vivo, detection of transacylation adducts in vivo may also be a 
consequence of acyl glucuronidation. 
However, it must be remembered that to date, unlike the β-lactam antibiotics, 
immunogenicity of AG derived covalent adducts, has not yet been shown.  The only 
real evidence in the literature for the immunogenicity of AG adducts suggested by the 
generation of antibodies in rats exposed to RSA modified in vitro by diflunisal-AG 
through incubation (Worrall and Dickinson, 1995).  The requirement for co-
administration of Freund’s adjuvant to elicit antibody production, however, hardly 
provides good evidence for the immunogenicity of AGs.  With many drugs found to 
covalently bind to proteins without associations to toxicity, clearly an important next 
step in the research into the risk of acyl glucuronidation would be to investigate the 
immunogenicity of covalent adducts generated by AGs.  Consequently, it is clear that 
as well as confirming the covalent binding of AGs to serum albumin with other 
carboxylate compounds, investigations into the resulting immunogenicity is important.  
Approaches similar to those used in the investigation of β-lactam immunogenicity may 
be useful, where identification of circulating antibodies able to recognise the drug 
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isolated from drug-hypersensitive patients (Christie et al., 1988; Torres et al., 1997), 
and proliferation of lymphocytes isolated from hypersensitive patients following drug 
exposure or exposure to the drug target (Meng et al., 2011; El-Ghaiesh et al., 2012).  
Importantly, investigations into the covalent modification of proteins, and 
immunogenicity of these proteins should be undertaken, as outlined below, in 
combination with modified proteins also being tested for their immunogenicity.  
6.6.2. Considerations of disposition in the covalent modification of serum 
proteins by carboxylate compounds 
The disposition of AGs may provide further evidence for their role in hypersensitivity 
off-target ADRs associated with carboxylate compounds.  Generalised hypersensitivity 
reactions are usually considered to be a consequence extracellular covalent 
modification of proteins, resulting in the drug-hapten presentation by MHC-II 
molecules, and stimulation of CD4+ T-cells and B-cells (Pichler, 2003).  Consequently, 
due to the well-defined systemic circulation of AGs (Volland et al., 1990; Benet et al., 
1993; Mayer et al., 1993; Zia-Amirhosseini et al., 1994; Stangier et al., 2000; Zhou et 
al., 2001; Wang et al., 2006) acyl glucuronidation may be suggested to be the 
bioactivation pathway responsible for hypersensitivity ADRs to carboxylate 
compounds.  However, it is also possible that intrahepatically modified peptides may 
be exported outside the cell, and result in the stimulation of MHC-II responses.  
Suggested reactivity of oxidative metabolites of some carboxylate metabolites and 
their subsequently formed quinone-imines (Tang et al., 1999; Chen et al., 2006) may 
also have a role to play on the extracellular covalent binding of carboxylate 
compounds.   
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On the other hand, tissue-specific delayed hypersensitivity ADRs, as observed with 
diclofenac-induced hepatotoxicity, are thought to be associated with hapten 
presentation following the modification of intracellular proteins, with antigen 
presentation through MHC-I molecules, resulting in CD8+ T-cell responses (Pichler, 
2003).  This suggests modification of intracellular proteins is required for the 
development of hepatotoxic ADRs towards carboxylate compounds.  The intracellular 
nature of protein modification suggests that CRMs of carboxylate compounds unable 
to escape the hepatocyte also have a role to play in the pathogenesis of these ADRs.   
Immunohistochemical studies have been used to visualise and identify covalently 
modified hepatic proteins in the rat.  These studies have shown covalent modification 
of hepatic proteins to be located primarily on the canalicular membrane of 
hepatocytes.  AGs, as a consequence of their high canalicular concentrations, 
estimated to be between 50 to 5000 times higher than in the plasma (Sallustio et al., 
1996; Sallustio et al., 2000), have been hypothesised to be responsible for covalent 
adducts located across the canalicular membrane.  The high concentration of AGs at 
the canalicular membrane is considered to be a consequence of their high affinity for 
transport across the basolateral membrane into the hepatocyte by MRP3, and 
subsequently across the canalicular membrane by MRP2 and BCRP, as has been shown 
for diclofenac-AG through the selective transgenic knockout of mouse transporters 
(Lagas et al., 2010) and rats (Seitz et al., 1998).  Extensive reduction in the covalent 
binding of diclofenac through inhibition of glucuronidation (Kretz-Rommel and 
Boelsterli, 1993) and disruption of metabolite export by MRP2 (Seitz et al., 1998) also 
further suggests the potential of these metabolites to form covalent adducts to hepatic 
proteins in vivo.  Whilst these studies do provide strong evidence for the role of AGs to 
Chapter 6 – Final Discussion 
Page 277 
 
form covalent adducts in the liver, they may still arise as a consequence of the 
bioactivation of compounds into several metabolites other than AGs.  Until the 
physiological consequences of covalent binding are ascertained, questions will remain 
as to its role in toxicology. 
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6.7 SUMMARY 
Through this thesis, in vitro experiments revealed diclofenac-AG to be chemically 
unstable and protein reactive following in vitro incubation.  This revealed it was a 
suitable AG for use throughout the rest of the thesis to investigate AG protein 
reactivity in vivo.  Further in vitro experiments revealed that plasma hydrolysis may act 
alongside drug elimination to enhance the clearance of AGs from organisms.  
Experiments in the rat revealed it is not a suitable tool for investigating AG protein 
reactivity towards serum albumin, potentially as a consequence to species differences 
in the primary sequence between HSA and RSA.  The rapid plasma clearance of AGs 
was confirmed in the rat, with continuous infusion of diclofenac revealing an adaptive 
change resulting in an enhanced rate of plasma clearance of diclofenac, alongside 
induction of the ROS scavenger enzymes catalase and superoxide dismutase.  The 
absence of any signal of hepatotoxicity in these animals suggests these adaptive 
changes act to protect the animal from any deleterious consequences of drug-
exposure.  The final experiments in the thesis were focussed on the identification of 
whether the AG of diclofenac could be identified covalently bound to serum albumin 
isolated from patients receiving therapeutic doses of the drug.  The identification of 
glycation adducts to HSA isolated from 50% of patients tested identify for the first time 
that AGs can form covalent adducts in vivo.  The definitive identification of 
transacylation adducts in vivo, which is also novel, also further confirms that 
bioactivation at the carboxylic acid of site of carboxylate drugs results in the formation 
of CRMs capable of forming covalent adducts in vivo, however identification of CRM(s) 
responsible for these transacylation adducts was not possible.  These findings re-affirm 
concerns over the safety of the carboxylic acid functional group in pharmaceuticals, 
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and reaffirms anxiety over acyl glucuronidation as a potential toxification pathway.  To 
assess whether these covalent adducts actually are a toxicological concern, 
physiological consequences of these covalent modifications needs to be assessed.  
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Supplementary 1.1 Chemical synthesis of diclofenac-AG 
The first stage describes the synthesis of allyl α, β-D-glucuronate (Supplementary 
Figure 1B).  D-glucuronic acid (Supplementary Figure 1A) (4 g, 20 mmol) was stirred 
with polymer-bound fluoride (6.7 g, 20 mmol) in 30 ml of dry dimethylformamide at 
20°C for 3 hours.  Following this, 1.9 ml of 22 mmol allyl bromide was added and the 
reaction mixture was stirred at 40°C for 20 hours.  The reaction mixture was filtered 
away, and the resin washed twice with 10 ml dimethylfromamide.  The combined 
filtrate was concentrated under high vacuum to provide the crude products as a pale 
yellow oil.  Flash chromatographic separation using ethyl aceteate, isopropyl alcohol 
and dH2O at ratios of 5, 3, 1 (v/v) provided the ester at 75% yield. 
The second stage describes the conversion of allyl α, β-D-glucuronate to diclofenac 
allyl glucuronate (Supplementary Figure 1C).  Diisopropyl azodicarboxylate (0.1 ml, 0.5 
mmol) was slowly added over 10 mins to a solution of diclofenac (0.170 g, 0.5 mmol), 
triphenylphosphine (0.135 g, 0.5 mmol) and allyl α, β-D-glucuronate (0.12 g, 0.5 mmol) 
in 3 ml anhydrous tetrahydrofuran stirred under nitrogen at 0°C.  After 1 hour the 
solution was evaporated to dryness and purified using silica chromatography, eluting 
with 5% MeOH in dichloromethane.  Appropriate fractions were pooled and 
evaporated to give the product as an α/β mixture.  A second chromatography, eluting 
with 5% ethanol in diethyl ether provided the pure β product as a white solid with a 
yield of 30%. 
The final stage describes the conversion of 1-β diclofenac allyl glucuronate to 1-β 
diclofenac-AG (Supplementary Figure 1D).  A solution of 1-β diclofenac allyl 
glucuronate (0.3 mmol) and tetrakis(triphenylphosphine)palladium (0.03 mmol) made 
in dry tetrahydrofuran and cooled to 0°C.  To this mixture morpholine (0.3 mmol) was 
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added, with the reaction mixture stirred under nitrogen for 1 hour, and was 
subsequently evaporated to dryness.  The crude product was subsequently purified by 
chromatography, eluting with 20% ethanol-dichloromethane.  Appropriate fractions 
were concentrated to provide the desired 1-β diclofenac-AG product.  Occasionally, 
reversed-phase column chromatography (acetonitrile, dH2O, 10-40%) or 
recrystallization was required to remove residual traces of palladium.  Pure 1-β 
diclofenac-AG was obtained with a 75% yield in this step as a white solid.  
 
Supplementary figure 1:  Schematic representation of the chemical synthesis of 
diclofenac-AG.  Reaction intermediates are (A) D-glucuronide (B) Allyl α,β-D-
glucuronate (C) Diclofenac ally glucronate (D) Diclofenac-AG.  Reaction steps are (i) 
Stirring of (A) with polymer bound fluoride in dimethylformate at 20°C followed by 
addition of ally bromide at 40°C.  (ii)  Slow addition of diisopropyl azodicarboxylate to a 
solution of diclofenac, triphenylphosphine and (B) in anhydrous tetrahydrofuran at 
0°C.  (iii)  Addition of morpholine to a solution of (C) 
tetrakis(triphenylphosphine)palladium at 0°C. 
 
Purity of synthetic 1-β diclofenac-AG was assessed using a combination of LC-UV, 
tandem mass-spectrometric and NMR assessment.  For acceptable use in experiments, 
purity was above 98%.  LC-UV conditions as described in section 2.2.4 were used to 
assess diclofenac purity.    
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Supplementary Table 1:  MRM transitions for peptides modified by diclofenac-AG 
identified in either in vitro incubations in chapter 2, or in clinical samples in chapter 5 
Peptide Charge 
Q1 
Q3 
Transacylation Glycation 
137KYLYEIAR144 2+ 667.3 754.8 215.1 
137KYLYEIAR144 2+ 667.3 754.8 250.1 
137KYLYEIAR144 3+ 445.2 503.5 215.1 
137KYLYEIAR144 3+ 445.2 503.5 250.1 
181LDELRDEGKASSAK195 3+ 599.6 657.9 215.1 
181LDELRDEGKASSAK195 3+ 599.6 657.9 250.1 
181LDELRDEGKASSAK195 4+ 449.9 493.7 215.1 
181LDELRDEGKASSAK195 4+ 449.9 493.7 250.1 
191ASSAKQR197 2+ 513.2 600.7 215.1 
191ASSAKQR197 2+ 513.2 600.7 250.1 
191ASSAKQR197 3+ 342.5 400.8 215.1 
191ASSAKQR197 3+ 342.5 400.8 250.1 
198LKCASLQK205 2+ 613.3 700.7 215.1 
198LKCASLQK205 2+ 613.3 700.7 250.1 
198LKCASLQK205 3+ 409.2 467.5 215.1 
198LKCASLQK205 3+ 409.2 467.5 250.1 
349LAKTYETTLEK359 2+ 787.8 875.3 215.1 
349LAKTYETTLEK359 2+ 787.8 875.3 250.1 
349LAKTYETTLEK359 3+ 525.5 583.9 215.1 
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Supplementary Table 2:  MRM transitions for peptides modified by diclofenac-AG 
identified in either in vitro incubations in chapter 2, or in clinical samples in chapter 5 
Peptide Charge 
Q1 
Q3 
Transacylation Glycation 
349LAKTYETTLEK359 3+ 525.5 583.9 250.1 
349LAKTYETTLEK359 4+ 394.4 438.2 215.1 
349LAKTYETTLEK359 4+ 394.4 438.2 250.1 
429NLGKVGSK436 2+ 540.8 628.3 215.1 
429NLGKVGSK436 2+ 540.8 628.3 250.1 
429NLGKVGSK436 3+ 360.8 419.2 215.1 
429NLGKVGSK436 3+ 360.8 419.2 250.1 
433VGSKCCK439 2+ 558.7 646.2 215.1 
433VGSKCCK439 2+ 558.7 646.2 250.1 
433VGSKCCK439 3+ 372.8 431.1 215.1 
433VGSKCCK439 3+ 372.8 431.1 250.1 
525KQTALVELVK534 2+ 703.8 791.4 215.1 
525KQTALVELVK534 2+ 703.8 791.4 250.1 
525KQTALVELVK534 3+ 469.5 527.9 215.1 
525KQTALVELVK534 3+ 469.5 527.9 250.1 
539ATKEQLK545 2+ 548.3 635.7 215.1 
539ATKEQLK545 2+ 548.3 635.7 250.1 
539ATKEQLK545 3+ 365.8 424.1 215.1 
539ATKEQLK545 3+ 365.8 424.1 250.1 
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Supplementary Table 3:  Summary of HSA peptides identified as modified in clinical 
samples, showing cation exchange fractions modified peptides were detected and 
their representative m/z values 
Patient 
Cation 
exchange 
fraction 
Peptide Transacylation Glycation Ion 
N01 
39-40 198LKCASLQK205  G 700.8 2+ 
41-42 198LKCASLQK205 T  612.8 2+ 
41-42 429NLGKVGSK436 T  540.3 2+ 
41-42 539ATKEQLK545 T  547.7 2+ 
43-44 191ASSAKQR197 T  512.7 2+ 
51-52 181LDELRDEGKASSAK195 T  599.3 3+ 
N02 
41-42 198LKCASLQK205 T  612.8 2+ 
41-42 429NLGKVGSK436 T  540.3 2+ 
41-42 539ATKEQLK545 T  547.7 2+ 
43-44 191ASSAKQR197 T  512.7 2+ 
51-52 181LDELRDEGKASSAK195 T  599.3 3+ 
N03 
41-42 198LKCASLQK205 T  612.8 2+ 
41-42 539ATKEQLK545 T  547.7 2+ 
43-44 191ASSAKQR197 T  512.7 2+ 
N08 
39-40 198LKCASLQK205  G 700.8 2+ 
39-40 198LKCASLQK205  G (-H2O) 691.9 2+ 
39-40 525KQTALVELVK534 T  469.2 3+ 
41-42 198LKCASLQK205 T  612.8 2+ 
41-42 429NLGKVGSK436  G 628.3 2+ 
41-42 539ATKEQLK545 T  547.7 2+ 
43-44 191ASSAKQR197  G 600.7 2+ 
43-44 191ASSAKQR197 T  512.7 2+ 
43-44 433VGSKCCK439 T  559.2 2+ 
51-52 525KQTALVELVK534  G 435.6 3+ 
N09 
43-44 191ASSAKQR197  G 600.7 2+ 
43-44 191ASSAKQR197 T  512.7 2+ 
N10 43-44 191ASSAKQR197 T  512.7 2+ 
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Supplementary Table 4:  MRM transitions run for detection of peptides modified by 
diclofenac-AG.  None of the peptides represented in this table were identified as 
modified following either in vitro incubations of diclofenac-AG with HSA (Chapter 2) or 
HSA isolated from patients receiving therapeutic doses of diclofenac (Chapter 5).  
Peptide Charge 
Q1 
Q3 
Transacylation Glycation 
1DAHKSEVAHR10 2+ 714.3 801.8 215.1 
1DAHKSEVAHR10 2+ 714.3 801.8 250.1 
1DAHKSEVAHR10 3+ 476.5 534.9 215.1 
1DAHKSEVAHR10 3+ 476.5 534.9 250.1 
11FKDLGEENFK20 2+ 752.8 840.3 215.1 
11FKDLGEENFK20 2+ 752.8 840.3 250.1 
11FKDLGEENFK20 3+ 502.2 560.3 215.1 
11FKDLGEENFK20 3+ 502.2 560.3 250.1 
146HPYFYAPELLFFAKR160 3+ 726.3 784.6 215.1 
146HPYFYAPELLFFAKR160 3+ 726.3 784.6 250.1 
146HPYFYAPELLFFAKR160 4+ 544.9 588.7 215.1 
146HPYFYAPELLFFAKR160 4+ 544.9 588.7 250.1 
161YKAAFTECQAADK174 2+ 970.8 NA 215.1 
161YKAAFTECQAADK174 2+ 970.8 NA 250.1 
161YKAAFTECQAADK174 3+ 647.5 705.9 215.1 
161YKAAFTECQAADK174 3+ 647.5 705.9 250.1 
161YKAAFTECQAADK174 4+ 485.9 529.7 215.1 
161YKAAFTECQAADK174 4+ 485.9 529.7 250.1 
210AFKAWAVAR218 2+ 649.3 736.8 215.1 
210AFKAWAVAR218 2+ 649.3 736.8 250.1 
210AFKAWAVAR218 3+ 433.2 491.5 215.1 
210AFKAWAVAR218 3+ 433.2 491.5 250.1 
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Supplementary Table 5:  MRM transitions run for detection of peptides modified by 
diclofenac-AG.  None of the peptides represented in this table were identified as 
modified following either in vitro incubations of diclofenac-AG with HSA (Chapter 2) or 
HSA isolated from patients receiving therapeutic doses of diclofenac (Chapter 5). 
Peptide Charge 
Q1 
Q3 
Transacylation Glycation 
275LKECCEKPLLEK286 2+ 912.9 NA 215.1 
275LKECCEKPLLEK286 2+ 912.9 NA 250.1 
275LKECCEKPLLEK286 3+ 608.9 667.2 215.1 
275LKECCEKPLLEK286 3+ 608.9 667.2 250.1 
275LKECCEKPLLEK286 4+ 456.9 500.6 215.1 
275LKECCEKPLLEK286 4+ 456.9 500.6 250.1 
367VFDEFKPLVEEPQNLIK383 3+ 775.1 833.4 215.1 
367VFDEFKPLVEEPQNLIK383 3+ 775.1 833.4 250.1 
367VFDEFKPLVEEPQNLIK383 4+ 581.6 625.3 215.1 
367VFDEFKPLVEEPQNLIK383 4+ 581.6 625.3 250.1 
473VTKCCTESLVNR484 2+ 872.8 960.4 215.1 
473VTKCCTESLVNR484 2+ 872.8 960.4 250.1 
473VTKCCTESLVNR484 3+ 582.2 640.6 215.1 
473VTKCCTESLVNR484 3+ 582.2 640.6 250.1 
473VTKCCTESLVNR484 4+ 436.9 480.7 215.1 
473VTKCCTESLVNR484 4+ 436.9 480.7 250.1 
542EQLKAVMDDFAAFVEK557 3+ 706.9 765.3 215.1 
542EQLKAVMDDFAAFVEK557 3+ 706.9 765.3 250.1 
542EQLKAVMDDFAAFVEK557 4+ 530.4 574.2 215.1 
542EQLKAVMDDFAAFVEK557 4+ 530.4 574.2 250.1 
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Supplementary Table 6: Concomittant medications and patient characteristics of 
patients N01-N03 analysed for covalent binding of diclofenac-AG to human serum 
albumin, and plasma concentrations of diclofenac and diclofenac-AG 
 N01 N02 N03 
Sex Male Female Female 
Date of birth 
(dd/mm/yy) 
07/11/1968 05/02/1945 06/07/1959 
Diclofenac dose 50mg bid EC 50mg bid EC 
50mg am 
75mg pm EC MR 
Diagnosis 
Rheumatoid 
arthritis (2010) 
Rheumatoid 
arthritis (1998) 
Rheumatoid 
arthritis (1990) 
Other medical 
issues 
Sciatica 
Osteoporosis 
fracture L2 
Erosive antral 
gastritis 
Carcinoma Breast 
(10/2010) 
Concomitant 
medications 
Methotrexate 
25mg/wk  
(Oct 2010) 
Methotrexate 
10mg/wk  
(02/2010) 
Methotrexate 
20mg/wk  
(1999) 
Folic Acid Folic Acid (02/2010) 
Folic acid  
5mg /wk 
Leflunomide 
(02/2011) 
Prednisolone 
Calcichew D3 Forte 
bid 
 Alendronate 
Prednisolone 5mg 
daily (12/2010) 
 Calcichew D3 Forte Omeprazole 
 Dermovate 
Tamoxifen 20mg 
daily (Dec 2010) 
 
Etanercept 
(12/2009) 
Zoladex iv monthly 
(Dec 2010) 
 
Omeprazole 
(04/2011) 
 
 
Citalopram 
(04/2011) 
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Supplementary Table 7:  Concomittant medications and patient characteristics of 
patients N08-N10 analysed for covalent binding of diclofenac-AG to human serum 
albumin, and plasma concentrations of diclofenac and diclofenac-AG 
 N08 N09 N10 
Sex Male Male Female 
Date of birth 
(dd/mm/yy) 
16/12/1947 17/12/1962 09/04/1934 
Diclofenac dose 50mg tds EC 50mg tds 50mg bid 
Diagnosis 
Rheumatoid arthritis 
(approx. 1980s) 
Ankylosing 
Spondylitis 1977 
 
Massive swelling 
right knee 
Jan2011, working 
diagnosis OA. 
Other medical 
issues 
Insulin dependent 
diabetes mellitus 
Coronary artery 
bypass graft 
Wegener’s 
Granulomatosis 
with left ICA 
occlusion 
associated with left 
hemisphere 
Infarction (2006) 
Generalised nodal 
osteoarthritis; 
migraine since 
childhood; 
hypertension; 
 
Concomitant 
medications 
Sulfasalazine 
Azathioprine 
150mg/day 
Co-codamol prn 
Hydroxychloroquine 
Simvastatin 
40mg/day 
Lansoprazole 15mg 
OD 
Insulin 
Lansoprazole 
15mg/day 
 
Aspirin Paracetamol prn  
Atenolol   
Paracetamol   
Alendronate   
Beclomethasone   
Rosuvastatin   
Adcal   
Thyroxine   
Ramipril   
Tadalafil   
 
